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Abstract 
 
Osteoarthritis (OA) is a chronic degenerative disease of the joint. Current 
treatments for this disease (such as glucocorticoid steroids) aim to reduce pain 
and increase mobility. Intra-articular injection is used in OA as treatment can 
be targeted to affected joints only. There is currently a lack of sustained release 
formulations for intra-articular injection. 
 
The aim of this thesis was to produce and characterise an injectable intra-
articular drug delivery system capable of providing delivery of the steroid 
dexamethasone phosphate (DXMP) over 3 months. This would be an 
injectable hydrogel that contains drug loaded nanoparticles. 
 
Initially two systems Pluronic F127 gels and polyelectrolyte complexes 
between hyaluronic acid (HA) and chitosan were investigated. The complexes 
between HA and chitosan were selected for the hydrogel portion of this system 
as they showed the greatest stability and promise in initial studies. To improve 
the polyelectrolyte complex properties a modified HA was synthesised. This 
modified polymer caused faster complex formation and produced stronger, 
more resilient complexes. 
 
DXMP was incorporated into poly(glycerol-adipate) (PGA) nanoparticles. A 
low but sufficient drug loading was achieved and particles were found to give a 
sustained drug release over 28 days. 
 
 ii 
Nanoparticles were found to be efficiently incorporated and well retained 
within complexes. Nanoparticles slightly improved complex formation and 
properties. Composites were able to be formulated into an injectable form. 
 
Drug release from directly loaded complexes was rapid. A full release profile 
was not determined from composites of nanoparticle loaded complexes; 
however, over 60% of the loaded drug was recovered after 56 days of release 
study. Dexamethasone crystals were also incorporated directly into complexes 
to investigate the necessity of the use of nanoparticles. This gave a sustained 
drug release over 90 days making this system worthy of further investigation. 
These results highlight the different responses of these systems using drugs 
with different hydrophobicities. 
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CHAPTER 1 - INTRODUCTION 
 
1.1 General Introduction to Osteoarthritis 
1.1.1 Introduction 
 
Osteoarthritis (OA) is a degenerative disorder of the synovial joint that is 
characterised by a progressive loss of articular cartilage (Brandt et al., 2003, 
Buckwalter and Martin, 2006). As the disease progresses the entire joint 
becomes affected (Pollard et al., 2008, Brandt et al., 2003). Osteoarthritis is a 
monoarthritis as it develops within individual joints; this contrasts with 
rheumatoid arthritis (RA), the most prevalent polyarthritis, which affects many 
joints in sufferers (Woolf and Pfleger, 2003). 
 
Any synovial joint can be affected by osteoarthritis, but the joints most 
commonly affected are the knee, hip, hand, foot, and spine (Woolf and Pfleger, 
2003). The main symptom of this disease is joint pain. Other symptoms 
include tenderness, stiffness and loss of movement in affected joints (Pelletier 
et al., 2001, Woolf and Pfleger, 2003, Buckwalter and Martin, 2006). 
 
1.1.2 Risk Factors 
 
A number of risk factors for osteoarthritis have been identified and include 
obesity (Woolf and Pfleger, 2003, Aspden, 2011), joint deformity or 
malalignment (Brandt et al., 2003, Buckwalter and Martin, 2006), gender (OA 
shows a higher prevalence in females) (Woolf and Pfleger, 2003, Brandt et al., 
2003), age (Woolf and Pfleger, 2003, Buckwalter and Martin, 2006), genetics 
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(Woolf and Pfleger, 2003, MacGregor et al., 2000) and joint trauma 
(Buckwalter and Martin, 2006, Gelber et al., 2000, Woolf and Pfleger, 2003). 
 
Age is one of the primary risk factors for OA as physiological changes that 
occur in the aging joint make it more susceptible to OA. These include a 
softening of the cartilage surface and decreases in the strength of the cartilage 
matrix components (Goldring and Goldring, 2007, Aigner et al., 2007). 
Despite the strong link with age it is not unknown for osteoarthritis to develop 
in individuals under 45 years old. This is relatively uncommon and the 
prevalence increases rapidly after this age (Woolf and Pfleger, 2003).  
 
The link between obesity and osteoarthritis has been found to be more complex 
than it might initially seem. The increased loads on the joints due to obesity 
might be expected to explain this link. However there is growing evidence that 
other metabolic factors may be more important. The hormones leptin and 
adiponectin are produced by adipose tissue and have been found to increase the 
levels of degradative factors that are important in OA (Aspden, 2011, Dumond 
et al., 2003, Aspden et al., 2001, Clouet et al., 2009, Kang et al., 2010). 
 
1.1.3 Prevalence 
 
2VWHRDUWKULWLVLVWKHZRUOG¶VPRVWFRPPRQDUWKULWLVDQGWKHPRVWFRPPRQMRLQW
disease. The World Health Organisation estimates that 18% of women and 
10% of men over 60 years of age worldwide have symptomatic osteoarthritis 
(Woolf and Pfleger, 2003). In the UK it has been estimated by Arthritis Care 
that there are 8.5 million people living with symptomatic osteoarthritis 
(Arthritis Care, 2004). Due to the slow development of OA changes in joints 
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can occur long before symptoms are experienced. Radiographic evidence of 
OA is found in about 25% of adults over 50 years old (National Collaborating 
Centre for Chronic Conditions, 2008, Woolf and Pfleger, 2003, Peat et al., 
2006), but only about half of these people are symptomatic. 
 
1.1.4 Impact 
 
Osteoarthritis has a huge impact and it has been estimated that OA was the 
eighth leading non-fatal burden of disease in the world in 1990 (Woolf and 
Pfleger, 2003). We are living in an aging population and as OA has a strong 
association with aging it is predicted to become the fourth leading cause of 
disability by 2020 (Woolf and Pfleger, 2003). 
 
The demands that this disease places on the health services are therefore huge. 
In the UK 2 million adults visit their GP every year due to osteoarthritis. Over 
60,000 hip replacements, costing around £450 million, were carried out in 
2006/7 in the UK of which 94% were due to OA (National Collaborating 
Centre for Chronic Conditions, 2008). The total cost of this disease in the UK 
has been estimated to be equivalent to 1% of Gross National Product per year 
(National Collaborating Centre for Chronic Conditions, 2008), which includes 
the effect of 36 million lost working days due to osteoarthritis in 1999/2000. 
 
1.2 Synovial Joint Physiology 
 
To understand osteoarthritis it is necessary to be familiar with the physiology 
of synovial joints and so a brief overview is included in the following sections. 
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1.2.1 General Structure 
 
Synovial joints are the most common and most mobile type of joint present in 
the human body. The other two types of structural joint in the body are simpler 
and less mobile. They are fibrous and cartilaginous joints, in which the bones 
are directly connected by collagen fibres and cartilage respectively. 
 
The healthy synovial joint is an organ composed of a number of different cell 
and tissue types (Brandt et al., 2003). These include the subchondral bone, 
articular cartilage, synovial membrane and the joint capsule. The basic 
structure of a synovial joint shown in Figure 1-1, and consists of two bones 
held in position by the joint capsule. The articulating surfaces of the bones are 
covered in cartilage and separated by the synovial cavity which is filled with 
synovial fluid. More detailed descriptions of these components follow below. 
 
Figure 1-1 Diagram showing the features of a normal synovial joint and the major 
changes observed in osteoarthritis.  
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1.2.2 Cartilage 
 
The bone surface within the joint is covered by a protective layer of hyaline 
cartilage known as articular cartilage. This layer helps to resist the mechanical 
forces within the joint, protects the bone and provides a low friction surface for 
joint movement (Aigner et al., 2006). Cartilage is a relatively acellular tissue 
with chondrocytes being the only cells present. The primary component of 
cartilage is its specialised extracellular matrix. 
 
Cartilage can be divided into zones depending on its depth. The layer exposed 
to the synovial fluid is called the superficial zone. In that order below that are 
the middle zone, deep zone and calcified zone (Buckwalter et al., 2005). The 
calcified zone links the cartilage to the bone and acts to relieve the shear 
stresses that would occur with a straight division (Pollard et al., 2008). 
 
1.2.2.1 Extracellular matrix 
 
The extracellular matrix (ECM) is the major component of articular cartilage. 
It is composed of structural and connective proteins, as well as proteoglycans 
and tissue fluid- 80% of the wet weight of cartilage is water (Pollard et al., 
2008). The major structure of hyaline cartilage is shown in Figure 1-2. It is a 
network of fibrillar type II collagen fibres which retains the proteoglycan 
aggrecan (Buckwalter et al., 2005). Collagen is a protein rich in glycine (found 
roughly every third residue) and proline. Three individual collagen chains of 
around 1000 amino acids come together to form triple-helical fibrils which 
further associate to form long collagen fibres. 
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Figure 1-2 Diagram showing the zonal differences in biochemical composition and 
organisation of articular cartilage.  
Reproduced with permission and copyright © of the British Editorial Society of Bone and Joint 
Surgery (Pollard et al., 2008). 
 
Aggrecan is a proteoglycan consisting of a core protein linked to a large 
number (c. 100-300) of glycosaminoglycan (GAGs) molecules, mostly 
chondroitin sulphate and keratan sulphate. GAGs are polysaccharides 
composed of disaccharides of a hexuronic acid and a hexosamine with various 
sulphations. Aggrecan molecules are bound to large hyaluronan molecules by a 
link protein to make a huge complex (Brandt et al., 2003). 
 
The sulphate groups present in GAGs make aggrecan highly negatively 
charged. These charges cause a high osmotic pressure and leads to the large 
volume of water in cartilage (Alford and Cole, 2005). The high water content 
combined with the repulsive forces between negative charges causes 
expansion, which the tensile strength of the collagen fibres acts to contain. The 
expanded structure provides cartilage with its compressive strength and it can 
resist loads of up to 15 to 20 MPa, which occur for short periods (less than a 
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second) during vigorous activity (Seireg and Arvikar, 1975, Sharma et al., 
2007). 
 
A number of minor components are present in articular cartilage, as shown in 
Figure 1-2. These include various other collagens, such as types VI, X, XI and 
XVI (Buckwalter et al., 2005), which have various functions, for example 
Type IX acts as a link to other components of the ECM (Buckwalter et al., 
2005, Aigner et al., 2006) and type XI is involved in fibril synthesis (Aigner et 
al., 2006). Cartilage also contains a variety of other proteins and proteoglycans 
such as decorin, biglycan, chondroadherin, fibronectin, and cartilage 
oligomeric matrix protein (COMP) (Pollard et al., 2008, Aigner et al., 2006, 
Sofat, 2009). These components fulfil a variety of roles such as stabilising the 
collagen framework and regulating matrix turnover (Pollard et al., 2008).  
 
The composition and organisation of cartilage varies by zone (Buckwalter et 
al., 2005). The superficial zone is relatively rich in collagen, with relatively 
thin fibres arranged parallel to the surface. This arrangement provides 
resistance to shear forces and produces a protective surface. In the middle zone 
the collagen fibres are thicker and arranged at angles to the surface. The deep 
zone is the richest in aggrecan and has the thickest collagen fibres, which are 
arranged perpendicular to the surface and help provide compressive strength 
(Buckwalter et al., 2005). 
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1.2.2.2 Chondrocytes 
 
Chondrocytes make up about 1% of the volume of articular cartilage 
(Buckwalter et al., 2005). Chondrocytes are found within cavities known as 
lacunae and are adapted to anoxic, high pressure conditions (Holland and 
Mikos, 2003). The main function of chondrocytes is to synthesise the ECM 
components of cartilage (Buckwalter et al., 2005). Chondrocytes within mature 
articular cartilage are quiescent and do not undergo mitosis (Goldring and 
Goldring, 2007). Chondrocyte numbers and morphology vary between 
cartilage zones (Buckwalter et al., 2005). 
 
The turnover rate for healthy cartilage is very slow, with the estimated half-life 
for collagen in cartilage being 100 years and for aggrecan is around 5 years 
(Brandt et al., 2003). The natural turnover requires the breakdown of old 
molecules which is carried out by enzymes in the matrix metalloproteinase 
(MMP) and the ADAMTS (a disintegrin and metalloproteinase with 
thrombospondin motif) families (Aigner et al., 2006). MMP-1 and MMP-13 
are the most important enzymes in the degradation of type II collagen (Pollard 
et al., 2008). ADAMTS-4 and ADAMTS-5 are responsible for the initial 
cleavage of aggrecan, which is further degraded by MMPs (Pollard et al., 
2008), particularly MMP-3 (Aigner et al., 2006). The ability of chondrocytes 
to maintain and repair cartilage diminishes with age, which has been attributed 
to a reduction in their anabolic capacity (Buckwalter et al., 2005, Goldring and 
Goldring, 2007, Aigner et al., 2007). 
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Cartilage can be categorised according to its proximity to chondrocytes. These 
zones are identified and characterised in Figure 1-2. The zone surrounding the 
chondrocytes is the pericellular zone which is rich in proteoglycans and 
lacking in fibrillar collagen. It is also rich in type VI collagen which links 
chondrocytes to type II collagen fibrils (Aigner et al., 2006). Surrounding this 
]RQHLVWKHWHUULWRULDO]RQHZKLFKFRQWDLQVDµEDVNHW¶RIWKLQFROODJHQILEUHVWKDW
gives the cells some mechanical protection (Buckwalter et al., 2005). Well 
away from chondrocytes is the interterritorial zone which makes up about 90% 
of cartilage volume (Pollard et al., 2008, Buckwalter et al., 2005). 
 
1.2.3 Synovial Membrane and Joint Capsule 
1.2.3.1 Synovial membrane 
 
The synovial membrane contains the only other population of cells in the 
synovial joint. The intima layer of the synovial membrane faces the synovial 
cavity and is composed of a thin layer of cells known as synovial lining cells 
(SLCs) (Momberger et al., 2005). SLCs can be divided into two distinct types. 
Type A SLCs are macrophage like cells that make up around a third of the 
SLC population (Gerwin et al., 2006), and act to remove large molecular 
weight debris from the joint. Type B SLCs are fibroblasts that secrete the 
components of synovial fluid (Athanasou, 1995, Momberger et al., 2005).  
 
Below the intima is the subsynovium or subintima which is composed of loose 
connective tissue with an extracellular matrix rich in collagen, hyaluronan, 
decorin and biglycan (Gerwin et al., 2006, Burt et al., 2009). It also contains 
adipose cells, blood and lymph vessels (Burt et al., 2009). 
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The synovial membrane is highly vascularised and allows an ultrafiltrate of 
plasma to enter the synovial cavity (Gerwin et al., 2006). This fluid makes up 
the liquid portion of synovial fluid and supplies nutrients and oxygen to the 
cartilage. The synovium also contains the only nerves within the joint which 
provide pain feedback and control synovial blood flow (Gerwin et al., 2006).  
 
1.2.3.2 Joint capsule 
 
The joint capsule surrounds the synovium and along with associated ligaments 
and muscles acts to hold the joint together by resisting the expansive forces 
from cartilage and joint loading (Aigner et al., 2006). 
 
1.2.4 Synovial Fluid 
 
Synovial fluid is a viscous fluid that fills the synovial cavity. A human joint 
contains between 0.5 and 2ml of this fluid (Brandt et al., 2003). The fluid is an 
ultrafiltrate of blood plasma containing similar plasma proteins but in reduced 
amounts (Ropes et al., 1940). Synovial fluid also contains other glycoprotein 
components that are permanently present within the joint. 
 
The defining characteristic of synovial fluid is that it contains a high 
concentration of hyaluronic acid (around 3.5mg/ml) (Gerwin et al., 2006, 
Curtiss, 1964). Hyaluronic acid (HA) has an average molecular weight in 
healthy joints of between 4 and 10 mDa (Dahl et al., 1985) and is the primary 
reason for the high viscosity and characteristic viscoelastic properties of 
synovial fluid (Mensitieri et al., 1995).  
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1.2.4.1 Hyaluronic acid 
 
Hyaluronic acid is composed of a repeating disaccharide of D-glucuronic acid 
and D-N-acetyl glucosamine (Liao et al., 2005), as shown in Figure 1-3. 
Unlike all other GAGs HA is not sulphated (Volpi et al., 2009, Ponedel'kina et 
al., 2008). HA is often referred to as hyaluronan as it is ionised at a 
physiological pH (Liao et al., 2005). 
O
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Figure 1-3 Structure of hyaluronic acid showing disaccharide repeating unit. 
 
In solution HA has a level of ordered structure (Scott and Heatley, 1999) 
which is stabilised by hydrogen bonding between neighbouring disaccharide 
repeats, interactions between hydrophobic patches and interchain hydrogen 
bonding (Scott and Heatley, 1999, Scott and Heatley, 2002). HA adopts a 
twisted chain secondary structure, which can further associate to form an 
DQWLSDUDOOHOȕ-sheet like tertiary structure (Scott and Heatley, 1999, Liao et al., 
2005). Antiparallel means that the HA chains in this structure run parallel but 
in opposite directions. Chain interactions can also lead to the formation of 
weak and transient molecular networks in high molecular weight HA (Scott, 
1998). These structures are more stable than a random coil but can be disrupted 
and reversibly denatured (Scott and Heatley, 2002). 
 
HA is synthesised by hyaluronan synthase (HAS) enzymes and in humans 
there are three isoforms of this enzyme. HAS2 is the isoform predominantly 
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expressed in the joint and produces high molecular weight hyaluronan (c. 
2MDa) (Liao et al., 2005, Bastow et al., 2008). Synthesis occurs at the plasma 
membrane of the type B synoviocytes, with the polymer being simultaneously 
exported by a transmembrane pore. The multi-drug resistance transporters 
MDR-1 (multidrug resistance-associated protein 1) and MRP-5 (multidrug 
resistance-associated protein 5) have been implicated as these transporters 
(Momberger et al., 2005, Prehm and Schumacher, 2004). 
 
HA is degraded by two mechanisms in vivo which are enzymatic hydrolysis 
and scission reactions involving reactive oxygen species (ROS) (Volpi et al., 
2009). Little is known about the relative contributions of these two 
mechanisms to overall HA degradation. Enzymatic hydrolysis occurs through 
the action of hyaluronidases (HYAL), which can also degrade other GAGs. 
0DPPDOLDQ K\DOXURQLGDVHV DUH ȕ-endo-N-acetylglucosaminidase and 
hydrolase enzymes (Volpi et al., 2009). There are 3 functionally active HYAL 
enzymes in humans. HYAL-1 (lysosomal) and HYAL-2 
(glycosylphosphatidylinositol (GPI) linked to the external surface of the cell 
membrane) are the major hyaluronidases (Volpi et al., 2009, Stern et al., 2007). 
PH-20 is an enzyme involved in sperm penetration of the ovum (Volpi et al., 
2009, Stern et al., 2007). 
 
It has been suggested that these enzymes work in tandem to mediate HA 
degradation. HYAL-2, CD44, HARE and RHAMM, act as extracellular 
receptors for HA (Liao et al., 2005, Bastow et al., 2008) which traffic HA to 
acidic endosomes. In these endosomes HYAL-2 digests HA to medium sized 
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fragments. These fragments are moved to the lysosomes for further 
degradation by HYAL-1 and other lysosomal enzymes (Volpi et al., 2009, 
Yoshida et al., 2004, Liao et al., 2005, Bastow et al., 2008). Enzymatic 
degradation of HA produces fragments with an identical chemical structure to 
the full chain polymer. 
 
Degradation by ROS produces fragments that contain products of O2 
metabolism such as aldehydes and hydroperoxides (Volpi et al., 2009). The 
ROS species mainly responsible for HA degradation are the hydroxyl radical 
(OH
·
), hypochlorous acid (HOCl) and peroxynitrite (ONOO
-
) (Volpi et al., 
2009, Stern et al., 2007). There are various mechanisms for these degradations 
which have been reviewed by Volpi et al. and Stern et al. (Stern et al., 2007, 
Volpi et al., 2009). It is possible that HA degradation by ROS is sacrificial to 
scavenge and remove free radicals (Liao et al., 2005, Volpi et al., 2009). 
 
1.2.4.2 Other constituents 
 
Synovial fluid also contains lubricin (0.05 mg/ml), which is a glycoprotein that 
helps provide lubrication (Bao et al., 2011). The synovial ECM prevents 
plasma proteins greater than 160 kDa entering the joint and causes overall 
protein levels to be a third of those found in plasma (c. 20 mg/ml) (Curtiss, 
1964, Mavraki and Cann, 2009). The filtering also acts to relatively enrich 
albumin, which makes up around 60% of protein in synovial fluid but only 
around 40% of that in plasma (Curtiss, 1964, Mavraki and Cann, 2009). The 
majority of the rest of the protein in synovial fluid is globulins. 
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1.2.4.3 Functions 
 
The main functions of synovial fluid are to facilitate joint movement and 
protect the articular surfaces. Synovial fluid acts as a lubricating layer between 
the bones but its viscoelastic properties allow it to also act as an elastic shock 
absorber upon impacts (Mensitieri et al., 1995). Synovial fluid also has an 
essential role in supplying nutrients to chondrocytes (Momberger et al., 2005). 
 
Synovial fluid undergoes a rapid turnover with the blood acting as a sink for 
small molecules, which is seen by ions in synovial fluid being in equilibrium 
with plasma (Brandt et al., 2003). Synovial fluid is also drained by the well-
developed lymphatic vessels in the subsynovium (Burt et al., 2009, Xu et al., 
2003). HA is retained for longer due to its high molecular weight partially 
excluding it from lymph vessels. HA is still completely turned over in around 
36h (Gerwin et al., 2006, Butoescu et al., 2009a). 
 
1.3 Disease Progression in Osteoarthritis 
 
Osteoarthritis causes changes throughout the synovial joint. The most 
important is the progressive loss of articular cartilage. Other changes include 
sclerosis of subchondral bone, osteophyte formation, synovial thickening and 
changes in synovial fluid (Aigner et al., 2006, Brandt et al., 2003). Figure 1-1 
summarises the main changes seen in osteoarthritis. 
 
The early stages of the disease are outlined below, followed by a summary of 
how the disease progresses beyond this point. Finally the most important 
changes in the later stage disease are summarised. 
 15 
1.3.1 Early Osteoarthritis 
 
Investigation into early osteoarthritis has been challenging due to the long 
development before symptoms appear. Changes naturally occur in the joint, for 
example with aging, that increase the risk of osteoarthritis but that are not 
necessarily a precursor to OA. Despite the challenges a picture of the early 
stages of OA is beginning to emerge. 
 
The first observed change in the development of osteoarthritis is a loss of 
aggrecan from the outer layers of articular cartilage (Arden and Cooper, 2006). 
Changes in proteoglycan levels cause changes in the swelling behaviour of 
cartilage and can lead to oedema. Oedema causes stretching and thinning of the 
collagen which makes fibres more susceptible to breakage (Brandt et al., 
2003). Breakage of fibres leads to the formation of surface cracks, and surface 
fibrillation is one of the first macroscopic changes observed in osteoarthritis 
(Brandt et al., 2003, Buckwalter et al., 2005). 
 
Chondrocytes counteract decreased proteoglycan levels by increasing synthesis 
and removing damaged cartilage components (Dijkgraaf et al., 1995). This 
increases anabolic and catabolic processes in an attempt to repair the cartilage.  
 
1.3.2 Progression to Clinical Osteoarthritis 
 
A key transition occurs in the development of osteoarthritis, which is a shift 
from hypertrophic cartilage, where there is an increase in both anabolism and 
catabolism, to catabolic processes dominating. The causes of this progression 
are not fully known but there are contributions from numerous factors. 
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In early osteoarthritis increased levels of anabolic factors which mediate 
cartilage repair have been observed. These include TGF-ȕ (transforming 
growth factor-beta) and IGF-1 (insulin-like growth factor 1) (Goldring and 
Goldring, 2007, Blom et al., 2004). As OA progresses these become 
overwhelmed by larger increases in catabolic cytokines (Aigner et al., 2006, 
Freemont, 2006, Bondeson et al., 2006). 
 
Changes in the cartilage repair process are thought to be important. Over time 
repair can become ineffectual, for example due to aging chondrocytes or 
further damage to the cartilage (Buckwalter et al., 2005). This causes a decline 
in cartilage quality leading to an increased susceptibility to further damage. 
Repeated damage may eventually cause dysregulation of the repair process and 
lead to increased degradation. At a molecular level it has been suggested that 
the activation of MMP-13 is important. Activation is thought to occur due to 
aggrecan depletion around chondrocytes allowing collagen fibrils to interact 
with a receptor that activates MMP-13 (Xu et al., 2007). 
 
1.3.3 Cytokines 
 
Aberrant cytokine signalling is a major factor in osteoarthritis. The two key 
cytokines in osteoarthritis are IL-ȕ interleukin-1 beta) and TNF-Į tumour 
necrosis factor-alpha). Levels of both are increased in osteoarthritis 
(Furuzawa-Carballeda and Alcocer-Varela, 1999, Benito et al., 2005, 
Bondeson et al., 2006). IL-ȕ DQG 71)-Į cause cartilage destruction both 
individually and synergistically, as in combination their effects exceed those 
from one alone (Page Thomas et al., 1991). 
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IL-ȕ DQG 71)-Į are expressed by synovial macrophages and chondrocytes. 
These cytokines cause increased expression of ECM degrading enzymes 
(Pelletier et al., 2001, Sofat, 2009, Goldring and Goldring, 2007). They cause 
an overexpression and activation of iNOS (inducible nitric oxide synthase) in 
chondrocytes (Grabowski et al., 1997, McInnes et al., 1996). They also induce 
the release of inflammatory mediators including reactive oxygen species 
(Mathy-Hartert et al., 2008), prostaglandin E2 (PGE2), IL-6, IL-17, IL-18 and 
leukaemia inhibitory factor (LIF) (Van den Berg, 2002, Alaaeddine et al., 
1999, Atik, 1990, Benito et al., 2005, Furuzawa-Carballeda and Alcocer-
Varela, 1999, Farahat et al., 1993). 
 
Other pro-inflammatory cytokines have also been implicated in osteoarthritis. 
These include oncostatin M (Barksby et al., 2006), IL-8 (also known as CCL2) 
(Alaaeddine et al., 1999, Furuzawa-Carballeda and Alcocer-Varela, 1999, 
Sellam and Berenbaum, 2010), other prostaglandins (Wittenberg et al., 1993, 
Benito et al., 2005) and leukotriene B4 (Atik, 1990, Wittenberg et al., 1993). 
Normally there is a balance between pro- and anti- inflammatory cytokines. 
This balance is further disrupted in OA by reductions in anti-inflammatory 
cytokines such as IL-4, IL-10, IL-13 and IL-1Ra (IL-1 receptor antagonist) 
(Furuzawa-Carballeda and Alcocer-Varela, 1999, Smith et al., 1997, Sutton et 
al., 2009). 
 
1.3.4 Enzymes 
 
Enzymes are responsible for the majority of degradation seen in osteoarthritis. 
These are mostly enzymes naturally involved in cartilage turnover, with the 
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enzymes most responsible being the MMP and ADAMTS families (Cawston 
and Wilson, 2006, Aigner et al., 2006). There is evidence that enzymes of the 
cathepsin family are also increased in OA (Konttinen et al., 2002, Hou et al., 
2002). A minor role in aggrecan degradation may be played by glycosidase 
enzymes (Pasztoi et al., 2009, Ortutay et al., 2003, Sugimoto et al., 2004). 
 
MMPs and ADAMTS are extracellular proteinase enzymes involved in ECM 
turnover throughout the body. The most important in OA are considered to be 
MMP-1 (Catterall and Cawston, 2003), MMP-3 (Sandell and Aigner, 2001), 
MMP-13 (Catterall and Cawston, 2003, Sandell and Aigner, 2001), ADAMTS-
4 (Sandell and Aigner, 2001, Davidson et al., 2006) and ADAMTS-5 (Sandell 
and Aigner, 2001, Davidson et al., 2006). The synovium and chondrocytes are 
both sources of these enzymes (Davidson et al., 2006, Goldring and 
Berenbaum, 2004). MMP-13 is considered to be highly important in OA as 
raised levels are found in patients and its preferential inhibition significantly 
reduces collagen cleavage (Sofat, 2009, Davidson et al., 2006, Billinghurst et 
al., 1997, Mitchell et al., 1996, Johnson et al., 2007). ADAMTS-5 is the most 
important aggrecanase (Glasson et al., 2005, Plaas et al., 2007) and is the 
enzyme primarily responsible for aggrecan release in OA (Little et al., 1999).  
 
Other MMPs and members of the ADAM (a disintegrin and metalloproteinase- 
enzymes closely related to ADAMTS) family have been implicated in 
osteoarthritis. These include MMP-2 (Aigner et al., 2006, Davidson et al., 
2006, Arican et al., 2000), MMP-7 (Aigner et al., 2006), MMP-8 (Aigner et al., 
2006, Sofat, 2009), MMP-9 (Davidson et al., 2006, Sofat, 2009, Arican et al., 
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2000), MMP-14 (Aigner et al., 2006, Davidson et al., 2006, Sofat, 2009), 
ADAM-10 (Aigner et al., 2006) and ADAM-15 (Aigner et al., 2006). 
 
TIMPs (tissue inhibitor of metalloproteinases) are natural regulators of MMP 
activity (Cawston and Wilson, 2006). Four TIMPs are known which have 
variable activities toward different MMPs (Le Graverand-Gastineau, 2010), 
and TIMP-3 is also active against ADAMTS-4 and ADAMTS-5 (Le 
Graverand-Gastineau, 2010). TIMP-1 is the most expressed TIMP in the joint 
(Davidson et al., 2006), and shows reduced expression in OA (Sandell and 
Aigner, 2001, Davidson et al., 2006). Increases in MMP levels overwhelm the 
capacity of TIMPs and this contributes to the degradation seen in OA. 
 
Due to their potency and to provide a greater control of their action most 
MMPs are secreted as proenzymes (Nagase et al., 2006). Activation of these 
pro-MMPs often occurs through the action of proteinases, including other 
MMPs and active versions of the same enzyme (Nagase et al., 2006, Dreier et 
al., 2004). Once the degradative state emerges in OA and if enzyme expression 
continues then a self-perpetuating, uncontrolled activation occurs.  
 
1.3.5 Synovial Inflammation 
 
Osteoarthritis is not considered to be an inflammatory arthritis. Inflammation 
is not a primary factor in the disease and no neutrophils are found in the 
synovium. Rheumatoid arthritis (RA) is an inflammatory arthritis and shows 
extensive neutrophil infiltrates.  
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In most osteoarthritis patients there are some signs of inflammation in the 
synovium (Hill et al., 2007, Pelletier et al., 2008, Haraoui et al., 1991). A 
magnetic resonance imaging study showed a thickening of the synovial lining 
cell layer in 73% of OA patients (Bonnet and Walsh, 2005). The inflammation 
varies with time and between individuals. For much of the time it may be 
localised and at sub-clinical levels (Myers et al., 1990, Bonnet and Walsh, 
2005), with acute flares occurring that can reach the inflammation levels seen 
in RA (Haraoui et al., 1991, Myers et al., 1990). 
 
Synovial inflammation may be initiated and driven by molecular fragments 
from cartilage destruction (Sellam and Berenbaum, 2010, Ghosh and Cheras, 
2001). These fragments can lead to the activation and proliferation of synovial 
lining cells (Hamerman and Klagsbrun, 1985, Aigner et al., 2006). Often a 
moderate synovial hyperplasia is seen in early OA which becomes a general 
synovitis as the disease progresses (Oehler et al., 2002, Aigner et al., 2006). 
 
Cytokines and other soluble factors are known to be important mediators of 
synovial inflammation. The inflamed synovial membrane is also an important 
source of cytokines and enzymes in osteoarthritis. Synovial macrophage 
depletion has caused a significant reduction in TNF-Į,/-1 and MMP levels in 
OA (Bondeson et al., 2006, Blom et al., 2007). 
 
([WHQVLYHLPPXQHFHOOLQILOWUDWLRQGRHVQ¶WRFFXULQ2$+RZHYHUWKHUHFDQEH
a scattered infiltration of the subsynovium (Nakamura et al., 1999, Sakkas and 
Platsoucas, 2007). This infiltration includes activated T cells, B cells and 
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macrophages (Nakamura et al., 1999, Benito et al., 2005, Sakkas and 
Platsoucas, 2007). Mast cells are naturally present in the joint to provide an 
immune response (Dean et al., 1993) and have been found to be increased in 
number and activated in OA (Dean et al., 1993). Mast cells may have a role in 
maintaining chronic synovitis in OA, as mast cell accumulation is associated 
with many chronic inflammatory conditions (Nigrovic and Lee, 2007).  
 
Synovial synovitis causes remodelling within the synovium. Angiogenesis is 
closely related to inflammation throughout the body and has been observed in 
inflamed osteoarthritic synovium (Walsh et al., 2007). This angiogenesis is 
driven by the proangiogenic factors VEGF (vascular endothelial growth factor) 
(Haywood et al., 2003), with a smaller contribution from HIF-1Į (hypoxia 
inducible factor-Į (Giatromanolaki et al., 2003). As VEGF causes tissue 
remodelling it causes increased expression of MMPs (Murata et al., 2008). 
Remodelling of the lymph system has also been observed in OA with lymph 
vessels extending further into the subintima (Xu et al., 2003). 
 
1.3.6 Chondrocytes 
 
Chondrocytes in OA can change from their quiescent form, and undergo 
apoptosis or aberrantly divide or gain an altered phenotype (Aigner et al., 
2001, Aigner et al., 2006). The most common phenotypic change is 
dedifferentiation as this can be induced by IL-ȕDQG71)-Į (Seifarth et al., 
2009, Aigner et al., 2006). Dedifferentiation causes chondrocytes to change 
into a more fibroblast like cell leading to changes in gene expression. Cartilage 
specific genes are no longer expressed and other genes are aberrantly 
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expressed (Aigner et al., 1997, Vondermark et al., 1977). For example collagen 
types I and III as well as tenascin have been detected in OA cartilage (Aigner 
et al., 1993, Salter, 1993). 
 
Abnormal proliferation of chondrocytes occurs in an attempt to repair cartilage 
and leads to cells in OA often being found in clusters (Aigner et al., 2001, 
Rothwell and Bentley, 1973). The accumulation of matrix components in 
chondrocytes can lead to their apoptosis (Horton et al., 2005, Yang et al., 
2005). There is an increased turnover of type VI collagen in OA (McDevitt et 
al., 1988, Buckwalter et al., 2005). This molecule helps to provide a protective 
layer around the chondrocytes, and its increased turnover be responsible for 
some of the changes seen in chondrocytes (Aigner et al., 2006). 
 
1.3.7 Reactive Oxygen Species 
 
Reactive oxygen species (ROS) are highly toxic oxygen species produced by 
metabolic processes in the mitochondria. In general they are free radicals and 
contain an unpaired electron, however some ROS such as hydrogen peroxide 
are not radicals (Volpi et al., 2009). Superoxide (O2
·-
) is a ROS that is 
produced in the mitochondria. The amount of superoxide radical in the cell is 
controlled by superoxide dismutase (SOD) which reduces it to hydrogen 
peroxide, which itself is eliminated by catalase or glutathione peroxidase 
(Afonso et al., 2007). If not controlled, superoxide and hydrogen peroxide can 
react together in the presence of transition metals to form the highly damaging 
hydroxyl (OH
·
) and peroxyl radicals (ROO
·
) (Afonso et al., 2007). 
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There is a plenty of evidence of ROS involvement in osteoarthritis. Measures 
of oxidative damage in cartilage increase with age and OA stage (Afonso et al., 
2007). This suggests that ROS and oxidative stress play a role in both OA and 
chondrocyte senescence (Henrotin et al., 2005). Further evidence comes from a 
greater SOD activity in OA synovial fluid, which as an inducible enzyme 
would suggest there are higher radical levels (Ostalowska et al., 2006). IL-ȕ
is known to deregulate cellular ROS defences (Mathy-Hartert et al., 2008). 
ROS are also associated with sites of inflammation as they are produced in the 
oxidative burst associated with phagocytosis (Afonso et al., 2007), and it is 
therefore likely that ROS have a role in maintaining the synovitis in OA. 
 
Another radical produced in cells is nitric oxide (NO
·
), which is a reactive 
nitrogen species that has an important role in cellular signalling. Nitric oxide is 
produced by the enzyme nitric oxide synthase (NOS), which has three 
isoforms: endothelial (eNOS), neuronal and inducible (iNOS). 
 
Chondrocytes express both eNOS and iNOS (Henrotin et al., 2005). TNF-Į
and IL-ȕ KDYH EHHQ IRXQG WR FDXVH RYHUH[SUHVVLRQ RI L126 LQ FKRQGURF\WHV
(Henrotin et al., 2005), with IL-ȕEHLQJPRUHSRWHQW (Mazzetti et al., 2001). 
Mechanical stress also induces NO production (Henrotin et al., 2005). These 
factors lead to increased levels of NO in osteoarthritis. NO has been found to 
inhibit collagen and proteoglycan synthesis (Henrotin et al., 2005, Mazzetti et 
al., 2001); activate MMPs (Mazzetti et al., 2001); induce chondrocyte 
apoptosis (Nesic et al., 2006, Mazzetti et al., 2001, Goldring and Berenbaum, 
2004); cause matrix stiffness and brittleness (Nesic et al., 2006); and cause 
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insensitivity to the anabolic effects of IGF-1 (Henrotin et al., 2005). There is 
some evidence that ROS may be more important in RA and that NO is more 
important in OA (Mazzetti et al., 2001).  
 
1.3.8 Synovial Fluid 
 
The major change seen in osteoarthritic synovial fluid is a reduction in 
concentration and mass of hyaluronic acid (Volpi et al., 2009). HA in OA is 
generally found at a concentration of 0.5-1.2 mg/ml (Praest et al., 1997, 
Yoshida et al., 2004), compared to around 3.6mg/ml in a healthy joint. The 
molecular weight of HA in healthy individuals is around 7 MDa weight 
average (Mw), and around 2 MDa number average (Mn) (Dahl et al., 1985). In 
OA these values are reduced to a molecular weight of around 5 MDa Mw, and 
around 0.5 MDa Mn (Dahl et al., 1985). The difference in these changes is 
caused by changes in the weight distributions of HA. There is a reduction in 
the number of the largest HA molecules and a large increase in smaller 
fragments (Dahl et al., 1985). There is also a high variation in HA distributions 
between patients. 
 
There are a number of potential explanations for these changes in OA. Firstly it 
has been found that the expression of hyaluronic acid synthase-2 (HAS-2) is 
reduced in OA (Momberger et al., 2005, Volpi et al., 2009, Bastow et al., 
2008). HAS-3 has been found to be upregulated by IL-ȕDQG7NF-Į(Volpi et 
al., 2009), but it produces lower weight HA (around 200kDa) and so would 
contribute to the reduced molar mass (Volpi et al., 2009). Also the level of 
hyaluronidase enzyme HYAL-2 is increased in OA (Yoshida et al., 2004). 
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ROS are also capable of breaking down HA, but the contribution of ROS to 
HA degradation is not well known (Volpi et al., 2009). In OA ROS levels are 
increased and cellular ROS defences are depleted, so it is therefore likely that 
ROS do make a significant contribution to HA degradation (Stern et al., 2007, 
Afonso et al., 2007, Nagaya et al., 1999). 
 
Increases in the volume of synovial fluid also occur in OA, but the magnitude 
of this change varies widely between patients. Volumes of synovial fluid have 
been found to range from just above normal to over 20 ml in some cases (Dahl 
et al., 1985, Balazs, 2009). Synovial inflammation increases the vascular 
permeability which causes a dilution of synovial fluid and allows proteins to 
enter more easily. Protein levels in inflamed joints are between 30 to 70% of 
those in plasma, compared to around 30% normally (Burt et al., 2009). This 
also leads to an increase in the relative abundance of globulins in OA synovial 
fluid (Larsen et al., 2008).  
 
These changes in synovial fluid act to drastically alter its properties. Healthy 
synovial fluid acts as a lubricating fluid at low shear rates but forms an elastic 
shock absorbing solid at higher shear rates (Gerwin et al., 2006, Mensitieri et 
al., 1995). In osteoarthritic synovial fluid these shock absorbing properties are 
lost, and these changes can be seen clearly in the rheology of the fluid, as 
shown in Figure 1-4. In healthy fluid at low frequencies of shear stress WKH*ƍƍ
(representing liquid properties) H[FHHGV WKH*ƍ (representing solid properties) 
and synovial fluid is liquid. At higher frequencies, which occur during physical 
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exercise, WKH*ƍ H[FHHGV WKH *ƍƍ meaning that the elastic properties dominate 
and it acts as a solid shock absorber. The cross-over point between *ƍand *ƍƍ 
shift to higher frequencies with age and OA. These frequencies come to exceed 
those naturally found (Balazs, 2009, Mensitieri et al., 1995). In OA the shock 
absorbing properties are lost, reducing the protective mechanisms in the joint 
and leading to an increase in damage. 
 
Figure 1-4 Rheology frequency sweeps of healthy, aged and osteoarthritic synovial fluid. 
Reproduced with kind permission from Springer Science and Business Media: (Mensitieri et 
al., 1995) © 1995 Chapman and Hall 
 
1.3.9 Osteophytes, Subchondral Bone Sclerosis and Capsular Fibrosis 
1.3.9.1 Osteophytes 
 
Osteophytes are aberrant growths of new bone thought to occur in an attempt 
to stabilise the degenerating joint. Their formation is driven by overexpressed 
anabolic cytokines. Exogenous application of TGF-ȕ DQG %03-2 (bone 
morphogenetic protein-2) caused osteophyte formation (Aigner et al., 2006, 
van Lent et al., 2004) showing that these cytokines are key mediators. 
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Osteophyte development starts with mesenchymal precursor cells following 
normal processes that occur during development to produce a structure that 
resembles adult articular cartilage (Aigner et al., 2006). However there are 
differences as osteophytes show no distinct transition between calcified and 
non-calcified cartilage and have a more random cell organisation. These 
factors suggest that the new tissue lacks the mechanical properties of the 
original. 
 
The fact that OA is a disease of the whole joint is highlighted by the fact that 
the depletion of synovial macrophages prevents osteophyte formation (van 
Lent et al., 2004). This shows that synovial cells play an essential role in this 
process, which could be due to synthesis and secretion of BMP-2 and BMP-4 
(Sellam and Berenbaum, 2010, van Lent et al., 2004, Blom et al., 2004). 
 
1.3.9.2 Subchondral bone sclerosis 
 
Subchondral bone sclerosis is a thickening and remodelling of the underlying 
bone (Aigner et al., 2006). There is some debate as to whether this remodelling 
acts as an effect (as is generally accepted) or is a cause of changes in cartilage 
(Aigner et al., 2006, Goldring and Goldring, 2007, Ge et al., 2006). Changes in 
the subchondral bone are evident in the early stages of osteoarthritis. Greater 
and more significant changes are seen in more developed OA focused below 
areas of cartilage destruction and include sclerosis, necrosis, formation of 
subchondral cysts and fibrosis in bone marrow (Aigner et al., 2006, Dijkgraaf 
et al., 1995). Where a total destruction of the cartilage has occurred, the bone 
plate becomes exposed and this can allow synovial fluid to enter the bone and 
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access the bone marrow. The synovial fluid induces changes in mesenchymal 
SUHFXUVRUFHOOVDQGOHDGVWRWKHGHYHORSPHQWRIFDUWLODJHµWXIWV¶ (Aigner et al., 
2006, Buckwalter and Martin, 2006). 
 
1.3.9.3 Capsular fibrosis 
 
Capsular fibrosis can occur in late stage osteoarthritis and is a thickening of 
collagen within the joint capsule, which is the structure that surrounds the joint 
to stabilise it. Capsular fibrosis is often responsible for the reduction in joint 
motion that occurs in osteoarthritis (Aigner et al., 2006).  
 
1.3.10 Vicious Cycle  
 
Advanced OA develops into a situation where a vicious cycle propagates and 
maintains the disease (Sofat, 2009). Matrix fragments in synovial fluid lead to 
the activation of chondrocytes and synoviocytes, causing the production of 
various factors such as TNF-Į ,/-ȕ DQG K\GURO\WLF HQ]\PHV (Benito et al., 
2005, Page Thomas et al., 1991, Sellam and Berenbaum, 2010). This is 
supported by evidence that collagen fragments upregulate chondrocyte 
expression of MMP-2, MMP-9 and MMP-13 (Fichter et al., 2006); Cathepsins 
B, L and K (Ruettger et al., 2008); IL-1ȕ, IL-6 and IL-8 (Klatt et al., 2009). 
These soluble factors cause further cartilage damage, releasing more fragments 
and thus propagating the cycle. The cycle can be further enhanced by the 
autocrine action of TNF-ĮDQG,/-ȕ(Sadouk et al., 1995). 
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1.4 Drug Treatments for Osteoarthritis 
1.4.1 Current Treatments 
 
A number of drug treatments are currently used against osteoarthritis, but none 
are able to cure this disease and reverse the joint damage. Current treatments 
focus on providing symptomatic relief by reducing pain as well as maintaining 
and increasing joint mobility. This reduces disability and improves the quality 
of life of sufferers. Disease modifying drugs, known as DMOADs (disease-
modifying OA drugs) have been, and continue to be, the subject of extensive 
research and more details on these are given in a following section. 
 
A number of non-pharmacological treatments are used for the treatment of 
osteoarthritis, including weight loss, exercise, transcutaneous electrical nerve 
stimulation, acupuncture and nutraceuticals (National Collaborating Centre for 
Chronic Conditions, 2008). Nutraceuticals are food supplements with potential 
health effects, but there is no evidence of any efficacy of these in OA. 
 
The most common first line treatments for osteoarthritis are paracetamol and a 
topical non-steroidal anti-inflammatory drug (NSAID). Paracetamol is 
preferred to an oral NSAID due to its better long term safety profile, 
particularly in relation to the gastric tract. If these treatments are not sufficient 
to relieve pain then an oral NSAID or cyclooxygenase (COX-2) inhibitor is 
usually considered. Further treatments include intra-articular steroids or 
hyaluronic acid. Opioids are used only when other treatments have failed or are 
FRQWUDLQGLFDWHG&DSVDLFLQWKHFKHPLFDOWKDWJLYHVFKLOOLSHSSHUVWKHLUµKHDW¶
is an alternative topical treatment that provides pain relief.  
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When all other treatments have been considered surgical options are available. 
A variety of surgical treatments have been used to treat osteoarthritis. These 
range from joint lavage to attempted joint repair to total joint replacement. 
Joint replacement has been shown to be a very effective last resort treatment 
and over 55,000 hip replacements were carried out in 2006/7 to treat 
osteoarthritis (National Collaborating Centre for Chronic Conditions, 2008). 
 
1.4.2 Intra-articular Delivery for Osteoarthritis 
1.4.2.1 Current treatments 
 
Intra-articular (IA) delivery is an attractive delivery route for OA and is 
currently utilised in main line therapy. OA is not a systemic disease and affects 
individual joints; therefore this form of local delivery targeted to joints where 
drug is needed reduces systemic exposure and side effects. The reduction of 
side effects is particularly important for OA as it is a chronic disease so there is 
a need for well tolerated long term treatments (Gerwin et al., 2006). Intra-
articular delivery avoids problems associated with other administration routes. 
 
Various steroid and hyaluronic acid formulations are approved for 
administration by IA injection (Gerwin et al., 2006). Corticosteroids are anti-
inflammatory drugs used to treat a wide variety of diseases and for OA provide 
relief from pain and inflammation. The chronic systemic administration of 
steroids can lead to severe side effects, such as diabetes, hypertension, 
glaucoma and cataracts. Therefore systemic delivery of these drugs is not used 
in OA and they are administered by IA injection (National Collaborating 
Centre for Chronic Conditions, 2008). Corticosteroids formulated as solutions 
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(e.g. dexamethasone phosphate) are rapidly removed from the synovial cavity. 
They have half-lives of only a couple of hours (Larsen et al., 2008) and are 
completely cleared within 5 days (Bias et al., 2001). Despite this rapid 
clearance, trials have found they can reduce pain for up to 4 weeks (Bellamy et 
al., 2005a). 
 
Suspension formulations (e.g. dexamethasone acetate, triamcinolone 
acetonide) have been used to increase the retention time of corticosteroid drugs 
within the joint (Derendorf et al., 1986). These suspensions are composed of 
drug crystals and only give a slight increase in retention time as they simply 
rely on their limited solubility (Bias et al., 2001, Derendorf et al., 1986). 
Crystals cause irritation or inflammation in the joint and they can even cause 
cartilage damage. Gout and pseudogout are known as crystal induced arthritis. 
Corticosteroid suspension formulations therefore have a closely controlled 
crystal size (around 20µm) to reduce the risk of damage (Derby et al., 2008). 
 
A Cochrane review on steroid injections for knee osteoarthritis concluded that 
there was proof of a reduction in pain for up to 3 weeks (Bellamy et al., 
2005a). The effectiveness of this treatment has also been shown in other joints 
such as the ankle (Ward et al., 2008). The risks associated with intra-articular 
administration have led the American College of Rheumatology to recommend 
a minimum of 3 months between intra-articular corticosteroid injections 
(Butoescu et al., 2009a, Clouet et al., 2009). In the UK corticosteroid injections 
are recommended only as an adjuvant therapy in moderate to severe pain 
(National Collaborating Centre for Chronic Conditions, 2008). 
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The other major intra-articular treatment for osteoarthritis is hyaluronic acid. 
This treatment was first proposed in the 1970s (Rydell and Balazs, 1971). The 
rationale was to restore the natural protective viscoelastic properties of 
synovial fluid which are lost in osteoarthritis, which has led to this treatment 
also being known as viscosupplementation. A number of HA preparations for 
IA injection are marketed and these have various molecular weights. There are 
also a number of cross linked preparations available. A summary of different 
hyaluronic products for osteoarthritis is given in Table 1-1. 
Trade Name Molecular weight  
(kDa) 
Cross-Linking Manufacturer 
Hyalgan
®
 500-730 No Fidia (Italy) 
Artz
®
/ 
Supartz
®
 
600- 1,200 No 
 
Seikagaku (Japan) 
Othrovisc
®
 1,000 -2,900 No Anika Therapeutics 
(USA) 
Euflexxa
®
 2,400-3,600 No Ferring 
Pharameuticals 
(USA) 
Fermathron
®
 1,000 average No Biomet (Belgium) 
Synvisc-One
®
 
(Hylan GF-20) 
6,000 average Yes Genzyme (USA) 
Monovisc
®
 High Yes Anika Therapeutics 
(USA) 
Durolane
®
 N/A Yes Q-Med (Sweden) 
Gel-One
®
 N/A Yes Seikagaku (Japan) 
Table 1-1 Marketed intra-articular hyaluronic acid treatments. 
Information on cross-linking taken from (Prestwich and Kuo, 2008). 
 
A Cochrane review on viscosupplementation in the knee found similar benefits 
to NSAIDs and a prolonged effectiveness compared to corticosteroids for up to 
13 weeks (Bellamy et al., 2005b). This period of effectiveness is despite the 
rapid clearance of HA, which is not quite as fast as the clearance of small 
molecules. For example Hyalgan has a half-life of 17 hours and the high 
molecular weight component of Synvisc has a half-life of around 9 days in the 
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joint (Brandt et al., 2000). HA injections are not available on the National 
Health Service in the UK due to the costs of this treatment (National 
Collaborating Centre for Chronic Conditions, 2008). 
 
There is in vitro evidence that HA has anti-inflammatory and 
chondroprotective effects (Moreland, 2003). With these effects there could be 
a disease modifying effect of HA; however clinical trials have found no such 
effect (Pelletier and Martel-Pelletier, 2007). 
 
1.4.2.2 Challenges for intra-articular delivery 
 
Intra-articular administration has a number of challenges. One of the greatest is 
the rapid clearance that occurs from the synovial cavity. Molecules that are 
smaller than around 500 Daltons have a half-life of around an hour in the joint 
(Larsen et al., 2008). This rapid clearance can be seen in the fact that after 
intra-articular injection drug can be detected in blood plasma within an hour 
(Bias et al., 2001). Larger molecules are resident for longer but are still cleared 
within a few hours (Larsen et al., 2008). 
 
Intra-articular delivery is a physically tricky route for administration. Even 
with experienced practitioners there is the risk of infection or that the injection 
will be incorrectly sited. The correct localisation of injections can be ensured 
by using imaging techniques (Schumacher, 2003), however this increases the 
cost and complexity. Aspiration of synovial fluid before IA injection is an 
easier way to ensure correct localisation and is beneficial as it reduces oedema 
in the joint, reducing the pressure and discomfort (Schumacher, 2003, Jones et 
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al., 1993). Good sterile practice and avoidance of injecting through inflamed 
skin can reduce the risk of infection to acceptable levels (Jones et al., 1993, 
Gerwin et al., 2006). These challenges mean that it is recommended to limit 
the frequency of administration by intra-articular injection, which creates a 
currently unmet need for sustained release formulations (Burt et al., 2009). 
 
1.4.2.3 Drug delivery systems for intra-articular delivery 
 
Various advanced drug delivery systems for intra-articular delivery have been 
investigated. A summary of systems is given in Table 1-2 and includes 
nanoparticles, microspheres and liposomes. These systems have followed four 
main methods to improve drug delivery. The first was to target the system for 
uptake by synovial macrophages to avoid release to the systemic circulation. 
The other three methods attempt to provide a sustained drug release. Firstly 
this was achieved by increasing the residence time in synovial fluid, which in 
the majority of cases was done by using particles too large to be taken up by 
phagocytosis. The other two methods were to produce systems that adhere to 
or penetrate the cartilage matrix or the synovium. The most interesting systems 
and results are described in more detail below. 
 
Intra-articularly administered liposomes are taken up by phagocytosis (Blom et 
al., 2007, Bias et al., 2001). One intra-articular liposome formulation under the 
trade name of Lipotalon
® 
has been approved for use in human therapy in 
Germany. It consists of dexamethasone 21-palmitate in lecithin coated vesicles 
of around 200nm in diameter (Bias et al., 2001). This liposome therapy can 
 35 
cause a reduction in pain for 28 days, but the drug is not detected in serum 
beyond 5 days (Bias et al., 2001). 
 
Particulate based drug delivery systems for intra-articular delivery have 
focused mainly on microparticles designed to avoid phagocytosis through their 
size. Studies have shown that the size limit for phagocytosis in the joint is 
around 10 to 15µm (Butoescu et al., 2009b, Liggins et al., 2004, Greis et al., 
1994). Latex particles of 15µm were sparingly taken up by a minority of cells 
and 45µm particles were not taken up at all (Greis et al., 1994). 
 
Various materials used in the production of particles have been found to be 
compatible in the joint; PLGA (poly(lactic-co-glycolic acid)) (Burt et al., 2009, 
Mountziaris et al., 2010), PLLA (poly(L-lactic acid)) (Burt et al., 2009, 
Ratcliffe et al., 1984), and albumin (Burt et al., 2009, Ratcliffe et al., 1984) 
were all well tolerated within the joint. Some materials are not well tolerated, 
for example certain synthetic materials caused collagenase synthesis which 
would lead to further joint damage (Greis et al., 1994). Injected particles have 
been found in general to penetrate or associate to the synovium (Ratcliffe et al., 
1987, Burgess and Davis, 1988, Mountziaris et al., 2010).  
 
Other approaches have been used to increase residence time in the joint. One 
example is a system containing magnetic iron nanoparticles that were retained 
in the joint using magnets (Schulze et al., 2005). Another system used cartilage 
adhesive nanoparticles (Rothenfluh et al., 2008). These particles used a 
cartilage binding peptide and 38nm particles were found to penetrate and bind 
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the cartilage matrix (Rothenfluh et al., 2008), however the particles were only 
followed for 96 hours in vivo and there was no investigation with any drug.  
 
Some more complex systems have also been investigated and are included at 
the end of Table 1-2. These include a system described as lipogelosomes, 
which contained liposomes within a carboxymethyl cellulose (CMC) hydrogel 
(Turker et al., 2005), but this system gave only a moderate increase in retention 
time. Another system used elastin-like polymers that thermally aggregate to 
form a depot after injection (Betre et al., 2006), however this system has not 
yet been loaded with drug. 
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References 
(Horisawa et 
al., 2002a) 
(Schulze et al., 
2005) 
(Rothenfluh et 
al., 2008) 
(Ishihara et al., 
2009) 
(Horisawa et 
al., 2002b) 
(Ratcliffe et 
al., 1984) 
(Butoescu et 
al., 2009) 
Results 
In vitro release over 20 days,  
21 day reduction in inflammation 
in rabbits 
External magnets used to retain 
particles in joint 
36nm penetrate cartilage and are 
retained, 
96nm are held in cartilage surface 
layers 
Inflammation reduced for 9 days 
in rats 
Nanospheres phagocytosed, 
Microparticles adhere to synovial 
membrane surface  
Albumin well tolerated in rabbits, 
Others caused some inflammation 
Taken up by phagocytosis, 
No inflammation in joint 
Size 
300-500nm 
Undefined 
38nm or 
96nm 
51 - 178nm 
265nm/25µm 
1 - 10µm 
1 or 10µm 
Drug 
Betamethasone 
phosphate 
Fluorescent label 
Fluorescent label 
Betamethasone 
phosphate 
Fluorescent label 
None 
Dexamethasone 
Materials 
PLGA 
PVA 
Iron NPs 
PPS and 
Pluronic F127 
with collagen 
binding peptide 
PEG-PLGA 
PLGA 
PLA, PBCA, 
gelatin or albumin 
PLGA 
Iron oxide NPs 
System 
Nanoparticles 
Nanoparticles 
Nanoparticles 
*Nanoparticles 
Nano/microparticles 
Microparticles 
Microparticles 
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References 
(Ramesh et al., 
1999) 
(Burgess and 
Davis, 1988) 
(Ratcliffe et al., 
1987) 
(Nishide et al., 
1999) 
(Bozdag et al., 
2001) 
(Brown et al., 
1998) 
(Tuncay et al., 
2000b) 
Results 
In vitro release over 10 days, 
Drug recovered from particles after 
7 days in joint 
Release in rabbit joint over 10 days, 
Particles located to synovium 
surface not phagocytosed 
Release in joint over 7 days, 
Particles localise to synovium 
All microspheres localised to fat,  
Particles degrade in 5 to 14 days 
depending on polymer mw in rabbit, 
No inflammation in joint 
In vitro release over 5 days for 
PLGA and 8 hours for albumin 
In vitro release over 48 h, 
Non inflammatory 
In vitro release over 7 days 
Size 
40-60µm 
90-110µm 
23µm 
3.5µm 
Under 20µm 
20 - 100µm 
PLGA 9µm 
Albumin 10µm 
10µm 
15µm 
Drug 
Dexamethasone 
Prednisolone 
Triamcinolone 
Radiolabel 
Fluorescent 
label 
Naproxen 
Proteins 
Diclofenac 
Materials 
PDLLA 
Albumin 
Albumin 
PDLLA 
PLGA 
Albumin 
Gelatin and 
Chondroitin 
sulfate 
Albumin 
System 
Microparticles 
Microparticles 
Microparticles 
Microparticles 
Microparticles 
Microparticles 
Microparticles 
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References 
(Tuncay et al., 
2000a) 
(Thakkar et al., 
2004a) 
(Thakkar et al., 
2004b) 
(Saravanan et al., 
2011) 
(Lu et al., 2007) 
(Bragdon et al., 
2001) 
(Liggins et al., 
2004) 
(Liang et al., 2005, 
Liang et al., 2004) 
(Mumper et al., 
1992) 
Results 
In vitro release over 5 days 
In vitro release over 5 days, 
Anti-inflammatory in rats over 18 days 
In vitro release over 4 days, 
Celocoxib detected in blood for over 24h 
In vitro release over 30 days 
In vitro release over 24 hours, 
MRT in rabbit joint  increase 10 fold 
Increased transynovial fluid flow in horse, 
Minimal inflammation seen 
In vitro release over 28 days, 
Reduced inflammation in rabbit 
In vitro release over 24h, 
No difference in plasma compared to free drug 
High retention in rabbit joints over 5 days, 
No uptake to lymph nodes 
Size 
5 - 10µm 
8 - 12µm 
8 - 16µm 
37 - 46µm 
3 - 12µm 
50µm 
10-35µm 
35-105µm 
77µm 
2 - 13µm 
Drug 
Diclofenac 
Celocoxib 
Celecoxib 
Diclofenac 
Flubioprofen 
Paclitaxel 
Paclitaxel 
Methotrexate 
Radionuclide 
Materials 
PLGA 
Chitosan 
Chitosan 
Gelatin 
Gelatin 
PLGA 
PLGA 
PLLA 
PLLA 
PLLA 
System 
Microparticles 
Microparticles 
Microparticles 
*Microparticles 
*Microparticles 
*Microparticles 
*Microparticles 
*Microparticles 
*Microparticles 
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References 
(Mountziaris et 
al., 2010) 
(Mountziaris et 
al., 2011) 
(Elron-Gross et 
al., 2009) 
(Lopez-Garcia et 
al., 1993) 
(Silva et al., 
1979) 
(Monkkonen et 
al., 1995) 
(Ceponis et al., 
2001) 
(Barrera et al., 
2000) 
(Williams et al., 
1996) 
Results 
Particles retained in synovial lining and 
well tolerated in rats 
In vitro release over about 14 days 
Bioadhesive liposomes, 
Reduced inflammation in rats over 17 days 
Prolonged retention in joint compared to 
free drug over 24 hours 
Anti-inflammatory effect for 14 days in RA 
patients 
Anti-inflammatory and protected 
cartilage in rabbit arthritis model with 
weekly injections 
Macrophage depletion in RA patients. 
Anti-inflammatory effect for 21 days 
Size 
20µm 
29 - 34µm 
Undefined 
Undefined 
Undefined 
160 - 180nm 
120 - 160nm 
1.2µm 
Drug 
Fluorescent label 
siRNA  
PEI 
Dexamethasone 
Diclofenac 
Triamcinolone 
acetonide 
21-palmitate 
Cortisol  
21-palmitate 
Clodronate 
Clodronate 
Lipid conjugated 
methotrexate 
Materials 
PLGA 
PLGA 
 
Lipid with HA 
or collagen 
Mixed lipids 
Mixed lipids 
Mixed lipids 
PC and 
cholesterol 
Various lipids 
System 
**Microparticles 
**Microparticles 
Liposomes 
*Liposomes 
*Liposomes 
*Liposomes 
*Liposomes 
*Liposomes 
 
4
1
 
 
References 
(Inoue et al., 2006) 
(Turker et al., 
2005) 
(Mierisch et al., 
2002) 
(Kim et al., 2011) 
(Betre et al., 2006) 
(Pedersen et al., 
2011) 
Results 
Retention in rabbit joint over 7 
days 
In vitro release over 2 days, 
Half-life in joint of over 24h 
In vitro release over 5 days 
In vitro and in vivo release 
over 28 days, 
Reduction in cytokine levels. 
Aggregating polymer was 
retained in joint 25 times 
longer than non-aggregating 
Peptides precipitate in water to 
form depot 
Size 
70µm 
250nm 
Undefined 
Undefined 
Undefined 
Undefined 
Drug 
bFGF 
Radiolabel 
TGF-ȕ 
Dexamethasone 
None 
None 
Materials 
Gelatin 
Liposomes in 
CMC gel 
Calcium 
alginate 
HA-tyramine 
H2O2 and HRP 
Elastin-like 
polypeptides 
Modified 
peptides 
System 
Hydrogel 
microparticles 
*Lipogelosomes 
Hydrogel 
*Hydrogel 
Thermal 
aggregates 
In situ 
precipitates 
  
Table 1-2 Intra-articular drug delivery systems.  
* designates system that was designed for RA ** designates system that was designed for temporomandibular joint disorders. Abbreviations used in 
table: bFGF- basic fibroblast growth factor; CMC- carboxymethyl cellulose; HA- hyaluronic acid; HRP- horseradish peroxidise; MRT- mean 
retention time; mw- molecular weight; NP- nanoparticle; PBCA- poly(butylcyanoacrylate); PC- phosphatidylcholine; PDLLA- poly(DL-lactic acid); 
PEG- (poly(ethylene glycol); PEI- poly(ethyleneimine); PLA- poly(lactic acid); PLGA- poly(lactic-co-glycolic acid); PLLA- poly(L-lactic acid); 
PPS- poly(propylene sulphide); PVA- poly(vinyl alcohol); RA- rheumatoid arthritis; siRNA- small interfering ribonucleic acid; TGF ȕ- 
transforming growth factor-beta. 
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1.4.3 Disease Modifying Drugs for Osteoarthritis 
 
Currently there are a lack of treatments for osteoarthritis that have a disease 
modifying effect (DMOAD) either by slowing disease progression or reversing 
changes that have already occurred. The effectiveness of any DMOAD could 
also be increased by earlier diagnosis and treatment (Qvist et al., 2008). OA is 
generally diagnosed once significant changes have occurred within the joint. 
Improvements in imaging techniques such as MRI (magnetic resonance 
imaging) (Burstein, 2006), or the identification of suitable biomarkers would 
allow for improved early diagnosis of OA (Pollard et al., 2008). 
 
1.4.3.1 DMOAD potential of current treatments 
 
There has been evidence that some current treatments can have a disease 
modifying effect. For example in vitro corticosteroids have been shown to 
inhibit production of IL-1, TNFĮDQGL126 (Pelletier et al., 2001, Tung et al., 
2002). Reductions in these key cytokines have the potential to exert a disease 
modifying effect, however clinical trials have found no evidence of this. A 
similar situation has been found with NSAIDs (Jiang et al., 2010). 
 
Effectiveness in OA animal models has often not translated to success in 
clinical trials. The animal models used may be partly to blame for this, as OA 
models mostly focus on recreating the cartilage damage seen (Bonnet and 
Walsh, 2005) and ignore the contributions of other structures within the joint. 
 
It is also challenging to prove a disease modifying effect in OA clinical trials. 
The regulatory guidelines to establish DMOAD efficacy are primarily focused 
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on joint space narrowing (JSN) (Hogenmiller and Lozada, 2006). JSN has a 
high deviation between patients (Le Graverand-Gastineau, 2010) but changes 
very slowly; the average change is 0.1mm/year (Hogenmiller and Lozada, 
2006). This slow change can lead to control groups undergoing such a small 
progression that it is not possible for a statistically significant improvement to 
be seen (Le Graverand-Gastineau, 2010). To overcome these problems clinical 
trials using JSN need large numbers of subjects and a long time frame, both of 
which increase costs (Le Graverand-Gastineau, 2010). Advances in MRI 
imaging techniques allow detailed imaging of the joint and give hope that more 
accurate measurements can be used in the future (Burstein, 2006). 
 
1.4.3.2 Novel DMOADs 
 
Novel DMOADs have targeted a number of systems, and include inhibitors of 
MMPs, iNOS, Cathepsin K and cytokine signalling. The recent history of 
DMOADs has been dominated by failed drugs. 
 
A good example of this is the field of MMP inhibitors (MMPi). These drugs 
have the potential to treat a number of diseases and have been the focus of 
much research. Safety problems have caused the termination of some clinical 
trials, with the main problem having been unexplained muscle pain (Cawston 
and Wilson, 2006). In other trials the in vitro promise has again failed to 
translate to benefits in clinical trials (Catterall and Cawston, 2003, Rengel et 
al., 2007). The search for MMP inhibitors continues due their huge therapeutic 
potential, and novel strategies are being pursued to produce more specific 
inhibitors. In OA, MMP-13 is an obvious target due its high expression and 
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novel specific MMP-13 inhibitors have been produced (Johnson et al., 2007, Li 
et al., 2011). 
 
Interfering in cytokine signalling is another approach that has been 
investigated and can be achieved in a number of ways including using 
neutralising soluble factors, receptor blockade or blocking intercellular 
signalling pathways. TNF-ĮQHXWUDOLVLQJDntibodies have been successful in the 
treatment of RA, but have caused little or no improvement in OA trials (Qvist 
et al., 2008). Blockade of the IL-1 receptor with the drug anakinra is utilised 
for the treatment of RA, but clinical trials in knee OA found no significant 
benefit (Clouet et al., 2009, Qvist et al., 2008, Chevalier et al., 2009). 
 
Potential drugs with DMOAD activity are currently undergoing clinical trials. 
Pfizer currently has an inhibitor of iNOS (SD 6010) in phase II trials with 
results due in 2012. Medivir has two candidate cathepsin K inhibitors (MIV-
710 and MIV-711) in preclinical development. Compounds with aggrecanase 
inhibitory activity are also in preclinical development (Le Graverand-
Gastineau, 2010, De Rienzo et al., 2009, Shiozaki et al., 2011). OA is a 
complex disease and it is likely that MMPs, aggrecanases and cathepsins are 
all involved in the degradation seen (Nagase and Kashiwagi, 2003). It may 
prove that combinations of inhibitors are required for successful therapy. 
 
A number of biological molecules with potential DMOAD action have been 
identified. These include the anti-inflammatory cytokines IL-10 (Pelletier et 
al., 2001) and IL-6 (Sellam and Berenbaum, 2010); as wells as osteogenic 
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protein 1 (Le Graverand-Gastineau, 2010); human growth hormone (Dunn, 
2010); BMP-7 (Hayashi et al., 2010); and lubricin (Le Graverand-Gastineau, 
2010, Bao et al., 2011). 
 
1.4.3.3 DMOAD potential of other drugs  
 
Drugs for other conditions have been investigated for potential DMOAD 
activity, for example some drugs have been found to have MMP inhibitory 
activity. Tetracyclines were developed as antibiotics but have been found to 
possess MMP inhibitory activity (Pelletier et al., 2001, Catterall and Cawston, 
2003). This inhibition is thought to be due to the ability of the tetracyclines to 
chelate the zinc in the MMP active site (Pelletier et al., 2001). Doxycycline 
hyclate is the only current FDA (Food and Drug Administration) approved 
MMPi treatment and is used for peridontitis (Catterall and Cawston, 2003, Li 
et al., 2011). 
 
For osteoarthritis minocycline and doxycycline have been shown to inhibit 
expression of MMP-1, MMP-3, aggrecanases and iNOS in chondrocytes and 
synoviocytes (Pelletier et al., 2001). However the only clinical trial undertaken 
has led to doxycycline not being recommended for OA treatment as it showed 
a minimal effect that was outweighed by safety concerns (Nuesch et al., 2009).  
 
Bisphosphonates were first used as a bone protective therapy (Catterall and 
Cawston, 2003). Tiludronate has been shown to inhibit MMP-1 and MMP-3 
(Catterall and Cawston, 2003). Intra-articularly delivered clodronate loaded 
liposomes deplete the synovial macrophages and cause reductions in 
 46 
expression of IL-ȕ71)-Į12003DQGFDUWLODJHGDPDJH (Barrera et al., 
2000, Blom et al., 2007, van Lent et al., 2004, Monkkonen et al., 1995, 
Ceponis et al., 2001). A clinical trial for clodronate in knee OA found it give a 
similar level of symptomatic relief as intra-articular HA (Rossini et al., 2009), 
however no assessment of DMOAD activity was made. 
 
Calcitonin is a thyroid hormone involved in calcium and phosphorous 
homeostasis which inhibits osteoclast bone resorption leading to its use as a 
treatment for osteoporosis (Le Graverand-Gastineau, 2010, Sondergaard et al., 
2010). It has also been shown to have chondroprotective properties in animal 
models (Qvist et al., 2008, Sondergaard et al., 2010, Karsdal et al., 2006). Two 
phase III trials for knee OA using oral formulations of salmon calcitonin are 
currently under way with results due shortly (Le Graverand-Gastineau, 2010, 
Qvist et al., 2008, Holm-Bentzen et al., 2010). 
 
1.5 Plan for Delivery System  
 
At the outset of this project the aim for this thesis was to investigate advanced 
delivery systems for osteoarthritis, with a focus on a targeted or 
environmentally activated delivery. Intra-articular injection is an established 
delivery route for osteoarthritis (Gerwin et al., 2006). It is a form of local 
delivery and therefore has a level of targeting by drug only being administered 
to diseased joints. However this delivery route has a number of challenges that 
are yet to be overcome (Burt et al., 2009). An advanced delivery system could 
therefore improve the efficacy of this delivery route for osteoarthritis.  
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The main challenge is the rapid clearance experienced from the synovial 
cavity. Also the American College of Rheumatology guidelines recommend a 
period of at least three months between IA steroid administrations. Together 
these factors have led to an unmet need for sustained release formulations. A 
delivery system that provided drug release over a three month period would 
improve the therapy available for osteoarthritis. This period is far greater than 
has currently been achieved (Kim et al., 2011). 
 
The period of delivery desired in this project exceeds what is possible from a 
particle based delivery systems and is also unlikely to be achieved with a 
hydrogel directly retaining drug. This project will therefore investigate an 
injectable hydrogel that contains a nanoparticle drug delivery system. The 
hydrogel will retain the nanoparticle system within the joint and allow a 
sustained release to occur over three months. 
 
1.6 Introduction to Hydrogels and Injectable Hydrogels 
1.6.1 Hydrogels 
 
Hydrogels are defined as colloidal gels where water is the dispersion medium, 
or as swollen macromolecular networks in water (Berger et al., 2004). 
Hydrogels can be formed by many substances but for this project only polymer 
hydrogels will be considered. Hydrogels have an extremely high water content 
of up to 99% and can vary from rigid to quite liquid-like (Hoffman, 2002). 
Hydrogels can be stabilised by physical and chemical means, including 
covalent cross linking, ionic bonding, hydrogen bonding, amphipathic 
stabilisation or by forming an interpenetrating network (IPN) (Hoffman, 2002). 
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IPNs are a strongly entangled combination of two polymers both in individual 
networks (Sperling and Mishra, 1996). 
 
Of particular interest in this project are injectable hydrogel systems and 
polyelectrolyte complexes, which can produce resilient hydrogels. These 
systems will both be introduced in more detail below. 
 
1.6.2 Injectable Hydrogels 
 
To allow administration of the proposed delivery system an injectable hydrogel 
is required. The most common approaches that have been investigated for 
producing injectable hydrogels are in situ polymerisation (Jagur-Grodzinski, 
2010, Yu and Ding, 2008), in situ cross-linking (Jagur-Grodzinski, 2010, Yu 
and Ding, 2008) and stimuli responsive polymers (Yu and Ding, 2008, 
Alexander and Shakesheff, 2006, Bajpai et al., 2008). Other approaches 
include the co-injection of polymers to form an IPN (Barbucci et al., 2010), 
stereocomplexation between different enantiomers (Jeong et al., 2002) or the 
action of enzymes to produce hydrogels (Chen et al., 2003). 
 
Chemical methods for the in situ polymerisation and in situ cross-linking have 
issues with biocompatibility. Polymerisation methods have focused on free 
radical polymerisations initiated by photosensitive or thermally sensitive 
initiators (Yu and Ding, 2008, Jeong et al., 2002). Cross-linking methods 
require additional cross linking agents or the use of polymers with highly 
reactive groups (Hoffman, 2002). All of these have the potential to cause 
damage in the body and so their biocompatibility is questionable.  
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Polymers that are responsive to many stimuli have been synthesised, including 
pH, temperature and ionic conditions. To produce an injectable system an 
obvious stimulus to utilise is temperature. A number of thermogelling 
polymers have been investigated, which include natural polymers such as 
cellulose derivatives (Ruel-Gariepy and Leroux, 2004), and synthetic polymers 
such as Pluronics (Ruel-Gariepy and Leroux, 2004, Yu and Ding, 2008), 
PLGA (Ruel-Gariepy and Leroux, 2004), PEG-PLGA (Yu and Ding, 2008), 
PNIPAM (poly(N-isopropylacrylamide)) (Jagur-Grodzinski, 2010, Ruel-
Gariepy and Leroux, 2004). 
 
1.6.3 Polyelectrolyte Complexes 
1.6.3.1 Introduction to polyelectrolyte polymers 
 
The term polyelectrolyte is applied to any polymer that has an ionisable group 
within its repeating unit. In aqueous solution polyelectrolytes undergo 
dissociation, which can be full or partial, to give repeating charges. It is 
possible for a polyelectrolyte to have mixed positive and negative charges on a 
single polymer chain. 
 
Polyelectrolyte solutions have unique properties due to their charges. Neutral 
polymers tend to have a random coil conformation in solution. The repulsive 
charges mean that polyelectrolytes often have a more extended and rigid 
structure. This structure can affect many other properties of the solution such 
as viscosity. Polyelectrolyte polymers are common in nature; for example 
nucleic acids contain a repeating phosphate group so are an anionic 
polyelectrolyte and polypeptides are mixed charge polyelectrolytes. 
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1.6.3.2 Polyelectrolyte complexation 
 
Mixing polymer solutions often results in immiscibility and phase separation 
(Harding et al., 1995). Phase separation can result from a segregation of the 
polymers into the different phases or the collection of the polymers into a 
polymer rich phase (Harding et al., 1995). The mixing of different 
polyelectrolyte solutions is no different and phase separation is common. This 
study will focus on complexation between oppositely charged polyelectrolytes. 
 
The mixing of oppositely charge polyelectrolyte solutions results in the 
formation of a polymer rich phase. This is caused by attractions between the 
polymers and can be described as associative phase separation or complex 
coacervation (Harding et al., 1995). Strong electrostatic interactions between 
oppositely charged polymers promote their association. However the close 
association of polymer chains restricts movement and causes an entropic 
barrier. The association of polymers also causes the release of associated 
counterions which become free to move. There are many of these ions and so 
the increase in their entropy balances the losses from polymer association 
(Harding et al., 1995). 
 
Phase separation can form different structures under different conditions. 
When there is a low overall charge in solution an insoluble polyelectrolyte 
complex network can form (Berger et al., 2004, Hamman, 2010). At high 
overall charge, such as when there is a large imbalance in the polymer 
concentrations, soluble small polyelectrolyte particles can form (Garnett, 1999, 
Hamman, 2010, Kabanov and Kabanov, 1998, Lee et al., 1997). 
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Polyelectrolyte particles have been utilised in drug and gene delivery (Garnett 
et al., 2009, Brown et al., 1998, Wu et al., 2007, Kabanov and Kabanov, 1998). 
 
For the intended application as a slow release delivery system it is desired to 
form a precipitated polyelectrolyte complex network. These will be referred to 
as polyelectrolyte complexes through the rest of this thesis. These 
polyelectrolyte complexes have many similarities to hydrogels, however as 
they are precipitates they cannot be strictly considered to be hydrogels. 
 
The production and stability of polyelectrolyte complexes is influenced by 
many different factors, with the most important factor being pH as both 
polymers must ionised for complexation to occur (Berger et al., 2004). 
Temperature, the ratio of polymers/charges (Hamman, 2010), molecular 
weight of the polymers (Hamman, 2010, Harding et al., 1995), polymer charge 
density (Hamman, 2010) and other ions present (Berger et al., 2004, Harding et 
al., 1995) can all affect the formation and stability of polyelectrolyte 
complexes. Salt ions can be highly disruptive to polyelectrolyte complex 
formation as the ions shield the polymer charges and prevent long range 
interactions. There is also a reduction in the counterion effect as there are more 
ions present in solution (Harding et al., 1995). A thorough mixing is required 
for a good complex formation (Hamman, 2010), and to achieve optimal 
complex formation mixing needs to be conducted under conditions where 
interaction does not occur (Berger et al., 2004). 
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Polyelectrolyte complexes have been found to be generally biocompatible (Lee 
et al., 1999). Polyelectrolyte complexes have been investigated for a number of 
applications including as membrane materials for drug release (Berger et al., 
2004, Lee et al., 1997); as medical materials for implants (Berger et al., 2004); 
for the isolation of proteins and nucleic acids (Dumitriu and Chornet, 1998); 
for wound healing and tissue engineering scaffold materials (Sechriest et al., 
1999, Suh and Matthew, 2000). 
 
1.7 Introduction to Nanoparticle Drug Delivery Systems 
1.7.1 General Introduction 
 
Colloidal drug delivery systems have been widely investigated for their 
potential to improve delivery of a variety of drugs. Drugs encapsulated within 
a colloidal carrier can provide a sustained or targeted drug delivery. There are 
many systems that fit within the category of colloidal carriers and the most 
commonly investigated systems are liposomes, polymer micelles and polymer 
nanoparticles (Johnston et al., 2011). Liposomes are a very successful drug 
delivery system and a number of liposomal formulations are on the market for 
cancer treatment (Johnston et al., 2011). Liposomes can however have 
problems with leakage and long term stability (Johnston et al., 2011). For these 
reasons a polymeric nanoparticle system was chosen for use in this project and 
an introduction to these systems is given below. 
 
1.7.2 Nanoparticle Drug Delivery Systems 
 
Particulate drug delivery systems are composed of polymer with drug 
entrapped within the polymer matrix or adsorbed onto the particle surface. 
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These particles can be formulated in a variety of sizes, but are generally in the 
micrometre to nanometre size range. Two key parameters in a particle delivery 
system are the polymer used and the formation method. These two factors can 
affect the drug loading and drug release of the particles. 
 
1.7.2.1 Polymers 
 
The polymer used for a drug delivery system must be biocompatible and have 
no toxic degradation products. A wide range of natural and synthetic polymers 
have been investigated for particulate systems, with the most common 
polymers being PLA (poly(lactic acid)), PLG (poly(glycolic acid)) and their 
copolymer PLGA (poly(lactide-co-glycolide) (Brewer et al., 2011). Many 
other polymers have also been investigated including poly(caprolactone) 
(Brewer et al., 2011, Rao and Geckeler, 2011), poly(alkylcyanoacrylate) (Rao 
and Geckeler, 2011, Cai and Xu, 2011) and poly(orthoesters) (Puri, 2007). 
 
1.7.2.2 Particle preparation 
 
Many methods have been investigated and used for the production of 
polymeric particles. The two methods most widely used are the emulsification 
solvent evaporation method and the interfacial deposition method. Other 
methods that have been used include spray drying, salting out and methods 
using supercritical carbon dioxide (Rao and Geckeler, 2011). 
 
The emulsification solvent evaporation method uses a water immiscible 
solvent to dissolve the polymer, which is emulsified into an aqueous phase 
containing surfactant. The organic solvent is evaporated causing the formation 
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of small polymer particles. This method was originally described by Beck et al 
(Beck et al., 1979) and has been widely used since (Rao and Geckeler, 2011). 
The main drawbacks are that particles cannot be produced without the presence 
of surfactant and residual organic solvent always remains. 
 
The interfacial deposition method uses a water miscible solvent to dissolve the 
polymer. This is added drop wise to an aqueous phase in which the polymer is 
insoluble. The rapid diffusion of solvent into the aqueous phase causes a 
decrease in interfacial tension, and there is also an increased interfacial surface 
area due to turbulence from magnetic stirring. Together this causes the 
formation of small solvent droplets without high speed mechanical mixing. 
This method has also been widely used and can be used to produce particles 
with or without surfactant present (Fessi et al., 1989). A disadvantage of this 
method is that it can give poor entrapment of water soluble drugs due to the 
accessible aqueous phase (Mishra et al., 2010). 
 
1.7.2.3 Drug loading 
 
The incorporation of drug into polymeric nanoparticles is a key factor for their 
use as a drug delivery system. A high drug loading level is desirable as a lower 
amount of nanoparticles will be required to deliver the desired drug dose. 
There are two methods used to load drug into nanoparticles. The most common 
is that drug is entrapped whilst the particles are being formed, alternatively 
drug can be adsorbed to the particle surface after formation. 
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When investigating drug loading two parameters can be calculated. 
Encapsulation efficiency refers to the proportion of drug available that is 
encapsulated within the particles and can be calculated using the formula: 
Encapsulation efficiency (%) = Mass of drug in nanoparticles x 100 
     Mass of drug used 
Drug loading refers to the proportion of drug in a particle by mass and can be 
calculated using the formula: 
Drug loading (%) = Mass of drug in nanoparticles x 100 
      Mass of nanoparticles 
Encapsulation efficiency is of most interest in terms of particle manufacture 
but the drug loading level is a more useful measure therapeutically as it relates 
to the dose of drug available within nanoparticles. Drug loading is also 
comparable between different nanoparticle samples. 
 
1.7.2.4 Drug release 
 
Drug release from nanoparticles can occur through a number of mechanisms. 
Firstly drug can diffuse out of the solid matrix leaving the particles intact 
(Washington, 1990). A subtly different mechanism involves penetration of 
release medium into the particles, which dissolves the drug and allows its 
diffusion into the bulk solution (Washington, 1990). Both these mechanisms 
are diffusion driven and affected by the surrounding concentration of drug. 
 
The final release mechanism occurs through the degradation of polymer and 
the breakdown of the particles (Washington, 1990). Polymer degradation can 
occur either through bulk hydrolysis or surface erosion. Bulk eroding polymers 
undergo chain cleavage throughout the system and overall tend to have less 
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reactive functional groups so generally degrade more slowly than surface 
eroding particles. For a sustained release it is desirable to have a bulk eroding 
polymer such as PLGA (Anderson and Shive, 1997). In most cases drug 
release occurs through a combination of mechanisms, and often leads to an 
initial rapid release known as a burst. A burst is not desirable as can give a 
high concentration of drug which can cause side effects and also reduces the 
ability of the system to give a sustained release. 
 
Drug release from nanoparticles is affected by a number of factors, with 
particle size considered to be the most important. With all other factors equal a 
slower, more sustained release with a smaller initial burst will occur with 
larger particles (Washington, 1990, Hans and Lowman, 2002, Dawes et al., 
2009). The properties of the polymer and drug also have important 
contributions to the rate of drug release. 
 
1.8 Thesis Aims 
 
The aim of this thesis was to produce and characterise a delivery system for 
OA and the initial plan for this system was outlined in section 1.5. This slow 
release drug delivery system for intra-articular injection was to be composed of 
a nanoparticle drug delivery system held within an injectable hydrogel. The 
aim was that the system will be able to provide a sustained release for three 
months as no current systems are able to give a delivery over such a timeframe. 
 
In order to identify the most suitable hydrogel an initial investigation of 
different hydrogels was undertaken. In chapter 3, two hydrogel systems using 
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different formation methods were investigated. Pluronic F127 was one selected 
system as this thermosetting polymer has been widely studied and has the 
required thermosetting properties. The other system used a different approach 
and selected a system capable of producing resilient gels, which were 
polyelectrolyte complexes between hyaluronic acid and chitosan. These two 
hydrogel systems are illustrated in Figure 1-5 with the nanoparticles that will 
also be included. This figure shows the proposed structure for this delivery 
system once it has formed after injection. 
 
Figure 1-5 Diagram of the two selected hydrogel systems for the proposed delivery 
system with nanoparticles. 
 
A number of the key properties of these hydrogels were investigated, which 
were the hydrogel formation, the complex strength and the stability of the 
hydrogels under physiological conditions. A formation within 30 minutes was 
required to avoid clearance from the synovial cavity and resilient hydrogels 
were required to withstand the challenging conditions within the joint. The 
production of an injectable formulation of the polyelectrolyte complexes was 
also investigated. 
 
Polyelectrolyte 
complex between 
chitosan and HA 
Pluronic F127 
thermosetting gel 
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There are also further considerations for the polyelectrolyte system particularly 
for their long term stability. Therefore a further investigation, within chapter 4, 
was carried out into a modified hyaluronic acid that would provide cross-links 
in the complexes to produce more resilient complexes that were more resistant 
to degradation. To improve the biocompatibility of the complexes reduced 
chitosan concentrations in the complexes were also investigated throughout 
this project.  
 
Glucocorticoid steroids are a current intra-articular therapy that is effective at 
relieving pain and other symptoms for up to three weeks. This short period of 
action means that this treatment could benefit from incorporation into a 
delivery system. This project therefore used the glucocorticoid steroid 
dexamethasone phosphate. This drug was incorporated into a nanoparticle 
delivery system which was then characterised, and this investigation was 
carried out in chapter 5. 
 
The combined nanoparticle and hydrogel system was also characterised, in 
chapter 6, for its ability to hold and retain high concentrations of nanoparticles 
to allow for the desired drug release. Finally the drug release from this system 
was characterised to ensure that it meets the aims. 
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CHAPTER 2 - GENERAL METHODS 
 
2.1 Materials 
2.1.1 Polymer Materials 
 
Pluronic F127 was purchased from Sigma-Aldrich (Poole, UK). Hyaluronic 
acid (sodium salt) with a molar mass of 2.2 MDa was purchased from Optima 
chemicals (Middlessex, UK) and was used as supplied.  Chitosan chloride with 
a molecular weight of 330 kDa (which corresponds to a mass of 275 kDa in 
free base form) and a degree of deacetylation of 95% was purchased from 
Novamatrix Biopolymers (Oslo, Norway) and was used as supplied. 
Poly(glycerol-adipate) backbone polymer was provided by Dr. G. Hutcheon 
(Liverpool John Moores University, UK), preparation is detailed in (Kallinteri 
et al., 2005) and polymer was used as received. 
 
2.1.2 Drug Materials 
 
Dexamethasone 21-phosphate disodium salt (98% minimum), dexamethasone 
(98% minimum), and RBITC (mixed isomers) were obtained from Sigma-
Aldrich (Poole, UK). 
 
2.1.3 Other Reagents 
 
All solvents were obtained from Fisher Scientific (Loughborough, UK) and 
were of laboratory reagent grade or better. All solvents used for HPLC were 
obtained from Fisher Scientific and were of HPLC grade. Purified water used 
was from an ELGA purification system (minimum UHVLVWLYLW\  0ȍFP
ELGA, Marlow, UK). Hyaluronidase enzyme (E.C. 3.2.1.35) of bovine 
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testicular source (1600 U/mg) was obtained from MP Biomedicals 
(Cambridge, UK). All dialysis membranes used were SpectraPor membranes 
(Spectrum Europe, Netherlands). Bovine serum and HBSS buffer (10X) were 
obtained from Invitrogen (Life Technologies, Paisley, UK). All other reagents, 
unless otherwise stated, were obtained from Sigma-Aldrich (Poole, UK) and 
were of laboratory reagent grade or better. 
 
2.2 Buffers 
2.2.1 Artificial Synovial Fluid 
 
As this study was investigating intra-articular injection it was desirable to 
utilise a buffer that is biologically relevant and mimetic of synovial fluid. The 
main components of synovial fluid are an electrolyte solution, protein and HA. 
A buffer that was named artificial synovial fluid (ASF) was produced that was 
mimetic of the salts present in synovial fluid. The salts present in synovial 
fluid are very similar to those present in plasma (Gerwin et al., 2006, Shanfield 
et al., 1988), and therefore Hank's Balanced Salt Solution (HBSS) was used as 
a base for ASF. 
 
2.2.2 Artificial Synovial Fluid with Protein 
 
Protein is another essential component of synovial fluid and so was also 
included into the buffer. This buffer was named ASFP (ASF with protein) and 
used the ASF buffer described above with added protein. The composition of 
synovial fluid is known to vary with disease state. As this delivery system is 
designed for use in osteoarthritis the composition aimed to reflect that. ASFP 
contained 33% (v/v) bovine serum as this is the approximate concentration of 
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protein in osteoarthritic synovial fluid (Gerwin et al., 2006, Curtiss, 1964, 
Mavraki and Cann, 2009). In healthy synovial fluid there is a greater 
proportion of albumin compared to globulins (Mavraki and Cann, 2009, 
Curtiss, 1964). In OA this balance is shifted as the vascular permeability 
increases allowing larger proteins to enter more easily (Burt et al., 2009, 
Larsen et al., 2008). Bovine serum was selected as it is readily available and is 
a relatively realistic mimic of the proteins in arthritic synovial fluid. 
 
2.3 Hydrogel Preparation and Characterisation 
2.3.1 Pluronics 
2.3.1.1 Pluronic solution preparation 
 
A stock Pluronic F127 solution (30% w/v) ZDVSURGXFHGE\WKH³FROGPHWKRG´
(Schmolka, 1972). Briefly, Pluronic polymer (15g) was slowly added to ice 
cold purified water (50ml) or PBS buffer (50ml, pH 7.4) under magnetic 
stirring. When all Pluronic polymer had been added the beaker was transferred 
to the fridge and left overnight to fully dissolve. Further periods of magnetic 
stirring were used as necessary until a fully dissolved solution was obtained. 
 
2.3.1.2 Pluronic hydrogel preparation 
 
Stock solution was diluted with purified water or PBS buffer (pH 7.4) to the 
required concentration between 5 and 20% (w/v). Hyaluronic acid (3.5mg/ml 
final concentration) was added during this dilution where desired. Solutions 
were incubated at 5°C to allow full mixing. In order to allow gel formation to 
occur solutions were transferred to either 22°C (room temperature in 
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laboratory) or a water bath at 37°C. Photographs were taken after vials 
containing hydrogel had been inverted for 1 minute. 
 
Hydrogel formation was assessed by rheology time sweeps, which were 
carried out as described in section 2.8.1.2. 16% (w/v) Pluronic samples were 
used. These samples were kept at room temperature before being loaded onto 
the rheometer plate (37°C) and measurements were started as soon as possible 
after this. 
 
2.3.1.3 Pluronic hydrogel rheology 
 
Rheology amplitude sweeps were carried out as described in section 2.8.1.2. 
These were carried out on 16% (w/v) Pluronic hydrogels which were formed 
onto the rheometer plate at 37°C. Once the hydrogels had formed 
measurements were started. T-tests were used to compare the results of 
different samples. 
 
2.3.1.4 Pluronic hydrogel degradation 
 
Pluronic degradation was assessed by monitoring the release of Pluronic from 
the hydrogel using a colourimetric assay. To produce the hydrogel a Pluronic 
solution (2ml, 16% w/v) was added to a dialysis membrane (molecular weight 
cut-off of 250 kDa) and heated to 37°C. The hydrogel was placed in a beaker 
of PBS buffer (30ml, pH 7.4) and then incubated in a water bath at 37°C. 
Buffer was replaced at regular intervals and the released Pluronic was 
quantified using a colourimetric assay (Al-Hanbali et al., 2007). For this assay 
dichloromethane (0.5ml) was added to a microcentrifuge tube. This was 
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followed by the test Pluronic solution (0.5ml) and a solution containing 0.4M 
ammonium thiocyanate and 0.1M anhydrous iron (III) chloride (0.5ml). The 
tubes were shaken for 20 minutes (Rotamix RM1, ELMI Ltd) and then 
subjected to centrifugation (MSE microcentaur, MSE, London, UK) at 
13,000rpm for 3mins. Absorbance of the organic layer was measured in a 
quartz cell at 510nm using a Beckman Coulter DU800 spectrophotometer 
(Beckman Coulter, High Wycombe, UK). 
 
2.3.2 Polyelectrolyte Complexes between Hyaluronic Acid and Chitosan 
2.3.2.1 Hyaluronic acid and chitosan solution preparation 
 
Stock solutions of hyaluronic acid (6mg/ml) and chitosan chloride (8mg/ml) 
were obtained by dissolution of the polymers in purified water, 1.2M NaCl 
solution or ASF, under magnetic stirring. Chitosan chloride was used in this 
study rather than the free base due to the increased solubility of this salt form. 
The free base form of chitosan is only soluble in acid solution below about pH 
6, however the chitosan chloride used here is soluble in water at neutral pH 
making it much more suitable for the intended application. 
 
2.3.2.2 Hyaluronic acid and chitosan polyelectrolyte complex formation 
 
Polyelectrolyte complexes between chitosan and hyaluronic acid were 
produced by adding hyaluronic acid (2.5ml of 6mg/ml) to a glass vial and 
making up the volume to 5ml with purified water or ASF. To give complexes 
with different polymer ratios, diluted chitosan solution (1ml of 2.5-6.2mg/ml 
depending on ratio) was added. To ensure a thorough mixing of the polymers a 
rigorous mixing protocol was followed: the vial was vigorously inverted 10 
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times and then agitated by vortex (Rotamixer, Hook & Tucker) for 30 seconds. 
The mixtures were then incubated in a 37°C water bath for 60 minutes to allow 
formation to occur. Photographs were taken at regular intervals during this 
incubation to show the formation of these complexes. 
 
To further assess the formation of these complexes, rheology time sweeps were 
carried out. These were conducted using the protocol described in section 
2.8.1.2. HA solution (in purified water, ASF, or ASFP) was added to the 
rheometer plate and allowed to equilibrate at 37°C. Chitosan was then added, 
the solution was thoroughly mixed and measurements were started as soon as 
possible. 
 
2.3.2.3 Rheology amplitude sweeps 
 
To assess the strength and integrity of complexes, rheology amplitude sweeps 
were carried out. Complexes were produced using triple volumes of all 
components. Complexes were extracted and placed on the plate of the 
rheometer. Amplitude sweeps were undertaken using the protocol described in 
section 2.8.1.2. T-tests and repeated measures ANOVA were used to analyse 
the results. 
 
2.3.2.4 Complex degradation 
 
A mass degradation method was used to assess the stability of complexes. 
Complexes were extracted and placed into purified water, ASF or ASFP (5ml). 
Samples were incubated in a water bath at 37°C with the buffer replaced 3 
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times per week. Complexes were extracted at each time point, dried in an oven 
and weighed. Repeated measures ANOVA was used to analyse the results. 
 
A further study was undertaken to investigate the strength of the complexes as 
they degrade using rheology amplitude sweeps. Complexes were prepared as 
for rheology amplitude sweeps, see section 2.3.3.3. Complexes were extracted 
and placed into ASF (15ml). Samples were incubated in a water bath at 37°C 
with the buffer replaced 3 times per week. Complexes were then extracted at 
each time point and placed on the plate of the rheometer. Amplitude sweeps 
were undertaken using the protocol described in section 2.8.1.2. 
 
2.3.2.5 Effect of salt on complex formation 
 
Complexes were produced by adding hyaluronic acid (2.5ml of 6mg/ml) to a 
glass vial. This was followed by 1.2M NaCl (0.5ml, 1ml, 1.5ml, 2ml, 2.5ml- to 
give final concentrations of 0.1M, 0.2M, 0.3M, 0.4M, 0.5M) and the solution 
was made up to 5ml with purified water. Diluted chitosan solution (1ml of 2.5-
6.2mg/ml) was added to give the desired polymer ratio. The solutions were 
then thoroughly mixed by vigorously inverting the vial 10 times and then 
agitating by vortex (Rotamixer, Hook & Tucker) for 30 seconds. The 
complexes were incubated in a 37°C water bath for 60 minutes to allow 
formation to occur and photographs were then taken. 
 
2.3.2.6 Complex formation by dialysis 
 
Hyaluronic acid in 1.2M NaCl (2.5ml of 6mg/ml) was added to a glass vial, 
made up to 5ml with purified water. Diluted chitosan solution (1ml of 2.5-
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6.2mg/ml) was added to give the desired polymer ratio. The solution was then 
thoroughly mixed by vortex (Rotamixer, Hook & Tucker) for 30 seconds, and 
placed in a dialysis membrane (10 kDa molecular weight cut-off). This was 
dialysed against purified water or ASF buffer (250ml) at 37°C, under magnetic 
stirring. Buffer was changed every 15 minutes for the first hour and then every 
30 minutes for the second hour. Photographs were taken at each buffer change. 
 
To further assess the formation of these complexes using this formation 
method, rheology amplitude sweeps were carried out. These were conducted 
using the protocol described in section 2.8.1.2. The dialysis samples were 
prepared as above, except using half volumes of all reagents. At each buffer 
change the appropriate sample was removed and transferred to the plate of the 
rheometer. 
 
2.4 Modified Hyaluronic Acid Preparation and Characterisation 
2.4.1 Synthesis of Modified Hyaluronic Acid 
 
A modified hyaluronic acid (HAM) with a cysteamine substitution of the 
carboxylate groups was produced. A 10% substitution of available carboxylate 
groups was aimed for. Three times the amount of cysteamine required by the 
stoichiometric ratio was used based on the expected reaction efficiency. 
 
Hyaluronic acid (2g, 5.06 mmol COOH) was dissolved in 200ml of 0.1M 
potassium phosphate buffer (pH 6.4). Cysteamine hydrochloride (0.172g, 1.52 
mmol) was dissolved in a small volume of buffer and added to the HA solution 
under magnetic stirring. To initiate the reaction 1-ethyl-3-(3-
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dimethylaminopropyl) carbodiimide (EDAC, 0.353g, 2.28mmol) was added. 
The pH was monitored throughout the reaction and maintained at 6.4 using 
0.1M HCl. After 1 hour and when there was no further change in pH the 
reaction solution was transferred to a dialysis membrane (10 kDa molecular 
weight cut-off) and dialysed against purified water for 48 hours to remove any 
by-products or unreacted cysteamine. The substituted hyaluronic acid was then 
lyophilised. HAM was then used in the same way as unmodified hyaluronic 
acid. 
 
2.4.2 Characterisation of Modified Hyaluronic Acid 
 
7KHVXOIK\GU\OJURXSFRQFHQWUDWLRQZDVGHWHUPLQHGE\(OOPDQ¶V WHVW (OOPDQ
1959). To a microcentrifuge tube HAM solution (200µl, 3mg/ml) was added, 
followed by 1M Tris buffer (100µl, pH  DQG P0 ¶-dithio-bis(2-
nitrobenzoic acid) in 50mM sodium acetate trihydrate (50µl). The volume was 
made up to 1ml with purified water. These solutions were incubated on ice for 
30 minutes. After this time the absorbance was measured at 412nm using a 
Beckman Coulter DU800 spectrophotometer (Beckman Coulter, High 
Wycombe, UK). A standard curve of sulfhydryl concentration was constructed 
using cysteine to allow quantification of sulfhydryl groups in HAM. 
 
2.5 Nanoparticle Preparation and Characterisation 
2.5.1 PGA Polymer Modification and Characterisation 
 
12kDa backbone PGA polymer was 40% substituted with C18 acyl (stearoyl) 
groups, using the published method (Kallinteri et al., 2005). PGA polymer (5g, 
0.42mmol) was dissolved in dried THF (50ml, dried using activated molecular 
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sieves) through heating under a gentle reflux in a N2 atmosphere. To this 
solution stearoyl chloride (3.28g, 3.65ml, 2.15mmol) dissolved in dried THF 
(12.5ml) was added. This was followed by the addition of pyridine (2.5ml), 
which was slowly added. The reaction was allowed to continue under gentle 
reflux overnight. 
 
The reaction mixture was cooled and chloroform (75ml) was added. This 
mixture was poured over a solution of purified water (50ml) and concentrated 
HCl (1.25ml) in a separating funnel. The organic layer was collected and a 
further 25ml of chloroform was poured over the remains in the separating 
funnel and the organic layer was again collected. The two organic layers were 
combined and poured over another solution of purified water (50ml) and 
concentrated HCl (1.25ml). The organic layer was collected and poured over 
purified water (100ml) and this was repeated once. The organic layer collected 
after this rinsing was dried using solid Mg2SO4, which was removed by 
filtration. The solvent was removed by rotary evaporation. The final solid was 
dried overnight under vacuum and the reaction was analysed using 
1
H-NMR 
(Bruker 400MHz spectrometer, Bruker Corporation, Coventry, UK) using 
acetone-d6 as a solvent. 
 
2.5.2 Nanoparticle Preparation 
 
Nanoparticles were prepared using 40% C18 substituted 12kDa PGA polymer 
by the interfacial deposition method as previously described (Kallinteri et al., 
2005, Meng et al., 2006). PGA polymer was dissolved in acetone and this 
solution (2ml, 10mg/ml) was added drop wise to an aqueous phase in a glass 
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vial under magnetic stirring. The aqueous phase used was as follows: for 
unloaded (blank) nanoparticles it was purified water (5ml); for DXMP loaded 
particles it was of purified water (5ml) containing DXMP (8mg); for RBITC 
loaded particles it was 0.01M HEPES buffer (6ml, pH 7.4) containing  RBITC 
(100µg). The acetone was allowed to evaporate off overnight. Particles were 
ILOWHUHG WKURXJK D ȝP FHOOXORVH QLWUDWH PHPEUDQH filters (Whatman) to 
remove flocculated particles where necessary. 
 
2.5.3 Separation of Unencapsulated Drug 
 
To separate unencapsulated drug from the DXMP particles gel permeation 
chromatography was used. This was carried out using a column (2.5x30cm) 
packed with Sepharose CL-4B gel, with purified water as an eluent. Fractions 
were collected by a fraction collector. Fractions containing eluted particles 
were combined and concentrated using Vivaspin 20 concentrators (10 kDa 
molecular weight cut-off, Sartorius Stedium Biotech, Germany) in a Centaur 2 
centrifuge (MSE, London, UK) for 30 minutes at 3000rpm. 
 
The separation of unencapsulated RBITC was achieved by dialysis. The 
nanoparticle suspensions were loaded into dialysis membrane (10kDa cut-off) 
and dialysed against purified water for 24h with regular changes of water. 
 
2.5.4 Nanoparticle Characterisation 
 
Nanoparticle size and zeta potential were determined using a Malvern 
Zetasizer Nano ZS (Malvern Instruments Ltd, UK) at 25°C. Size was 
determined by dynamic light scattering and zeta potential by laser doppler 
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micro-electrophoresis. Samples were diluted with purified water which had 
been filtered through 0.2µm membrane filters (Millipore, Watford, UK). The 
UHVXOWVZHUHDQDO\VHGXVLQJ6WXGHQW¶V7WHVW 
 
2.5.5 Analysis of Nanoparticle Drug Loading Levels 
2.5.5.1 Determination of RBITC loading levels 
 
RBITC loading levels were assessed using a direct method. Freeze dried 
nanoparticle samples were dissolved in a solvent mixture of acetone and 
methanol (2:1 ratio). The fluorescence of this solution was assessed using a 
fluorimeter as described in section 2.8.2. A standard curve of known 
concentrations of RBITC in acetone and methanol (2:1 ratio) was used to 
quantify the RBITC present. 
 
2.5.5.2 Method development for DXMP loading levels  
 
This development process aimed to produce a direct method for evaluation of 
drug loading. For a direct method it is necessary to disrupt nanoparticles to 
release the encapsulated drug. As PGA is a polyester it can be broken down 
through the use of sodium hydroxide. Freeze dried blank nanoparticles were 
taken (c.4mg), DXMP (3mg) was added followed by 2M NaOH (20ml). This 
mixture was sonicated and incubated overnight. The pH was then neutralised 
using 2M HCl. DXMP was quantified using high-performance liquid 
chromatography (HPLC), as described in section 2.8.3. 
 
This method was extended in an attempt to optimise the extraction of DXMP 
from the neutralised solution. Hexane washing was used to remove fatty acids, 
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where 7ml hexane was added to the neutralised solution. This mixture was 
vortexed, sonicated and centrifuged before the hexane was removed. A second 
wash using 5ml hexane was carried out. The aqueous phase was then analysed 
by HPLC, as described in section 2.8.3. 
 
A biphasic extraction protocol was also investigated. Freeze dried blank 
nanoparticles (c.4mg) were taken and DXMP (3mg) or dexamethasone (3mg) 
was added. To this dry mixture 1ml of purified water and 4ml of chloroform or 
dichloromethane (DCM) was added. These mixtures were sonicated and 
incubated overnight at 22°C. The aqueous layer was extracted and DXMP and 
dexamethasone were quantified using HPLC, as described in section 2.8.3. 
 
The DCM extraction method was extended to analyse the organic layer. The 
DCM from samples was diluted in methanol to improve its aqueous 
miscibility. This mixture was then analysed using HPLC, as described in 
section 2.8.3. 
 
2.5.5.3 Determination of DXMP drug loading levels 
 
An indirect method has previously been used to estimate the drug loading for 
DXMP loaded PGA nanoparticles (Kallinteri et al., 2005). This analysed free 
DXMP recovered from the column chromatography used to separate the 
unencapsulated drug. DXMP was quantified using HPLC, as described in 
section 2.8.3. 
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The optimised direct method for determination of DXMP drug loading was a 
biphasic DCM extraction. Freeze dried DXMP loaded nanoparticles had DCM 
added (4ml) followed by purified water (16ml). This mixture was sonicated 
and incubated overnight. After centrifugation the water and DCM layers were 
extracted. The DCM was diluted with methanol and the drug was quantified 
using HPLC, as described in section 2.8.3. 
 
2.5.6 Analysis of Drug Release from Nanoparticles 
2.5.6.1 RBITC release 
 
RBITC loaded nanoparticles (1ml) were added to a dialysis membrane (10 kDa 
molecular weight cut-off), with purified water or bovine serum (1ml). The 
sealed dialysis membrane was immersed in ASF (5ml) and incubated at 37°C 
in a water bath. At regular intervals the buffer was replaced with fresh buffer. 
Released RBITC was quantified using fluorimeter as described in section 
2.8.2. 
 
2.5.6.2 DXMP release 
 
DXMP loaded nanoparticles (1ml) were added to a dialysis membrane (10 kDa 
molecular weight cut-off). The sealed dialysis membrane was immersed in 
ASF (5ml) and incubated at 37°C in a water bath. At regular intervals the 
buffer was replaced with fresh buffer. Released drug was quantified using 
HPLC, as described in section 2.8.3. 
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2.6 Composite Preparation and Characterisation 
2.6.1 Composite Preparation 
 
Nanoparticle loaded polyelectrolyte complexes were produced using the same 
method as polyelectrolyte complexes, section 2.3.3.2. The only difference is 
that nanoparticle suspension (c. 4mg), as prepared in sections 2.5.2 and 2.5.3, 
was included in place of the purified water. The formation of the nanoparticle 
loaded complexes was characterised using the same methods as previously 
described, section 2.3.3.2. 
 
2.6.2 Composite Characterisation 
 
The nanoparticle loaded complexes were characterised using the same methods 
as previously described, except using nanoparticle loaded complexes. This was 
rheology amplitude sweeps as described in section 2.3.3.3 and mass 
degradation studies as detailed in section 2.3.3.4. 
 
2.6.3 Determination of Nanoparticle Incorporation into Composites 
 
Composites were removed from solution using 30µm nylon mesh filters 
(Millipore, Watford, UK). The fluorescence of the solution excluded from the 
complexes was analysed by fluorimetry, as described in section 2.8.2. 
Complexes were produced in the absence of nanoparticles and the complexes 
were removed as before; these solutions were then spiked with known 
concentrations of nanoparticles to allow the production of a standard curve. 
This allowed the concentration of particles present in solution to be calculated. 
Repeated measures ANOVA was used to analyse the results. 
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2.6.4 Nanoparticle Release 
 
Composites loaded with RBITC nanoparticles were extracted using 30µm 
nylon mesh filters (Millipore, Watford, UK). These were placed into 5ml of 
ASF or ASFP and incubated at in a water bath 37°C. At each time point this 
buffer was replaced and the nanoparticle concentration in the removed buffer 
was determined using a fluorimeter, as detailed in section 2.8.2. Repeated 
measures ANOVA was used to analyse the results. 
 
2.6.5 Enzyme Degradation 
 
Complexes loaded with RBITC nanoparticles were prepared. These 
composites were removed using 30µm nylon mesh filters (Millipore, Watford, 
UK) and were incubated in 0.1M formate buffer (5ml, pH 4.5) containing 
bovine testicular hyaluronidase (0.6U/ml) in a water bath at 37°C. At each time 
point the buffer was replaced and fluorescence in the removed buffer was 
measured by fluorimetry, as detailed in section 2.8.2. At the end of the study 
period HAase (5ml, 30U/ml) was added, this was done to break down any 
remaining complex and recover any retained particles. After incubation in a 
water bath at 37°C for 7 days the nanoparticle concentration was estimated 
using fluorimetry. Repeated measures ANOVA was used to analyse the results. 
 
2.6.6 Effect of Salt on Composite Formation  
 
The effect of salt on composite formation was investigated using the same 
method as described in section 2.3.3.5. The only difference was that 
nanoparticle suspension (0.25ml, c. 2mg) was included in place of water. 
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2.6.7 Dialysis Formation Method 
2.6.7.1 Composite formation by dialysis 
 
The dialysis formation method was the same as that used for the 
polyelectrolyte complexes, section 2.3.3.6, except that 2.5ml of nanoparticle 
suspension was included in the place of purified water. Formation of 
composites by this method was analysed using the same methods as previously 
described, section 2.3.3.6. 
 
2.6.7.2 Characterisation of composites formed by dialysis 
 
Formed composites prepared by the dialysis formation method were 
characterised using the same methods as used for bulk formed composites. 
These was nanoparticle incorporation (section 2.6.3), rheology amplitude 
sweeps (section 2.6.2), degradation (section 2.6.2), particle release (section 
2.6.5) and enzyme degradation (section 2.6.6). 
 
2.7 Drug Release from Composites 
2.7.1 DXMP Release from Drug Loaded Composites 
 
Complexes containing DXMP loaded nanoparticles were prepared. Composites 
were removed using 30µm nylon mesh filters (Millipore, Watford, UK) and 
were added to ASF buffer (5ml) and incubated at 37°C. Buffer was replaced at 
regular time points and was filtered through 30µm nylon mesh filters 
(Millipore, Watford, UK) to ensure no complex was removed. 
 
The collected release medium may contain intact nanoparticles. Therefore to 
allow the drug content to be analysed the direct method for the determination 
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of DXMP loading was used, as described in section 2.5.5.3. DXMP content 
was assayed by HPLC, as described in section 2.8.3. Repeated measures 
ANOVA was used to analyse the results. 
 
2.7.2 Complexes Loaded with Dexamethasone Crystals 
2.7.2.1 Crystal preparation and characterisation 
 
A suspension of dexamethasone crystals (6mg/ml) in purified water was 
prepared by sonication. The size of particles in this suspension was determined 
using a Coulter Counter (Beckman Coulter LS230, Beckman Coulter, High 
Wycombe, UK). 
 
2.7.2.2 Drug release from dexamethasone loaded complexes 
 
Dexamethasone suspension was loaded into complexes. Complexes were 
prepared as in section 2.3.3.2 but dexamethasone suspension (1ml, 6mg/ml) 
was included in place of the purified water. Complexes were removed using 
30µm nylon mesh filters (Millipore, Watford, UK), were added to ASF buffer 
(5ml) and were incubated in a water bath at 37°C. Buffer was replaced at 
regular time points. The release medium was diluted with methanol to 
solubilise dexamethasone and drug content was assayed by HPLC, as detailed 
in section 2.8.3. Repeated measures ANOVA was used to analyse the results. 
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2.8 Machine Techniques 
2.8.1 Rheology 
2.8.1.1 Introduction to rheology 
 
Rheology is a technique that investigates the viscoelastic properties of 
materials. Viscoelasticity is the combination of the viscous (liquid) and elastic 
(solid) properties that are found in materials such as hydrogels. Rheology 
investigates the flow and deformation of these viscoelastic materials to give 
information about the inherent structural properties of materials under dynamic 
conditions. 
 
Controlled stress deformation oscillatory rheology tests measurements were 
XVHGLQWKLVVWXG\7KHVHLQYROYHWKHDSSOLFDWLRQRIDVLQXVRLGDOVKHDUVWUHVVĲ
WRDVDPSOHDQGPHDVXULQJWKHLQGXFHGVWUDLQȖDQGWKHVKLIWLQSKDVHDQJOH
įRI WKHVWUHVVDQGVWUDLQ ,QDQ LGHDOHODVWLF solid the applied stress and the 
measured strain are in phase, hence a phase angle of 0° is obtained. In an ideal 
viscous liquid the shear stress is in phase with the shear rate and is out of phase 
with the strain, and hence a phase angle of 90° is seen. Viscoelastic materials 
have a phase angle of between 0° and 90° and this value represents the relative 
elastic and viscous properties of the material. 
 
)URP WKH PHDVXUHG SDUDPHWHUV WKH UKHRORJLFDO SDUDPHWHUV *ƍ DQG *ƍƍ FDQ EH
calculated through mathematical associations (Mezger, 2006)*ƍLVWKHHODVWLF
modulus and is a measure of the amount of deformation energy that is stored in 
the sample. This energy restores the original form of the sample once the strain 
is removed and represents the elastic (or solid) properties of a material. Gƍƍ LV
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the loss modulus and this is a measure of the energy applied that is dissipated 
as heat. Energy loss occurs when the applied stress is causing physical changes 
WRWKHVWUXFWXUHRIDPDWHULDO7KH*ƍƍFDQEHVHHQWRUHSUHVHQWWKHYLVFRXVRU
liquid) properties of a material. 
 
There are three main different measuring system geometries available for 
rheological tests (Mezger, 2006). Firstly there are concentric cylinders or cup 
and bob systems which are most suited to the measurement of low viscosity 
materials. There are also cone and plate systems but these are not 
recommended where a sample contains particles. Finally there are parallel 
plates and for the samples studied here these are the most appropriate system 
to use. 
 
A number of different rheology experiments can be carried out. One common 
type is stress amplitude sweeps. These experiments involve performing 
measurements at a set angular frequency and increasing the amplitude of the 
stress throXJKRXWWKHH[SHULPHQW)RUK\GURJHOVDWORZVWUHVVYDOXHVWKH*ƍDQG
*ƍƍDUHDWDSODWHDX7KLVLVNQRZQDVWKHOLQHDUYLVFRHODVWLFUDQJH/95$V
WKHVWUHVVLVLQFUHDVHG*ƍDQG*ƍƍUHPDLQFRQVWDQWZKLOVWWKHVDPSOHUHPDLQVLQ
the LVR. At the point where WKHYDOXHVRI*ƍDQG*ƍƍEHJLQWRGHFUHDVHUDSLGO\
the sample has become irreversibly damaged. The yield point is the shear 
stress value where this decrease occurs and shows the maximum shear stress 
that a sample can withstand without irreversible damage occurring. If the stress 
LVLQFUHDVHGIXUWKHUWKH*ƍZLOOIDOOEHORZWKH*ƍƍDQGWKLVFURVV-over is known 
as the flow point. 
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Another experiment type is time sweeps. These tests use a constant stress 
amplitude and frequency (such that the response is within the LVR) and the 
YDOXHV*ƍDQG*ƍƍDUHPRQLWRUHGDVWKH\FKDQJHZLWKWLPH7KLVLVSDUWLFXODUO\
useful for monitoring the formation of hydrogels. The important parameters 
KHUHDUHWKHJHODWLRQDQGWKHWLPHRYHUZKLFKWKH*ƍDQG*ƍƍFRQWLQXHWRHYROYH 
From a rheological point of view gelation can be defined as the point ZKHQ*ƍ
H[FHHGV*ƍƍ DV WKLV LVZKHQ WKH VROLGSURSHUWLHVH[FHHG WKH OLTXLGSURSHUWLHV 
7KHSKDVHDQJOH į FDQDOVREHXVHIXO WRPRQLWRU WKH relative FKDQJHV LQ*ƍ
DQG*ƍƍDVWKHVHSDUDPHWHrs are related by the equation tan į *ƍƍ*ƍ 
 
2.8.1.2 Rheology protocols 
 
Rheology was performed using a Physica MCR 301 rheometer (Anton Paar 
Ltd, Hertford, UK). Oscillatory shear stress amplitude sweeps were carried out 
on hydrogels or complexes at 37ºC. These used a 25mm parallel plate 
geometry with a gap size of 1mm, frequency of 1.59 Hz (10 rad/s) and strain 
ranging from 0.01 to 100% (30 measurements). From these results the value of 
WKH*ƍLQWKH/95ZDVH[WUDFWHG7KH\LHOGVWUHVVZDVFDOFXODWHGE\WKHHOastic 
stress method (Walls et al., 2003). This method calculates the maximum elastic 
VWUHVV*ƍȖZKLFKLVHTXLYDOHQWWRWKH\LHOGVWUHVVDQGKDVEHHQVKRZQWRJLYH
better yield stress estimates than other methods (Walls et al., 2003). 
 
Oscillatory shear stress amplitude sweeps to investigate the dialysis formation 
method were carried out on dialysis samples at 37ºC. These used a 50mm 
parallel plate geometry with a gap size of 1mm, a frequency of 1.59 Hz (10 
rad/s) and a strain ranging from 0.01 to 100% (15 measurements). 
 80 
For time sweep measurements solutions (2.5ml total volume) were placed on 
the fixed lower plate of the rheometer at 37 ºC. Measurements were started 
immediately using a 50mm parallel plate with a gap size of 1mm, a frequency 
of 1.59 Hz (10 rad/s) and a strain of 0.05 %.  
 
2.8.2 Fluorescence Spectrophotometer 
 
Fluorescence of RBITC containing solutions was measured using a Hitachi F-
4500 fluorescence spectrophotometer (ȜEx  QP ȜEm=575 nm, slit sizes- 
5nm, Voltage- 700V). Standard curves of RBITC or nanoparticle suspensions 
were used to quantify results as appropriate. 
 
2.8.3 HPLC 
 
HPLC was performed using an HP 1050 machine consisting of a pump, 
degasser, variable wavelength UV/visible detector, autosampler and 
Chemstation software. A method for simultaneous dexamethasone and 
dexamethasone phosphate determination was used (Puri, 2007). A reversed 
phase Lichrosphere 100 RP- HQGFDSSHG FROXPQ FP î PP ȝP
particle size) with a guard column was used. Mobile phase used was 0.1M 
phosphate buffer (pH 3.50- produced with HPLC analytical grade potassium 
phosphate monobasic from Sigma-Aldrich (Poole, UK)), methanol and 
acetonitrile in the ratio 50:36:14 with a flow rate of 1ml/min. 20µl of sample 
were injected and column eluent was monitored continuously at 240 nm. 
Standard curves for dexamethasone and DXMP were produced using known 
concentration standards that were run under the same HPLC conditions. 
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CHAPTER 3 - HYDROGEL SELECTION 
 
3.1 Introduction 
3.1.1 Requirements and Candidates for Hydrogels  
 
The aim of this project was to produce a long term release formulation for 
intra-articular injection. The properties required to achieve this include the 
time taken for gel formation, the stability of gels under physiological 
conditions and the ability to hold and retain nanoparticles. The formation of 
these hydrogels needs to be rapid to ensure that formation occurs before 
significant clearance occurs from the joint. 
 
In order to select a suitable hydrogel system an initial study was carried out on 
different hydrogel systems. Two hydrogels that used different methods of 
formation were selected for study. This allowed the most promising system to 
be identified. A commonly used approach for the production of injectable 
hydrogels is thermosetting polymers. Pluronic F127 was selected as the 
polymer to be used for this approach. The formation after injection due to the 
change in temperature is illustrated in the schematic in Figure 3-3. 
 
The other system selected was a polyelectrolyte system comprising of 
hyaluronic acid and chitosan which produces resilient gels. A more detailed 
introduction into each system is given in the following sections. 
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3.1.2 Pluronics 
 
Pluronics, also known as poloxamers, are a family of polymers with the 
general structure shown in Figure 3-1. They are tri-block co-polymers of 
poly(ethylene glycol) (PEG) and poly(propylene glycol) (PPG) in the form 
PEG-PPG-PEG, with different polymers produced with varying block lengths. 
Pluronic polymers are amphipathic as the PPG blocks are hydrophobic and the 
PEG blocks are hydrophilic. These synthetic polymers are biocompatible and 
are an FDA approved material. 
OH
O
O
O
H
n
 
m
 
CH
3
n
 
 
Figure 3-1 General structure of Pluronic polymers showing the tri-block composition. 
 
Some of the polymers in the Pluronic family are thermogelling. When 
solutions of these polymers are heated above a critical temperature they 
undergo a phase change to form a hydrogel. The gelation is also concentration 
dependent and requires a minimum critical concentration. The gelation 
depends on the amphipathic nature of Pluronics and is an entropic effect. It 
involves two separate processes which are micelle formation and the gelation 
of these micelles. Analysis has found that micelle formation is the major 
energetic event in gelation (Yu et al., 1992). After micelles have formed, 
gelation occurs through micelles becoming tightly packed forming a gel (Yu et 
al., 1992, Nanjawade et al., 2007, He et al., 2008). 
 
The thermogelling properties of Pluronic polymers allow them to be used as 
injectable hydrogels. For this project it is required to have a system that is 
liquid at room temperature and gels at body temperature. It is desirable to use a 
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room temperature solution for injection as this reduces the discomfort 
compared to a refrigerated solution. Pluronic F127 (also known as poloxamer 
407) was chosen for study as it has been widely used in hydrogel production 
and forms a gel within the required temperature range (Chung et al., 2008, 
Malmsten and Lindman, 1992). The composition of Pluronic F127 is on 
average PEG106-PPG69-PEG106  with a molecular weight of around 12,500 Da 
(Yu et al., 1992).  
 
Pluronic F127 hydrogels have been investigated for use in injectable drug 
delivery systems for controlled protein delivery (Kim and Park, 2002, Stratton 
et al., 1997, Chung et al., 2008) and for opthalmic delivery (Nanjawade et al., 
2007). Pluronic F127 hydrogels have also been utilised for sustained drug 
release (Cafaggi et al., 2008, Jeong et al., 2002, Ruel-Gariepy and Leroux, 
2004, Guzman et al., 1992), with a release over a maximum of 10 days 
achieved (Ruel-Gariepy and Leroux, 2004). 
 
3.1.3 Polyelectrolyte Complexes between Chitosan and Hyaluronic Acid 
3.1.3.1 Chitosan 
 
Chitosan (Ch) is the partially deacetylated form of the biopolymer chitin. 
Chitin is found in the cell walls of fungi and the exoskeletons of insects and 
crustaceans. Chitosan is produced by chemical deacetylation of chitin and 
generally has a degree of deacetylation between 70 and 95% (Hamman, 2010, 
Wang et al., 2011). Chitosan is a random copolymer of D-glucosamine and N-
acetylglucosamine with a molecular weight of up to 1000 kDa, structure shown 
in Figure 3-2 (Hamman, 2010). 
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Figure 3-2 Structure of chitosan showing acetylated (left) and deacetylated (right) 
glucosamine monomers. 
 
The D-glucosamine residues have a free amine group which can become 
protonated (pKa~6.5) (Berger et al., 2004), meaning that chitosan is a 
polyelectrolyte. Chitosan in its free base form is not soluble in water and needs 
to be dissolved in acid (El-hefian and Yahaya, 2010). Therefore for this study 
the more soluble chitosan chloride was used. 
 
Chitosan is considered to be biocompatible and has been approved by the FDA 
for use in wound healing products. A study looking at chitosan in the joint 
found that chitosan caused fibrous tissue formation in the first week (Lu et al., 
1999). As the experiment continued this decreased and overall chitosan was 
generally well tolerated despite the use of acidic chitosan solutions (Lu et al., 
1999). Chitosan is also known to be biodegradable. Degradation occurs 
through enzymes such as lysozyme and low molecular weight chitosan is then 
excreted via the kidneys (Wang et al., 2011, Rani et al., 2010).  
 
As chitosan is a polyelectrolyte it has been used for the preparation of 
polyelectrolyte complexes. It has been used in combination with various 
naturally derived polyanions including carboxymethyl cellulose (Berger et al., 
2004, Dumitriu and Chornet, 1998), carrageenan (Berger et al., 2004, 
Hamman, 2010), liganosulphates (Fredheim and Christensen, 2003), heparin 
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(Berger et al., 2004, Dumitriu and Chornet, 1998), and hyaluronic acid 
(Denuziere et al., 1996, Berger et al., 2004, Hamman, 2010); as well with 
synthetic polymers such as poly(acrylic acid) (Hamman, 2010, Berger et al., 
2004). 
 
3.1.3.2 Chitosan and hyaluronic acid polyelectrolyte complexes 
 
The structure and synthesis of hyaluronic acid has been introduced in section 
1.2.4.1. The carboxylate groups (pKa~3) present in HA mean that it is a 
polyelectrolyte. HA has most commonly been used been investigated in 
polyelectrolyte complexes with chitosan, which form precipitated and phase 
separated complexes (Berger et al., 2004). The strong electrostatic interactions 
between the amine groups of chitosan and the carboxylate groups of HA mean 
that these complexes are stable through a wide pH range (Denuziere et al., 
1996).  
 
These precipitated polyelectrolyte complexes have been used to promote 
wound healing, although the efficacy has shown mixed results (Denuziere et 
al., 1998, Lee et al., 2003, Denuziere et al., 1996). These complexes have also 
been utilised for nasal protein drug delivery, and gave a release of 40% of 
incorporated insulin over 5 hours in vitro (Luppi et al., 2009). These studies 
have shown that these complexes are biocompatible and are tolerated by 
chondrocytes in vitro (Lee et al., 2003, Boughellam, 2007, Denuziere et al., 
1998). These studies all used pre-formed complexes but this project aims to 
form complexes after injection. 
 
 86 
Complexes between HA and chitosan have also been used in other forms. 
These include as polyelectrolyte films for tissue engineering (Cloyd et al., 
2007, Feng et al., 2005); and as polyelectrolyte multilayers to confer 
antibacterial properties on titanium (Chua et al., 2008), or to promote 
lymphocyte binding (Vasconcellos et al., 2010) or in development of a 3D 
liver model (Kim et al., 2010). Complexes have also been produced that avoid 
precipitation, including polyelectrolyte nanoparticles for protein delivery 
(Hamman, 2010, Parajo et al., 2010, de la Fuente et al., 2008) and soluble 
complexes produced with PEG conjugated chitosan (Wu et al., 2007). 
 
3.1.4 Chapter Aims 
 
This chapter selected the hydrogel portion of the delivery system. Two 
potential systems were investigated and characterised, these were Pluronic 
F127 hydrogels and polyelectrolyte complexes between chitosan and 
hyaluronic acid. The formation, degradation and rheological properties of the 
hydrogels were assessed to allow the selection of the most suitable system. 
These hydrogels were also assessed for their ability to be formulated as an 
injectable system. 
 
The precipitated polyelectrolyte complexes are not injectable but the free 
polymers are easily injectable. Therefore to produce an injectable system 
complexation must be prevented. Polyelectrolyte complex formation is known 
to be disrupted by high salt concentrations (Lee et al., 2003). Therefore using a 
high concentration salt solution would produce an injectable liquid and after 
injection the salt can diffuse away to allow complex formation. This approach 
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was assessed for its potential to produce injectable polyelectrolyte complexes. 
This transition is represented in Figure 3-3, illustrating how complex formation 
after injection in the lower physiological salt concentration. 
 
Figure 3-3 Schematic to show the factors driving hydrogel formation in the proposed 
injectable formulations. 
Polymers are represented by lines and electrolytes by dots, colours represent charge and the 
key factor that causes hydrogel formation in both systems is identified, which is the salt 
concentration or temperature. 
 
Chitosan is a material that is generally recognised as safe, but it has been 
shown to have some toxic effects (Liggins et al., 2004) and the effects of 
chitosan in the joint are less well known (Lu et al., 1999). Therefore a reduced 
chitosan concentration in these complexes may be an advantage to improve 
their biocompatibility and this was also investigated. 
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3.2 Materials and Methods 
3.2.1 Materials 
 
The materials used are detailed in section 2.1. 
 
3.2.2 Pluronics 
3.2.2.1 Pluronic solution preparation 
 
Pluronic solutions were prepared using the method detailed in section 2.3.1.1. 
 
3.2.2.2 Pluronic hydrogel preparation 
 
Pluronic hydrogels were produced using the method described in section 
2.3.1.2. 
 
3.2.2.3 Pluronic hydrogel rheology 
 
Rheology amplitude sweeps were carried out on Pluronic hydrogels as detailed 
in section 2.3.1.3. 
 
3.2.2.4 Pluronic hydrogel degradation 
 
Pluronic hydrogel degradation was assessed using the method described in 
section 2.3.1.4. 
 
3.2.3 Hyaluronic Acid and Chitosan Polyelectrolyte Complexes  
3.2.3.1 Hyaluronic acid and chitosan solution preparation 
 
Solutions of hyaluronic acid and chitosan were prepared as described in section 
2.3.2.1. 
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3.2.3.2 Hyaluronic acid and chitosan polyelectrolyte complex formation 
 
Polyelectrolyte complexes were prepared as detailed in section 2.3.2.2 and the 
formation was assessed using the methods in section 2.3.2.2. 
 
3.2.3.3 Rheology amplitude sweeps on polyelectrolyte complexes 
 
Rheology amplitude sweeps on polyelectrolyte complexes were carried out 
using the method described in section 2.3.2.3. 
 
3.2.3.4 Polyelectrolyte complex degradation 
 
The degradation of polyelectrolyte complexes was assessed using the method 
described in section 2.3.2.4. 
 
3.2.3.5 Effect on salt on complex formation 
 
The effect of salt on polyelectrolyte complexes formation was analysed using 
the method described in section 2.3.2.5. 
 
3.2.3.6 Complex formation by dialysis 
 
Polyelectrolyte complexes were prepared by the dialysis method described in 
section 2.3.2.4. The formation of these complexes was analysed using the 
methods detailed in section 2.3.2.6. 
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3.3 Results 
3.3.1 Pluronics 
3.3.1.1 Pluronic hydrogel formation 
 
Pluronic F127 is a thermogelling polymer with a lower critical transition 
temperature between liquid and gel forms. Hydrogel formation from this 
polymer is dependent on both polymer concentration and temperature. To 
assess the transition from liquid to gel a qualitative study was undertaken. This 
study investigated Pluronic F127 solutions at room temperature (22°C) (the 
temperature of the injected solution) and body temperature (37°C) to allow the 
identification of a concentration that would gel between these temperatures. 
This concentration would be a suitable concentration for an injectable 
hydrogel. After administration the Pluronic mixture will be exposed to a 
number of components that are naturally present within the joint and therefore 
the effect that salt and hyaluronic acid had on gelation was investigated. 
 
Initial studies showed that the required concentration of Pluronic F127 was 
between 15% and 20% (w/v). The results of studies on Pluronic F127 solutions 
in this range are presented in Figure 3-4. Photographs were taken after vials 
had been left inverted for 1 minute, to show any flow that occurred in the 
samples. All concentrations in this range were found to be liquid at 22°C. At 
37°C polymer concentrations of 17% and above produced a rigid gel. 
Concentrations of 15% and 16% produced less rigid gels, which showed some 
creep. The inclusion of a physiological salt concentration alone had no visual 
effect on the gel formation. Hydrogel formation was disrupted by the inclusion 
of hyaluronic acid at a physiologically relevant concentration (3.5mg/ml). No 
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hydrogel formed in the 15% solution and a greater creep was seen in 16%, 
17% and 18% samples. When salt and HA were included together this seemed 
to reverse some of the disruptive effects seen. Solutions of 18% and below all 
exhibited reduced creep compared to when hyaluronic acid was included alone, 
Figure 3-4. 
 
Figure 3-4 Photographs showing the thermal gelation of Pluronic F127 solutions in 
synovial relevant conditions.  
Pluronic F127 solutions at concentrations between 15% and 20% (w/v) were prepared in water 
or PBS. Hyaluronic acid at 3.5mg/ml was included where indicated. The vials were 
photographed at the indicated temperature after being left inverted for 1 minute. The position 
of the Pluronic liquid or gel is indicated with an arrow.  
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From these results 16% solutions can be seen to be lowest concentration that 
gave a good hydrogel formation in all conditions. Further studies on the 
Pluronic system were conducted using this concentration. It is desirable to 
reduce the Pluronic concentration used as at high concentrations there are some 
concerns over toxicity and osmotic effects. A study on Pluronic F127 for 
ophthalmic applications concluded that a concentration of 16% was the 
maximum that is desirable (Talasaz et al., 2008). Although a different route of 
administration will be used here, it is likely that similar concentrations would 
be tolerated in the joint. 
 
3.3.1.2 Analysis of hydrogel formation by rheology 
 
Rheology can be used to investigate the internal strength and viscoelastic 
properties of materials. Rheology time sweeps can be used to monitor the 
FKDQJH LQ WKH UKHRORJLFDO SDUDPHWHUV *ƍ DQG *ƍƍ ZLWK WLPH *ƍ LV WKH VWRUDJH
PRGXOXVWKDWUHSUHVHQWVWKHHODVWLFRUVROLGSURSHUWLHVRIDPDWHULDODQG*ƍƍLV
the loss modulus that represents the viscous (or liquid) properties. The changes 
in these parameters with time can therefore be used to monitor hydrogel 
formation quantitatively. The important features in rheology time sweeps that 
show hydrogel formation are the cross-RYHU SRLQW ZKHUH *ƍ ILUVW H[FHHGV *ƍƍ
WKLV LVNQRZQDV WKHJHODWLRQSRLQWDQG WKH WLPHRYHUZKLFK WKH*ƍ DQG *ƍƍ
continue to evolve. 
 
For these samples rheology time sweeps were carried out at 37°C to mimic 
formation in the body. Room temperature solutions were added to the plate of 
the rheometer and measurements started as soon as possible afterwards. This 
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was done to mimic the temperature transition after injection. The results of this 
study are presented in Figure 3-5. Pluronic F127 solutions in water and those 
including HA included showed an instantaneous gelation and little change in 
*ƍYDOXHGXULQJ WKHVWXG\7KH LQFOXVLRQRISK\VLRORJLFDOVDOWFDXVHGDVOLJKW
retardation in gel formation. Gelation still occurred before measurements 
VWDUWHG EXW WKH *ƍ LQFUHDVHG WKURXJKRXW WKH HQWLUH  PLQXWHV RI WKH VWXG\
Inclusion of both salt and hyaluronic acid acted to reduce the negative effects 
VHHQZLWKSK\VLRORJLFDOVDOWDORQH,QWKLVFDVHWKH*ƍUDSLGO\HYROYHGRYHUWKH
first 5 minutes before reaching a plateau. 
 
Figure 3-5 Rheology time sweeps showing Pluronic F127 hydrogel formation in synovial 
relevant conditions.  
Rheology time sweeps were conducted at 37°C on Pluronic F127 solutions (16% (w/v)) with 
added synovial fluid components; PBS (pH 7.4) and/or HA (3.5mg/ml)*ƍVTXDUHVDQG*ƍƍ
(triangles) are plotted on the primary y-D[LV SKDVH DQJOH į- diamonds) is plotted on the 
secondary axis. 
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3.3.1.3 Gel integrity 
 
The integrity and strength of formed hydrogels was assessed through the use of 
rheology amplitude sweeps, which investigate the responses of samples to 
increasing shear stresses. When interpreting stress amplitude sweeps there are 
two important features that represent gel integrity. Firstly is the value of Gƍ in 
WKHOLQHDUYLVFRHODVWLFUHJLRQ/95WKH/95LVZKHUHWKHYDOXHRI*ƍGRHs not 
change with increasing shear stress. The other important feature is the yield 
stress; this is the value of the shear stress at the end of the LVR where Gƍ 
begins to fall. For both of these parameters, the higher the value the more 
resistant the gel is to shear stresses. 
 
The results of rheology amplitude sweeps on 16% Pluronic hydrogels with 
added physiological components are presented in Figure 3-6. This figure 
shows both the raw results as well as the extracted Gƍ and yield stress values. 
This showed that strong and resistant hydrogels were formed. The inclusion of 
physiological salt and hyaluronic acid produced no significant changes in the 
*ƍRU\LHOGVWUHVV 
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Figure 3-6 Rheology amplitude sweeps of Pluronic F127 hydrogels in synovial relevant 
conditions. 
Rheology amplitude sweeps were carried out on Pluronic F127 hydrogels (16% (w/v)) at 37°C. 
Where indicated, PBS (pH 7.4) and/or HA (3.5mg/ml) were included. Top: Raw rheology 
amplitude sweep results. *ƍ VTXDUHV DQG *ƍƍ WULDQJOHV DUH SORWWHG DJDLQVW VKHDU VWUHVV
%RWWRP*UDSKVKRZLQJ*ƍDQG\LHOGVWUHVVYDOXHVH[WUDFWHGIURPUDZUHVXOWV*ƍYDOXHV- red; 
yield stress- blue. 
 
3.3.1.4 Degradation 
 
The degradation of Pluronic F127 hydrogels was investigated as stability over 
extended time periods is essential for the intended application. A degradation 
study was carried out with the gel retained within a dialysis membrane. The 
released Pluronic was quantified using a colourimetric assay. The results of 
this study are shown in Figure 3-7. This showed that the hydrogel lost over 
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half of its Pluronic content in 24 hours. The rate of diffusion of Pluronic across 
the dialysis membrane may have slowed the measured rate of degradation. 
This is supported by the fact that the Pluronic recovered from within the 
membrane after 24 hours was a liquid. This liquefaction shows another 
problem with the degradation of Pluronics. Hydrogel formation requires a 
critical concentration of Pluronic. When the concentration falls below this level 
the hydrogel will become liquefied, even though a relatively high 
concentration of Pluronic remains. 
 
Figure 3-7 Graph showing Pluronic F127 loss during hydrogel degradation and a 
photograph of the recovered solution after 24 hours. 
Pluronic F127 hydrogels (16% (w/v)) were held within a dialysis membrane (250 kDa 
molecular weight cut-off) at 37°C. PBS buffer was used as dialysate and was replaced at each 
time point. Mass of Pluronic in release buffer was assessed by a colourimetric assay. 
Photograph of recovered Pluronic solution after 24 hours of degradation at 37°C is shown, 
with vial inverted for 1 minute before the picture was taken. 
 
3.3.2 Polyelectrolyte Complexes 
3.3.2.1 Complex formation 
 
Polyelectrolyte complexes form spontaneously from mixtures of negatively 
charged hyaluronic acid and positively charged chitosan. A reduced 
concentration of chitosan in the production of the polyelectrolyte complexes is 
desirable to keep possible toxic effects to a minimum. Therefore an initial 
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photographic study was conducted to investigate the effects of reducing 
chitosan concentration on complex formation, and the results are shown in 
Figure 3-8. The ratios of polymers in these complexes are expressed as the 
ratio of the charged group concentrations. This is the ratio of the amine groups 
of chitosan (Ch) to the carboxylate groups of hyaluronic acid (HA). 
 
 
 
  1:1              0.9:1               0.8:1               0.7:1 
 
0.6:1             0.5:1             0.4:1 
Complexes prepared in water 
 
  1:1                0.9:1               0.8:1               0.7:1 
 
0.6:1              0.5:1                0.4:1 
Complexes prepared in ASF 
Figure 3-8 Photographs showing Ch:HA complexes of various polymer ratios prepared in 
water or ASF buffer. 
Ch:HA complexes were prepared at the indicated polymer ratio in water or ASF. Complexes 
were incubated at 37°C for 60 minutes before photos were taken. 
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Salt is known to disrupt polyelectrolyte formation and this initial study 
therefore also investigated the effect that physiological salt concentrations had 
on complex formation. This was done by preparing complexes in artificial 
synovial fluid (ASF) buffer, which is a buffer mimetic of the salts present in 
synovial fluid. The results of this study are presented in Figure 3-8 and show 
that in water the 1:1 ratio produced compact and well defined complexes. As 
chitosan concentration decreased the complexes became smaller and less well 
defined with small exclusions from the main complex. In physiological salt the 
complexes formed but appeared less compact with a more fibrous structure. At 
lower chitosan concentrations there was a greater disruption when salt was 
present, which is shown in the 0.4:1 Ch:HA ratio complex which was almost 
totally disrupted in ASF buffer. A greater turbidity in the bulk solution was 
seen in ASF. This can be attributed to the polymer forming small complex 
particles, rather than becoming incorporated into the bulk complex. 
 
The rate of complex formation was of interest as a rapid formation is required 
for this system. The kinetics of complex formation were investigated through 
photography of the forming complexes and rheology time sweeps. The results 
of the photographic study are shown in Figure 3-9 and show that precipitation 
occurred immediately and was followed by a slower contraction and 
condensation. This reorganisation occurred within 30 minutes after which time 
there was very little visual change. The polymer ratio does not visually affect 
the rate of complex formation and a similar precipitation and reorganisation 
was seen at all Ch to HA ratios studied between 0.5:1 and 1:1. 
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 0 minutes          10 minutes           20 minutes           30 minutes 
 
40 minutes          50 minutes           60 minutes 
Ch:HA 1:1 complexes 
 
0 minutes          10 minutes           20 minutes           30 minutes 
 
40 minutes          50 minutes           60 minutes 
Ch:HA 0.7:1 complexes 
 
0 minutes          10 minutes          20 minutes           30 minutes 
 
40 minutes          50 minutes           60 minutes 
Ch:HA 0.5:1 complexes 
Figure 3-9 Photographs showing the formation of Ch:HA complexes in water at different 
polymer ratios. 
Chitosan and HA were mixed at varying ratios and incubated at 37°C. Photographs were taken 
at the indicated times. 
 
The results of the rheology time sweeps, Figure 3-10, showed that gelation for 
the 1:1 ratio complexes occurred after around 30 mLQXWHV 7KH *ƍ YDOXH
LQFUHDVHG UDSLGO\ XQWLO DIWHU DURXQG  PLQXWHV 7KH SKDVH DQJOH į FDQ
provide further information on complex formation. The phase angle shows the 
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UHODWLYH OHYHOV RI *ƍ WR *ƍƍ ZLWK D VPDOOHU SKDVH DQJOH ZKHQ WKHUH LV KLJKHU
relativH *ƍ &KDQJHV LQ WKH SKDVH DQJOH FDQ WKHUHIRUH VKRZ WKH RYHUDOO
formation of the complexes. The phase angle values confirmed what was seen 
LQ WKH*ƍYDOXHV7KHSKDVHDQJOHUDSLGO\GHFUHDVHGEHIRUH OHYHOOLQJRIIDIWHU
about 150 minutes showing that formation was complete. The 0.5:1 ratio 
FRPSOH[HVVKRZHGDVLPLODURYHUDOOWLPHRIIRUPDWLRQXQWLOWKH*ƍDQGSKDVH
DQJOHYDOXHVZHUHVWDEOHEXWJHODWLRQZKHQ*ƍH[FHHGHG *ƍƍ WRRN ORQJHUDW
around 60 minutes. The time of formation differed from the visual 
observations because the rheological measurements were carried out in a thin 
film and not a bulk solution, which slowed formation. 
 
Figure 3-10 Rheology time sweeps showing the formation kinetics of Ch:HA complexes.  
Rheology time sweeps were conducted at 37°C. Chitosan and HA were mixed on the plate of 
the rheometer and measurements were started as soRQDVSRVVLEOHDIWHUZDUGV*ƍVTXDUHVDQG
*ƍƍ WULDQJOHVDUHSORWWHGRQ WKHSULPDU\ \-D[LVSKDVHDQJOH į- diamonds) is plotted on the 
secondary axis. 
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The formation of complexes in vivo will occur in the presence of other 
synovial fluid components. Therefore to investigate the effect that these 
compounds had on formation further rheology time sweeps were carried out 
and the results of this study are presented in Figure 3-11. Physiological salt 
was found to slightly delay complex gelation but did not affect the overall 
formation time. It DOVR FDXVHG D VOLJKW UHGXFWLRQ LQ WKH ILQDO *ƍ OHYHO ZKLFK
would suggest that salt also affects the overall complex strength. Inclusion of 
plasma proteins as well as salt (as ASFP) caused a more rapid complex 
gelation and formation. In this case gelation occurred almost instantaneously 
and formation was complete after about 60 minutes. The addition of protein 
DOVR DFWHG WR VOLJKWO\ UHVWRUH WKH *ƍ RI WKH IRUPHG FRPSOH[HV EXW QRW WR WKH
level seen in complexes formed in water alone. 
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Figure 3-11 Rheology time sweeps showing the formation kinetics of Ch:HA complexes in 
synovial relevant conditions. 
Rheology time sweeps were conducted at 37°C on mixtures of chitosan and HA at a 1:1 ratio. 
Chitosan and HA were mixed on the plate of the rheometer with any additional components 
DQGPHDVXUHPHQWVZHUHVWDUWHGDVVRRQDVSRVVLEOHDIWHUZDUGV*ƍVTXDUHVDQG*ƍƍWULDQJOHV
are plotted on the primary y-D[LVSKDVHDQJOHį- diamonds) is plotted on the secondary axis. 
 
3.3.2.2 Complex integrity 
 
To assess the integrity and strength of the polyelectrolyte complexes rheology 
amplitude sweeps were used. Complexes were produced using different HA 
concentrations to investigate the ability to produce complexes with different 
rheological properties. Complexes are required that are resilient to the 
challenging forces experienced within the joint, however complexes which are 
too rigid may cause damage to the joint. The response of the joint to these 
complexes is unknown at the present time. The ability to produce complexes 
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with a variety of properties therefore allows complexes with optimal properties 
to be used once these have been determined. 
 
The results of rheology amplitude sweeps on polyelectrolyte complexes are 
presented in Figure 3-12. These show that 1:1 ratio complexes were the most 
UHVLVWDQWWRVKHDUVWUHVVH[KLELWLQJWKHKLJKHVW*ƍDQG\LHOGVWUHVVYDOXHV$WD
+$ FRQFHQWUDWLRQ RI PJPO WKH *ƍ YDOXHV IRU   DQG  UDWLR
complexes were all similar. At a ratio of 0.7:1 aQG EHORZ WKH *ƍ EHFDPH
significantly lowered (P<0.001). For complexes prepared using 3mg/ml HA, 
ZKLFKZDVWKHFRQFHQWUDWLRQXVHGSUHYLRXVO\DPRUHJUDGXDOGHFOLQHLQ*ƍZDV
seen. Comparing consecutive ratios found significant differences between 1:1 
and 0.9:1 (P<0.01); 0.8:1 and 0.7:1 (P<0.01); 0.6:1 and 0.5:1 (P<0.05) Ch:HA 
ratio complexes.  
 
&RPSOH[HV SURGXFHG XVLQJ PJPO +$ VKRZHG VPDOOHU GLIIHUHQFHV LQ *ƍ
values. A significant difference was found between 1:1 complexes and 
complexes of 0.6:1 and below (P<0.05). At all HA concentrations the yield 
stresses showed a more gradual decline as chitosan concentration was reduced 
and there were few significant differences. A comparison was then carried out 
on complexes with the same polymer ratios but produced using different HA 
concentrations. This found significant differences between 6mg/ml HA and 
both other concentrations in samples of 0.5:1 ratio and above (P<0.001). 
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Figure 3-12 *UDSKVVKRZLQJ*ƍDQG\LHOGVWUHVVYDOXHVIRU&K+$FRPSOH[HV 
*ƍ DQG \LHOG VWUHVV YDOXHV ZHUH H[WUDFWHG IURP UKHRORJ\ DPSOLWXGH VZHHSV FDUULHG RXW RQ
&K+$FRPSOH[HV IRUPHGDW&ZLWKWKH LQGLFDWHGSRO\PHUUDWLR7RS*ƍYDOXHV LQ/95
bottom: yield stress values. For both graphs the HA concentration used to prepare complexes 
was as follows: 6mg/ml- red; 3mg/ml- blue; 1.5mg/ml- black. 
 
3.3.2.3 Complex degradation 
 
The long term stability of these complexes is important for their use as a slow 
release delivery system. The degradation of these complexes was therefore 
assessed using a mass loss method. The results of this study are presented in 
Figure 3-13. Complexes incubated in water showed only a negligible mass loss 
for the 56 days of the study. Complexes incubated in a physiological salt 
concentration showed significantly greater level of degradation in both Ch:HA 
1:1 and 0.5:1 ratio complexes (P<0.001). During the degradation an initial 
mass loss occurred over 2 weeks after which only a minimal mass loss 
occurred. A greater stability was found in the 1:1 ratio complexes as 69% of 
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the initial complex mass remained after 56 days whereas only 46% of the 0.5:1 
ratio complexes remained (P<0.001). 
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Figure 3-13 Mass degradation profiles of Ch:HA complexes in water or ASF. 
Ch:HA complexes were prepared and then incubated in water or ASF at 37°C. Buffer was 
changed regularly and at each time point complexes were extracted, dried and weighed. 
 
3.3.2.4 Evaluation of injectable formulation 
 
To make an injectable formulation with these hydrogels it is proposed that 
complexation will be prevented by using salt. To investigate the feasibility of 
this method it was first necessary to investigate the effect that salt has on 
complex formation. This would allow the necessary concentration of salt 
required to prevent complexation to be determined. 
 
The results of this photographic study are presented in Figure 3-14. This 
showed that the 1:1 ratio complexes were able to form in 0.3M salt or below. 
As salt concentration increased there was a gradual decrease in the definition 
of the complexes which took on a woolly appearance. At 0.4M salt 
concentration a very diffuse complex was visible. Then at 0.5M salt no 
complex formation was visible at all and the solution was easily passed 
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through a 25G needle. A 25G needle is the largest needle that can be used for 
intra-articular injection in rats. A 22G needle can be used for administration to 
humans but for ease of in vivo animal studies and patient comfort the use of a 
25G needle is desirable. The 0.5:1 ratio complexes were visibly less stable in 
salt. A salt concentration of 0.4M entirely prevented complex formation and at 
a concentration of 0.3M only a very small diffuse complex was formed. In 
0.2M salt and below the 0.5:1 ratio complexes were able to form into a 
compact and well defined form.  
 
0M              0.1M            0.2M           0.3M           0.4M             0.5M  
Ch:HA 1:1 
 
0M              0.1M            0.2M           0.3M           0.4M             0.5M  
Ch:HA 0.5:1 
Figure 3-14 Photographs showing the effect of salt on Ch:HA complex formation. 
Ch:HA complexes were prepared in the presence of increasing concentrations of NaCl. 
Mixtures were incubated at 37°C for 60 minutes to allow complex formation to occur before 
photographs were taken. 
 
It was decided from these results to use a 0.5M concentration of sodium 
chloride to prevent complexation as this was the lowest concentration that 
completely prevented complex formation at all Ch:HA ratios. To investigate 
the formation of complexes from these high salt solutions a dialysis method 
was used. This method mimics the in vivo diffusion of salt that would allow 
complex formation to occur. Initially this dialysis formation method was 
investigated through photography of the forming complexes. 
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The results of this, presented in Figure 3-15, showed that for Ch:HA 1:1 
complexes there was a rapid complex formation by this method. Small 
dispersed precipitates formed within 15 minutes of dialysis in both water and 
ASF buffer which was followed by a slower aggregation of these complexes 
for up until 60 minutes. After this time no further changes occurred. At the 1:1 
ratio there were few differences between dialysis against water and ASF. 
 
 
0 mins                   15 mins                  30 mins                  60 mins 
Ch:HA 1:1 in water 
 
0 mins                   15 mins                  30 mins                  60 mins 
Ch:HA 1:1 in ASF 
Figure 3-15 Photographs showing Ch:HA 1:1 complex formation by dialysis. 
Solutions containing complex components were prepared in 0.5M NaCl. These mixtures were 
dialysed against water or ASF at 37°C with the buffer replaced every 15 minutes. Photographs 
were taken at each buffer change. 
 
To further assess the formation using this method rheology amplitude sweeps 
were carried out on the forming complexes. This method used the whole 
solution from within the dialysis membrane and was done in order to assess the 
entire system and to provide a fair comparison between samples. This is 
different to the previous rheology amplitude sweeps which used extracted 
formed complexes. The important features in these results are therefore 
different. The first important feature is the appearance of a well defined linear 
YLVFRHODVWLF UHJLRQ /95 7KH /95 LV ZKHUH WKH *ƍ YDOXH LV FRQVWDQW ZLWK
LQFUHDVLQJ VKHDU VWUHVVHV 7KH VHFRQG LPSRUWDQW IHDWXUH LV WKH LQFUHDVH LQ *ƍ
and yield stress values; this shows increases in the complex strength. 
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The results of this study are shown in Figure 3-16. These show that in 1:1 ratio 
complexes a detectable complex formation occurred in 15 minutes using both 
water and ASF buffer as the dialysDWH$JUDGXDOLQFUHDVHLQWKH*ƍDQG\LHOG
stress was seen over 60 minutes and shows that a gradual and continued 
formation of complex occurred. These results confirm the observations made 
in the photographic study of these complexes. 
 
Figure 3-16 Rheology amplitude sweeps showing Ch:HA 1:1 complex formation by 
dialysis. 
Solutions containing complex components were prepared in 0.5M NaCl. These mixtures were 
dialysed against water or ASF at 37°C with the buffer replaced every 15 minutes. Rheology 
amplitude sweeps were carried out on the recovered mixtures at 37°C. *ƍ VTXDUHV DQG *ƍƍ
(triangles) are plotted with against shear stress. Left: dialysis against water; Right: dialysis 
against ASF. Time of dialysis is shown in the legend and is the same for both graphs. 
 
The dialysis formation method was also investigated with 0.5:1 ratio 
complexes. The photographs in this case seem to show a minimal formation of 
polyelectrolyte complex, Figure 3-17. However the photographs did not show 
the entire situation as they were taken through the dialysis membrane. The 
camera was not as able to cope with the dialysis membrane as the human eye 
and so observations in the laboratory showed further details. It was observed 
that a decent level of formation occurred in water, although only small, 
discrete complexes were formed. This formation was slower than occurred at 
the 1:1 ratio. Complex was visible after 30 minutes and changes were observed 
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throughout the 120 minutes of this study. Dialysis against ASF resulted in very 
little visible formation. Rheology amplitude sweeps on 0.5:1 Ch:HA ratio 
samples failed to show any measurable complex formation. 
 
0 mins                   15 mins                  30 mins                  120 mins        
Ch:HA 0.5:1 in water 
 
0 mins                   15 mins                  30 mins                  120 mins       
Ch:HA 0.5:1 in ASF 
Figure 3-17 Photographs showing Ch:HA 0.5:1 complex formation by dialysis. 
Solutions containing complex components were prepared in 0.5M NaCl. These mixtures were 
dialysed against water or ASF at 37°C with the buffer replaced every 15 minutes for 1 hour 
and then every 30 minutes. Photographs were taken at each buffer change. 
 
3.4 Discussion 
3.4.1 Pluronics 
 
Pluronic F127 was found to be liquid in solutions below 20% (w/v) at 22°C. 
Hydrogels were produced at 37°C in solutions of 15% and above. These results 
are in line with what has been previously observed for Pluronic F127. 
Solutions below 16% were found to be unable to form a gel at 37°C and a 20% 
solution had a gelation temperature of just above 20°C (Chung et al., 2008, 
Malmsten and Lindman, 1992). 
 
The effect that synovial fluid components had on complex formation was 
investigated. This produced contradictory results. For example the inclusion of 
a physiological salt concentration had no visual effect on gel formation. But 
the rheology study found that salt slowed gel formation and reduced resistance 
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to shear stress. However these methods looked at different factors. The visual 
studies looked at formed gels and creep under relaxed conditions. The 
rheology studies looked at the formation kinetics under dynamic shear stress. 
 
Previous studies have also shown that a number of small molecules can affect 
the gelation temperature of Pluronic F127. Sodium chloride has been found to 
reduce gelation temperature (Guzman et al., 1992, Malmsten and Lindman, 
1992, Vadnere et al., 1984), with urea and ethanol increasing gelation 
temperature (Vadnere et al., 1984). Therefore the addition of physiological salt 
in this study (as PBS) might have been expected to cause a reduction in 
gelation temperature. This was not seen, but as the 15% Pluronic solution in 
water was found to gel at 37°C this effect would have been hard to observe. No 
reduction in creep was seen with salt included which would have given an 
indication of a better hydrogel formation. 
 
The disruption of hydrogels when hyaluronic acid was included may be due to 
HA being a large polymer. High molecular weight PEG has been observed to 
raise the gelation temperature of Pluronic F127 (Gilbert et al., 1987) and a 
similar effect with HA would account for the disruption that was observed. 
This may have been caused by the HA polymer chains reducing the mobility of 
the Pluronic polymer chains and therefore disrupting their organisation into 
micelles and hydrogels. The rheology amplitude sweeps showed a slight 
increase in yield stress when HA was included. This change could be 
explained by the HA polymer chains stretching throughout the gel and 
providing a greater physical strength. The inclusion of both salt and hyaluronic 
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acid reversed some of the disruptive effects seen with one additive alone. Salt 
would become associated with the HA as a counterion and this would act to 
shield the charges on HA as well as reducing the free salt. This would account 
for the reversal of the effects seen. 
 
It was found that Pluronic F127 hydrogels were degraded within 24 hours. 
This rapid degradation is consistent with these hydrogels being physical gels. 
The degradation of these gels can occur simply through dissolution of the 
exterior of the gel. These results are similar to previous reports, where Pluronic 
F127 hydrogels were found to be rapidly degraded by surface dissolution 
within 24 hours (Jeong et al., 2002, Nanjawade et al., 2007, Chung et al., 
2008). 
 
The stability problems with Pluronics have been overcome by other 
investigators by the development of chemically modified Pluronic or Pluronic 
based systems. This has included cross-linked Pluronic hydrogels (Cohn et al., 
2005), Pluronic chains linked end to end (Cohn et al., 2006), or Pluronics 
modified with other polymers (He et al., 2008, Ruel-Gariepy and Leroux, 
2004, Kim and Park, 2002, Chung et al., 2008). However this approach has 
still not been able to produce hydrogels with the long term stability required 
for this delivery system.  
 
3.4.2 Chitosan and Hyaluronic Acid Polyelectrolyte Complexes 
 
A number of studies have been carried out on precipitated complexes between 
chitosan and HA. Generally the complexes have been produced and then dried 
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before use (Denuziere et al., 1998, Kim et al., 2004). The stoichiometry is 
often the only property investigated whilst the complexes are still in solution. 
Further studies were then carried out on the freeze dried complexes. It has also 
been most common for stoichiometric complexes to be investigated as this 
ensured that no excess polymer was present which would generally improve 
the biocompatibility. This leaves little relevant literature for comparison to the 
complexes produced in this study, which were in solution and used varying 
chitosan concentrations. 
 
Initial investigations found that precipitated complexes were able to form using 
reduced chitosan concentrations. Complexes were also found to be stable in 
physiological salt concentrations. These results show that these complexes 
would be able to form under physiological conditions.  
 
A rapid complex formation is required to prevent clearance from the joint 
before formation can occur. The polyelectrolyte complexes showed an 
immediate precipitation followed by a slower rearrangement. Complex 
formation was visually complete after 30 minutes, but rheology time sweeps 
showed changes continued for around 150 minutes. The differences between 
the visual observations and rheological results are due to the differences 
between these methods. Rheology was carried out on a thin film and this will 
limit the mobility of the polymers, and therefore a slower formation was 
observed. The rheology showed that 0.5:1 ratio complexes experience a 
slightly slower gelation, but overall formation time remained the same. This 
would be important in vivo as once the system is gelled it will not be subject to 
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clearance. Gelation refers to the whole system rather than the complexes alone 
as the rheology was carried out on the entire solution. 
 
6RPH VXGGHQ GURSV ZHUH VHHQ LQ *ƍ YDOXHV GXULQJ UKHRORJ\ WLPH VZHHSV
Figure 3-11. These may be due to slippage occurring as the plate used in the 
rheology was smooth (Walls et al., 2003). Slippage may cause slight deviation 
for individual results but will not affect the overall rheology results as smooth 
plates were used for all studies and all rheology was repeated to ensure 
consistent results. 
 
The effect that a number of synovial fluid components had on formation of 
these complexes was investigated. This study found that salt acted to slow 
formation. Salt will effectively shield the charges on the polymer, which 
reduces the interactions between polymers and causes slower formation. 
 
However these complexes are not suitable for use as an injectable formulation. 
No investigations have been carried out into an injectable system using these 
polymers alone. A protocol of sequential injection or co-injection could be 
devised to allow injection, but this would be unlikely to give a good and 
repeatable complex formation. It would also increase the complexity of 
administration for this system. A formulation using salt to prevent 
complexation was therefore investigated. 
 
It was first necessary to investigate the stability of the complexes in salt. 
Complexes between HA and chitosan were stable in salt concentrations of up 
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to 0.4M for 1:1 ratio complexes and up to 0.3M for 0.5:1 ratio complexes. The 
results for 1:1 ratio complexes agree with what has previously been reported. 
One previous study found that complexes between chitosan and HA did not 
form above 0.5M salt concentration (Lee et al., 2003). 
 
The lower stability of 0.5:1 ratio complexes in salt can be explained by the 
formation of polyelectrolyte particles rather than a gel. Polyelectrolytes are 
known to form into particles when there is a high overall charge in the 
solution. This high overall charge can be due to salt or due to an imbalance in 
polymer concentrations. At the 0.5:1 ratio there is an imbalance in the 
polymers and therefore less salt is required to reach the overall charge where 
small polyelectrolyte particles form. 
 
This stability in salt is better than some other polyelectrolyte complexes, for 
example chitosan with polyethyleneimine (Boughellam, 2007). The stability of 
these Ch:HA complexes is due to the compatibility of the polymers. Chitosan 
and HA both have low charge densities. There is one charge per residue for 
chitosan and one charge every other residue for HA (Denuziere et al., 1996, 
Luppi et al., 2009). These similar charge densities allow the polymers to bond 
tightly together and it has been suggested that this gives Ch:HA complexes 
their stability (Denuziere et al., 1996, Kim et al., 2004). 
 
The use of salt can therefore produce an injectable liquid. Complex formation 
from this liquid could then be achieved by dialysis. The Ch:HA 1:1 ratio 
showed complex formation after 15 minute and little difference was seen 
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between dialysis against water and ASF. This shows that these complexes have 
potential as an injectable system. 
 
The 0.5:1 Ch:HA ratio complexes showed a slower and less complete 
formation which can be explained by the lower stability of this ratio in salt. A 
greater reduction in salt is therefore needed before formation can occur which 
also prevents a more complete formation from occurring. The only question 
that arises with this formation method is the biocompatibility of the high salt 
concentrations. Studies have shown that this brief hypertonic challenge does 
not cause significant damage to chondrocytes in vitro (Boughellam, 2007). 
 
Rheology amplitude sweeps showed that complexes with a wide range of 
rheological properties can be produced. The 1:1 ratio complexes produced the 
most resilient complexes. The 1:1 ratio is the stoichiometric ratio and 
theoretically gives the best interaction and incorporation of polymers. These 
studies were conducted on complexes which entirely covered the plate of the 
rheometer (which is its measuring surface). The measurements are therefore 
comparable and do not reflect changing amounts of complex. 
 
The ideal rheological properties for these complexes within the joint are not 
known. The complexes need to be sufficiently resilient to shear stresses so that 
they are not immediately destroyed by the forces within the joint (Seireg and 
Arvikar, 1975, Sharma et al., 2007). They also need to be sufficiently flexible 
VRWKDWWKH\GRQ¶WFDXVHGDPDJHWRWKHMRLQW(Gerwin et al., 2006, Sharma et al., 
2007, Seireg and Arvikar, 1975). It has been shown that complexes with a 
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wide variety of rheological properties can be synthesised. Therefore if the 
complexes are found to not have the required properties during in vivo studies 
an alternative formulation could be used. 
 
,WZDVDOVRLQWHUHVWLQJWRQRWHZKHUHWKH*ƍDQG\LHOGVWUHVVYDOXHVZHUHVLPLODU
in complexes produced using different HA concentrations. The comparison 
was carried out between 1:1 complexes and complexes produced using double 
the HA concentration. In this comparison it would be expected that similar *ƍ
and yield stress values would be found with the 0.5:1 ratio at the higher HA 
concentration. This would be the case if complex properties were only affected 
by polymer concentration. It was found that for thH *ƍ similar values were 
found for 0.5:1 or 0.4:1 Ch:HA ratio complexes to the 1:1 ratio complexes 
using half the HA concentration. For yield stresses this same point occurred for 
the Ch:HA 0.6:1 ratio complexes. These results suggest that the properties of 
these complexes are affected by both the polymer ratio and concentration. 
 
It was intended to assess the degradation of these complexes through the 
quantification of released polymer. This method allows the monitoring of 
individual complexes throughout their degradation and means that the 
degraded complex would be available for further analyses. Various methods 
have been published for the quantification of chitosan and HA; examples 
include the use of ninhydrin for the quantification of chitosan (Leane et al., 
2004, Sahu et al., 2009, Shirosaki et al., 2009) and dye binding methods for 
both polymers (Wischke and Borchert, 2006, Park et al., 2005, Tang et al., 
2007, Johnston, 2000). However none of these methods were able to assess the 
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release with the required sensitivity or were not able to be successfully 
reproduced in trial studies. 
 
An alternative method was therefore required to monitor degradation. A mass 
loss method was chosen as this has been widely used to monitor the 
degradation of various hydrogels (Alexander and Shakesheff, 2006, Ferruti et 
al., 2005, Wu et al., 2007, Chung et al., 2008, Kim and Park, 2002, Tan et al., 
2009).  
 
The stability of these complexes in water shows the intrinsic stability of these 
complexes. The stability of these complexes in physiological salt is also 
impressive, with a significant proportion of complex remaining after 56 days. 
The degradation occurred in an initial burst which was followed by a period of 
minimal degradation which suggests that there is an initial loss of less well 
bound polymers from the surface leaving a strongly bonded core that is highly 
resilient to salt. 
 
The level of degradation is similar to another study carried out on cross-linked 
hydrogels of chitosan and hyaluronic acid (Tan et al., 2009). Tan et al. found a 
gradual degradation over 28 days in PBS with around 60% of the complex 
remaining after this time. Similar degradation profiles were seen with different 
polymer ratios except when there was a large excess of one polymer (9:1 
ratio). It is promising that the complexes in this study were produced without 
cross links but still have a similar degradation profile. 
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3.5 Conclusions 
 
The results obtained from these hydrogel systems show that the polyelectrolyte 
system has the most promising and favourable properties for the intended 
application. The Pluronic F127 hydrogels showed a lack of stability as they 
lost over half their Pluronic content within 24 hours.  
 
To improve the stability of Pluronic F127 hydrogels chemical crosslinking is a 
possible option. One of the attractions of the Pluronic polymers was the fact 
that they are a Food and Drug Administration approved material. Chemical 
modification would negate this advantage. Also the degradation of Pluronic 
hydrogels was so rapid that even with modifications it would be a challenge to 
produce hydrogels with the required stability. The maximum length of 
degradation that has been found with a chemically modified Pluronic F127 
hydrogel was 14 days in a physiological buffer (Chung et al., 2008, Kim and 
Park, 2002). 
 
However the results obtained for the polyelectrolyte system are promising. 
They show that complexes form rapidly, can be produced in an injectable form 
and have a high stability in physiological salt concentrations. Preliminary 
investigations also showed that these complexes are able to efficiently 
incorporate nanoparticles. The stability in salt is particularly encouraging as 
salt is known to be disruptive to polyelectrolytes. 
 
These promising properties have therefore led to the selection of this system 
for further study and the elimination of the Pluronic F127 hydrogels. The 
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stability seen with the polyelectrolyte complexes has come under less 
demanding conditions than those found within the joint. It would be desirable 
to have covalent cross-links within the system to provide a greater stability that 
may be required in vivo. These cross-links would also help to stabilise the 
reduced chitosan complexes and improve their properties. The next chapter 
therefore investigates the synthesis of a modified hyaluronic acid and its 
inclusion into polyelectrolyte complexes. 
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CHAPTER 4 - SYNTHESIS OF A MODIFIED 
HYALURONIC ACID AND ITS INCORPORATION 
INTO POLYELECTROLYTE COMPLEXES 
 
4.1 Introduction to Chemically Modified Hyaluronic Acids 
 
A variety of chemical approaches have been investigated for modifying 
hyaluronic acid in order to improve its properties. Modified hyaluronic acids 
have been used for applications such as eye surgery, anti-adhesion films and 
cosmetics (Prestwich and Kuo, 2008). A number of products utilising modified 
HA have been approved and are currently marketed. 
 
4.1.1 Types of Modification 
4.1.1.1 Carboxylate group modifications 
 
The structure of hyaluronic acid has two targets for chemical modification. 
These are the carboxylate group and the pendant hydroxyl group, which are 
illustrated in Figure 4-1. The carboxylate group in hyaluronic acid is the most 
common target for modifications. 
 
At this site carbodiimide chemistry is the most common scheme used. 
Carbodiimides react with carboxylates and in the presence of nucleophiles, 
such as amines or hydrazides, facilitate the formation of amides or esters 
respectively. Hyaluronic acid is water soluble and poorly soluble in other 
solvents. This means that the water soluble carbodiimide 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide (EDAC) has been widely used for HA 
modification. Examples of carbodiimide modifications include HA modified 
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with PEG (Moriyama et al., 1999); HA conjugated to a dye (Collis et al., 
1998); and HA with pendant thiol groups by using a hydrazide (Pouyani et al., 
1994, Shu et al., 2002) or cystamine as a nucleophile (Lee et al., 2007). 
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Figure 4-1 Structure of hyaluronic acid with the two most commonly modified groups 
marked with a star. 
 
Other reactions using carbodiimides are also possible. The reaction of EDAC 
alone with HA produces an N-acylurea adduct. These adducts can produce 
hydrogels as the acylurea interacts with other carboxylates within HA leading 
to gelation (Kuo et al., 1991). There have also been attempts to cross-link HA 
through carbodiimide chemistry, examples include a conjugation using 
multivalent hydrazides (Prestwich and Kuo, 2008), or a biscarbodiimide (Kuo 
et al., 1991, Prestwich, 2001). 
 
4.1.1.2 Hydroxyl group modifications 
 
Modification of the pendant hydroxyl groups on hyaluronic acid is also 
possible. Hyaluronic acid also contains hydroxyl groups on its sugar rings, but 
these are sterically hindered and much more challenging to modify. 
 
Hylans are a group of hyaluronic acids modified on their pendant hydroxyl 
groups and there are two main hylans with different modifications. Hylan A is 
a liquid HA and contains cross links between HA and proteins through the use 
* 
* 
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of formaldehyde (Band, 1998). Hylan B is a gel that is cross-linked through the 
use of divinylsulfone (DVS) (Band, 1998). DVS has also been used to cross-
link HA with other polymers such as carboxymethyl cellulose and 
hydroxyethylcellulose (Sannino et al., 2004). 
 
4.1.1.3 Other 
 
Modifications that target both the carboxylate and hydroxyl groups on HA 
have been investigated. Epoxides can react with amino, carboxyl and hydroxyl 
groups. The reaction of bisepoxides with HA produces a cross-linked product 
(Lindqvist et al., 2002). An alternative reaction scheme used 2-chloro-1-
methylpyridinium iodide to cause the formation of internal ester bonds between 
the HA hydroxyl and carboxylates (Barbucci et al., 2003, Barbucci et al., 
2002). 
 
4.1.2 Uses of Modified Hyaluronic Acid 
4.1.2.1 Prevention of post-surgical adhesions 
 
Modified hyaluronic acid hydrogels are widely used for the prevention of post-
surgical adhesions. Post-surgical adhesions are internal scar tissue that causes 
aberrant internal adhesions. They can be caused by infection, trauma or 
surgical damage. The rate of adhesions after surgery can be very high and can 
cause complications including pain and infertility (Yeo and Kohane, 2008). 
 
A number of modified hyaluronic acid hydrogels are commercially available 
for the prevention of adhesions. These include Seprafilm
®
 (Genzyme, USA), 
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Incert
®
-S (Anika Therapeutics, USA), Hyalobarrier
® 
(Nordic Pharma Group, 
France) and Hyaloglide
®
 (Anika Therapeutics) (Prestwich and Kuo, 2008). 
 
4.1.2.2 Viscosupplementation 
 
Hyaluronic acid is used to restore the protective properties of synovial fluid 
that are lost in osteoarthritis. A number of the currently available HA 
preparations for viscosupplementation contain chemically modified HAs, see 
Table 1-1. For example Hylan GF-20 (Genzyme, USA) is a combination of 
hylan A (90%) and hylan B (10%) (Prestwich and Kuo, 2008). 
 
4.1.2.3 Other uses 
 
Hyaluronic acid has been widely used for cosmetic applications and modified 
HA has been used as a dermal filler. Products marketed as dermal fillers 
include Restylane
®
 (Q-med, Sweden), Hylaform
® 
and Puragen
®
 (Mentor, 
USA) (Prestwich and Kuo, 2008). Modified HAs have also been used as 
wound dressings and as scaffolds for chondrocytes or dermal fibroblasts 
(Prestwich and Kuo, 2008). 
 
4.1.3 Modified Hyaluronic Acid in Hydrogels 
 
Many chemically modified hyaluronic acid derivatives have been incorporated 
into hydrogels and injectable hydrogels. An injectable HA hydrogel has been 
produced with HA conjugated to tyramine. Hydrogels were formed in situ 
through the action of HRP (horseradish peroxidise) (Lee et al., 2008). Another 
injectable hydrogel utilised separate cross-linking of HA and carboxymethyl 
cellulose to form an interpenetrating network (IPN) (Barbucci et al., 2010). An 
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IPN occurs where two crosslinked polymer networks become entangled with 
no bonding between the different polymers. These two hydrogels have been 
characterised but have not been investigated for any potential applications. 
 
Pluronic F127 and HA have been cross-linked together through 
photopolymerisation. This produced hydrogels that degraded gradually over 28 
days and gave a sustained protein release over 14 days in vitro (Kim and Park, 
2002). An injectable system composed of HA conjugated to a thermosensitive 
polymer has also been produced. This system consisted of PNIPAM 
conjugated to chitosan which was then conjugated to HA (Chen and Cheng, 
2009, Fang et al., 2008) and produced polymers with gelation temperatures 
around 30°C (Chen and Cheng, 2009, Fang et al., 2008). Hydrogels produced 
gave drug delivery over 2 days with hydrophilic drugs giving a burst release 
whereas hydrophobic drugs gave a more sustained delivery (Fang et al., 2008). 
 
Hyaluronic acid derivatives have not however been incorporated into 
precipitated polyelectrolyte complexes. The closest example has been the 
production of polyelectrolyte particles using a modified chitosan (Wu et al., 
2007). In this system PEG modified chitosan was used to improve the 
solubility of the system and avoid precipitated complexes. 
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4.1.4 Chapter Aims 
 
The aim in this chapter was to produce and characterise a modified hyaluronic 
acid (HAM). This modification was the inclusion of cysteamine on the 
carboxylate groups through a reaction catalysed by EDAC and the structure of 
the HAM is shown in Figure 4-2. 
 
The reaction was conducted in aqueous conditions and this is well known to 
produce low reaction yields (usually of around 30%). To overcome this three 
times the required molar amount of cysteamine was used. For this study the 
percentage modification of HA refers to the percentage of repeating units that 
have been modified. A 10% modification was aimed for. It was hoped that this 
would give increased stability but not interfere with the formation or 
biocompatibility of the complexes. 
 
HAM was then used in polyelectrolyte complexes. The properties of these 
complexes were assessed and compared to those prepared with unmodified 
HA. It was hoped that HAM would produce more resilient complexes that were 
more resistant to degradation. This would allow complexes to survive within 
the joint for three months, which is the aim for this delivery system. 
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Figure 4-2 Structure of the cysteamine modified hyaluronic acid (HAM) used in this 
study. 
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4.2 Materials and Methods 
4.2.1 Materials 
 
The materials used are detailed in section 2.1. 
 
4.2.2 Modified Hyaluronic Acid Preparation and Characterisation 
4.2.2.1 Synthesis of modified hyaluronic acid 
 
Modified hyaluronic acid was synthesised using the method in section 2.4.1. 
 
4.2.2.2 Characterisation of modified hyaluronic acid 
 
Modified hyaluronic acid was characterised using the method in section 2.4.2. 
 
4.2.3 Polyelectrolyte Complex Preparation and Characterisation 
4.2.3.1 Complex formation with modified hyaluronic acid 
 
Modified hyaluronic acid was used in exactly the same way as unmodified 
hyaluronic acid. Complexes were prepared as detailed in section 2.3.2.2 and 
the formation was assessed using the methods in section 2.3.2.2. 
 
4.2.3.2 Rheology amplitude sweeps 
 
Rheology amplitude sweeps on complexes containing modified hyaluronic acid 
were carried out as described in section 2.3.2.3. 
 
4.2.3.3 Complex degradation 
 
The degradation of complexes containing modified hyaluronic acid was 
analysed using the method described in section 2.3.2.4. 
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4.2.3.4 Effect on salt on complex formation 
 
The effect of salt on the formation of complexes containing modified 
hyaluronic acid was analysed using the method described in section 2.3.2.5. 
 
4.2.3.5 Complex formation by dialysis 
 
Complexes containing modified hyaluronic acid were prepared by the dialysis 
method described in section 2.3.2.4. The formation of these complexes was 
analysed using the methods detailed in section 2.3.2.6. 
 
4.3 Results 
4.3.1 Modified Hyaluronic Acid Synthesis and Characterisation 
 
Hyaluronic acid was reacted with cysteamine and EDAC in a 1:3:4 molar ratio 
(HA monomer:cysteamine:EDAC). The reaction was carried out in aqueous 
solution at room temperature. The reaction resulted in the production of a 
modified hyaluronic acid, which will be referred to as HAM. Characterisation 
of the polymer using NMR was unsuccessful due to the viscosity of hyaluronic 
acid solutions limiting the sample concentration and therefore preventing 
characterisation of the modification. 
 
(OOPDQ¶V 7HVW ZDV WKHUHIRUH XVHG WR GHWHUPLQH WKH FRQFHQWUDWLRQ RI
incorporated sulfhydryl groups. This found the modification level to be 0.91%, 
Table 4-1, which is much lower than originally intended. Initial investigations 
found that even these low modification levels caused changes in the complex 
properties. The modified HA was stable in solution and did not spontaneously 
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form hydrogels. This was the desired situation and is an advantage of the low 
modification level. 
Theoretical 
modification level 
Actual modification Standard Deviation 
10% 0.91% 0.03 
Table 4-1 +\DOXURQLFPRGLILFDWLRQOHYHOLQ+$0DVGHWHUPLQHGE\(OOPDQ¶V7HVW 
 
4.3.2 Characterisation of Complexes with Modified Hyaluronic Acid  
4.3.2.1 Complex formation 
 
A photographic study was undertaken to assess the formation of complexes 
with HAM. This study also investigated the ability of complexes to form in the 
presence of physiological salt. The results of this study are presented in Figure 
4-3. This found that complexes were similar in appearance to those produced 
with unmodified HA. The complexes retained the compact and well defined 
form seen with Ch:HA complexes. As the chitosan concentration was reduced 
the Ch:HAM complexes became smaller and had a more fibrous appearance. 
 
The only obvious difference between Ch:HAM and Ch:HA complexes was in 
the bulk solution. For Ch:HAM complexes this solution was cloudy at the 0.8:1 
ratio and below, whereas at 0.9:1 and 1:1 ratios it was clear. The Ch:HA 
samples showed a slight turbidity that was consistent at all ratios. The turbidity 
in the Ch:HAM complexes varied between batches, for example the 1:1 
complex produced in the formation study showed a turbid bulk solution, Figure 
4-4. Physiological salt caused a slight disruption of the Ch:HAM complexes 
and increased their fibrous appearance. In all cases visible formation occurred 
and there was a degree of turbidity in the bulk solution. 
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1:1                0.9:1                  0.8:1               0.7:1   
 
0.6:1               0.5:1                0.4:1 
Complexes prepared in water 
 
  1:1                 0.9:1               0.8:1                0.7:1   
 
0.6:1               0.5:1                0.4:1 
Complexes prepared in ASF 
Figure 4-3 Photographs showing Ch:HAM complexes of various polymer ratios prepared 
in water or ASF buffer. 
Ch:HAM complexes were prepared at the indicated polymer ratio in water or ASF. Complexes 
were incubated at 37°C for 60 minutes before photographs were taken. 
 
 
The formation kinetics of Ch:HAM complexes were studied using the same 
methods as the Ch:HA complexes, which were a photographic study and 
rheology time sweeps. These results showed a dramatic change in formation 
with Ch:HAM complexes forming immediately into compact complexes, 
Figure 4-4, with little change observed after this. There was no visual 
difference in the kinetics of formation between Ch:HAM complexes at 
different polymer ratios. 
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0 minutes             10 minutes            20 minutes            30 minutes  
 
40 minutes          50 minutes           60 minutes 
Ch:HAM 1:1 complexes 
 
 0 minutes           10 minutes           20 minutes           30 minutes  
 
40 minutes           50 minutes            60 minutes 
Ch:HAM 0.7:1 complexes 
 
0 minutes            10 minutes            20 minutes            30 minutes  
 
40 minutes           50 minutes            60 minutes 
Ch:HAM 0.5:1 complexes 
Figure 4-4 Photographs showing the formation of Ch:HAM complexes at different 
polymer ratios in water. 
Chitosan and HAM at varying ratios were mixed and incubated at 37°C. Photographs were 
taken at the indicated time. 
 
The results of the rheology time sweeps are presented in Figure 4-5 and 
confirm the visual observations. Ch:HAM complexes appeared to exhibit an 
instantaneous gelation, but in reality this occurred before measurements could 
start. The formation of Ch:HAM complexes was complete after 60 minutes 
ZKHQWKH*ƍYDOXHVWDELOLVHG. 
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Figure 4-5 Rheology time sweeps showing the formation kinetics of Ch:HAM complexes. 
Rheology time sweeps were conducted at 37°C. Chitosan and HAM, at different ratios, were 
mixed on the plate of the rheometer and measurements were started as soon as possible 
DIWHUZDUGV*ƍVTXDUHVDQG*ƍƍWULDQJOHVDUHSORWWHGRQWKHSULPDU\\-D[LVSKDVHDQJOHį- 
diamonds) is plotted on the secondary axis. 
 
The formation of complexes will occur within the joint. The effect that 
synovial fluid components had on formation was investigated through rheology 
time sweeps. These results, presented in Figure 4-6, showed that physiological 
salt caused a slowing in the formation of Ch:HAM complexes. There was a 
VOLJKW UHGXFWLRQ LQ WKH ILQDO *ƍ YDOXH ZKLFK VXJJHVWV WKDW VDOW DOVR VOLJKWO\
reduces the overall complex strength. When protein was also included (as 
ASFP) the formation kinetics were similar to those in water but the final *ƍ
value was still reduced. The presence of HA interfered with Ch:HAM complex 
formation, as the Gƍ evolved gradually over 150 minutes, rather than 60 
minutes as previously observed. 
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Figure 4-6 Rheology time sweeps showing the formation kinetics of Ch:HAM complexes 
under synovial relevant conditions. 
Rheology time sweeps were conducted at 37°C on Ch:HAM 1:1 ratio complexes. Chitosan and 
HAM were mixed on the plate of the rheometer with any additional components and 
PHDVXUHPHQWVZHUHVWDUWHGDVVRRQDVSRVVLEOHDIWHUZDUGV*ƍVTXDUHVDQG*ƍƍWULDQJOHVDUH
plotted on the primary y-D[LV SKDVH DQJOH į- diamonds) is plotted on the secondary axis. 
Buffer used for formation is shown in the legend. 
 
4.3.2.2 Complex integrity 
 
Rheology amplitude sweeps were conducted to assess the effect of HAM on 
FRPSOH[VWUHQJWK7KHNH\SDUDPHWHUVRI*ƍDQG\LHOGVWUHVVYDOXHVIURPWKHVH
amplitude sweeps are presented in Figure 4-7. These results showed that HAM 
caused an increase in gel strength of these complexes. At all polymer ratios 
VWXGLHG &K+$0 FRPSOH[HV KDG ODUJHU *ƍ DQG \LHOG VWUHVV YDOXHV WKDQ
equivalent Ch:HA complexes. These differences between Ch:HA and Ch:HAM 
complexes were statistically significant (P<0.05) at ratios between 1:1 and 
IRUERWK*ƍDQG\LHOGVWUHVVYDOXHV7KH LQFUHDVHV LQ\LHOGVWUHVVHVZHUH
 133 
UHODWLYHO\ODUJHUWKDQWKRVHRIWKH*ƍ7KHUDWLR&K+$0FRPSOexes had 
WKHJUHDWHVW*ƍDQG\LHOGVWUHVVYDOXHV7KLVZRXOGVXJJHVWWKDWWKHPRGLILFDWLRQ
has slightly altered the charge ratios of these complexes. This is expected as the 
ratios and chitosan concentrations were not recalculated to take account of the 
lost carboxylate groups in HAM. 
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Figure 4-7 *UDSKV VKRZLQJ *ƍ DQG \LHOG VWUHVV YDOXHV IRU &K+$ DQG &K+$0
complexes. 
*ƍ DQG \LHOG VWUHVV YDOXHV ZHUH H[WUDFWHG IURP UKHRORJ\ DPSOLWXGH VZHHSV FDUULHG RXW RQ
cRPSOH[HVDW&RIWKHLQGLFDWHGSRO\PHUUDWLRV7RS*ƍYDOXHLQ/95ERWWRP\LHOGVWUHVV
value. For both graphs: Ch:HA complexes- red; Ch:HAM complexes- blue. 
 
4.3.2.3 Complex degradation 
 
The long term stability of these complexes is a key property to allow for their 
use as a slow release delivery system. The effect of HAM on complex 
degradation was assessed using the mass degradation method used with the 
Ch:HA complexes. This showed that Ch:HAM complexes had a similar 
degradation profile to Ch:HA complexes, Figure 4-8. Ch:HAM complexes 
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were stable in ASF for the 56 days of the study and over 60% of the complex 
remained at the end of the study. The complexes showed an initial rapid mass 
loss over 2 weeks which was followed by minimal degradation. The Ch:HAM 
1:1 complexes showed a more gradual initial degradation, with a significant 
difference found between Ch:HAM 1:1 and Ch:HA 1:1 complexes at 7 days 
(P<0.001), but no significant differences were found at other time points. 
Analysis of the 0.5:1 ratio complexes showed that HAM caused a significant 
difference (P<0.01) compared to Ch:HA complexes at 56 days only. This 
shows that at this lower chitosan concentration HAM stabilised the complexes. 
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Figure 4-8 Mass degradation profiles of Ch:HA and Ch:HAM complexes in ASF. 
Ch:HA and Ch:HAM complexes were prepared and were then incubated in ASF buffer at 
37°C. Buffer was regularly changed and at each time point complexes were extracted, dried 
and weighed. 
 
Due to the forces that can occur within joints it is important to not only 
consider the complex mass loss but also the effects that this has on the integrity 
and strength of the complexes. In order to assess these properties degraded 
samples were analysed using rheology amplitude sweeps. The results of this 
study are presented in Figure 4-9. This shows that despite the significant mass 
ORVVWKHFRPSOH[HVUHWDLQHGWKHLULQWHJULW\DQGPXFKRIWKHLUVWUHQJWK7KH*ƍ
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values showed very little difference over the study period. The complexes 
DSSHDU WR H[KLELW D VOLJKW LQFUHDVH LQ *ƍ DIWHU  ZHHNV EHIRUH GURSSLQJ EDFN
after 8 weeks of degradation. The yield stress results showed a more gradual 
decline. This shows that there is a gradual loss of resistance to shear stresses 
whilst the overall structure and strength of the complexes is unaffected. 
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Figure 4-9 *ƍ DQG \LHOG VWUHVV YDOXHV IRU &K+$ DQG &K+$0 FRPSOH[HV GXULQJ
degradation in ASF. 
*ƍ DQG \LHOG VWUHVV YDOXHV were extracted from rheology amplitude sweeps carried out on 
GHJUDGHG FRPSOH[HV DW & 7RS *ƍ YDOXH LQ /95 ERWWRP yield stress value. For both 
graphs, the time of degradation in ASF: 0 days- blue; 28 days- red; 56 days- grey. 
 
This degradation study was extended to investigate the effect that protein had 
on complex degradation. The results of this study are presented in Figure 4-10. 
With protein present complex mass was found to increase during the study 
which could be explained by protein adsorption to the complexes. As proteins 
have a polyelectrolyte nature this would not be surprising as they can interact 
with the charges present on the polyelectrolyte complexes. 
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Complexes showed little change over the first 7 days, suggesting that during 
this period protein adsorption replaces the mass loss that was previously 
observed. This plateau was followed by a slow increase in complex mass until 
28 days. After this point the complexes diverged with Ch:HAM complexes 
stabilising and Ch:HA complexes continuing to gain mass. The only 
statistically significant differences were found between all samples after 56 
days (P<0.001); except between Ch:HAM 0.5:1 and Ch:HA 1:1 samples where 
the difference was not statistically significant. 
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Figure 4-10 Mass degradation profiles of Ch:HA and Ch:HAM complexes in ASFP. 
Ch:HA and Ch:HAM complexes were prepared were then incubated in ASFP buffer at 37°C. 
Buffer was regularly changed and at each time point complexes were extracted, dried and 
weighed. 
 
4.3.3 Evaluation of injectable formulation 
4.3.3.1 Stability in salt 
 
The aim was to produce an injectable formulation of these complexes. To 
achieve this salt was used to prevent complexation. Therefore the stability of 
Ch:HAM complexes in salt was important and this was assessed in a 
qualitative study. The results of this study are presented in Figure 4-11. At the 
Ch:HAM 1:1 ratio discrete compact complexes were formed in 0.1M NaCl and 
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below. At 0.2M and 0.3M salt a precipitated complex was produced which was 
more diffuse and is not well represented in the photographs. 0.4M and 0.5M 
NaCl gave a full disruption of Ch:HAM complexes. At the 0.5:1 Ch:HAM 
polymer ratio similar results were observed although a complete complex 
disruption occurred in 0.3M salt concentration and above. These results suggest 
that Ch:HAM complexes are slightly less stable in salt than Ch:HA complexes. 
 
 
0M             0.1M            0.2M            0.3M            0.4M             0.5M  
Ch:HAM 1:1 
 
0M             0.1M              0.2M             0.3M           0.4M          0.5M  
Ch:HAM 0.5:1 
Figure 4-11 Photographs showing the effect of salt on Ch:HAM complex formation. 
Ch:HAM complexes were prepared in the presence of the indicated concentration of NaCl. 
Mixtures were incubated at 37°C for 60 minutes to allow complex formation to occur before 
photographs were taken. Top: Ch:HAM 1:1; Bottom: Ch:HAM 0.5:1. 
 
4.3.3.2 Complex formation by dialysis 
 
As the complexes showed a broadly similar stability in salt 0.5M NaCl would 
continue to be used to prevent complexation. The formation of Ch:HAM 
complexes using the dialysis formation method was then assessed. 
Photography of forming complexes and rheology amplitude sweeps were 
utilised for this. Ch:HAM 1:1 complexes exhibited a rapid precipitation 
followed by a contraction into discrete complexes over an hour, Figure 4-12. 
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0 mins                   15 mins                  30 mins                  60 mins 
Ch:HAM 1:1 in water 
 
0 mins                   15 mins                  30 mins                  60 mins 
Ch:HAM 1:1 in ASF 
Figure 4-12 Photographs showing the formation of Ch:HAM 1:1 complexes by dialysis. 
Solutions containing complex components were prepared in 0.5M NaCl. These mixtures were 
dialysed against water or ASF at 37°C with the buffer replaced every 15 minutes. Photographs 
were taken at each buffer change. 
 
 
These results were confirmed by the rheology amplitude sweeps, Figure 4-13. 
A detectable formation occurred within 15 minutes and little change occurred 
after this time. This suggests that the contraction seen does not affect the 
overall complex structure and strength. When ASF was used as the dialysate 
there was a greater formation of small complexes that were not incorporated 
into the main complex. The rheology results showed no difference in the initial 
IRUPDWLRQ$IWHUWKLVSRLQWWKHUHZDVDJUDGXDOLQFUHDVHLQWKH*ƍVKRZLQJWKDW
ASF slightly slowed complex formation. Overall the formation of Ch:HAM 1:1 
complexes was similar to that found with Ch:HA complexes. 
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Figure 4-13 Rheology amplitude sweeps showing Ch:HAM 1:1 complex formation by 
dialysis. 
Solutions containing complex components were prepared in 0.5M NaCl. These mixtures were 
dialysed against water or ASF at 37°C with the buffer replaced every 15 minutes. Rheology 
DPSOLWXGH VZHHSV ZHUH FDUULHG RXW RQ WKH UHFRYHUHG PL[WXUHV DW & *ƍ VTXDUHV DQG *ƍƍ
(triangles) are plotted against shear stress. Left: dialysis against water; Right: dialysis against 
ASF. Time of dialysis is shown in the legend and is the same for both graphs. 
 
The 0.5:1 ratio was also investigated with the dialysis formation method. With 
water as the dialysate precipitation was seen within 15 minutes, Figure 4-14, 
and was followed by a contraction into discrete complexes over an hour. This 
was confirmed by rheology, where formation was detected after 45 minutes, 
Figure 4-7KH*ƍand yield stress values slowly increased for the remainder 
of the study period. Dialysis against ASF caused a reduced complex formation 
with only a very diffuse formation visible after 15 minutes. Formation 
proceeded slowly and after 60 minutes a small discrete complex was formed. 
Rheology amplitude sweeps on these samples failed to detect any complex 
formation. These results show that HAM has a positive effect on formation at 
the 0.5:1 ratio and caused a greater formation than was seen with HA. However 
the formation is still affected by physiological salt in the reduced chitosan 
samples. 
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0 mins                   15 mins                  30 mins                   60 mins        
Ch:HA 0.5:1 in water 
 
0 mins                   15 mins                  30 mins                  60 mins       
Ch:HA 0.5:1 in ASF 
Figure 4-14 Photographs showing the formation of Ch:HAM 0.5:1 complexes by dialysis. 
Solutions containing complex components were prepared in 0.5M NaCl. These mixtures were 
dialysed against water or ASF at 37°C with the buffer replaced every 15 minutes. Photographs 
were taken at each buffer change. 
 
Figure 4-15 Rheology amplitude sweeps showing Ch:HAM 0.5:1 complex formation by 
dialysis. 
Solutions containing complex components were prepared in 0.5M NaCl. These mixtures were 
dialysed against water at 37°C with the buffer replaced every 15 minutes. Rheology amplitude 
sweeps were carried on the recovered mixtures at 37°C. *ƍ VTXDUHV DQG *ƍƍ WULDQJOHV DUH
plotted against shear stress. Time of dialysis is shown in the legend. 
 
4.4 Discussion 
4.4.1 Modified Hyaluronic Acid 
 
A modified HA was successfully synthesised and characterised but the 
modification levels were below what was expected. HAM was found to have a 
modification level of 0.9% despite using a three fold excess of reactants to 
account for an expected low yield. The high molecular weight HA used in this 
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study limited the concentration that could be used due to the viscosity of the 
solution. This low concentration in aqueous conditions may account for the low 
UHDFWLRQ HIILFLHQF\ 7KH PRGLILFDWLRQ OHYHO ZDV GHWHUPLQHG E\ (OOPDQ¶V 7HVW
which measures the concentration of sulfhydryl groups present. Other methods 
for characterisation were investigated such as 
1
H-NMR, which was not 
effective due to the viscosity of HA solutions limiting sample concentration.  
 
High levels of HA modification have been achieved but generally these have 
involved more complex reaction schemes. The use of EDAC in combination 
with 1-hydroxybenzotriazole has produced substitution levels of 25 to 80% 
(Lee et al., 2007, Luo and Prestwich, 2001). Hydrazides with EDAC have been 
able to give substitution levels of 25 to 40% (Shu et al., 2002). These are 
exceptional and in general modification levels using EDAC have been below 
10% (Moriyama et al., 1999, Ponedel'kina et al., 2008). 
 
Other reaction schemes also have produced many substitutions of around 10%. 
For example a methacrylated HA needed a 6 to 10 fold excess of reactants to 
produce a 5 to 10% modification level (Leach et al., 2003). A method using 2-
chloro-1-methylpyridinium iodide produced a 5 to 10% modification (Gamini 
et al., 2002). It has been reported that carbodiimide mediated conjugation to 
primary amines with HA results in negligible coupling (Luo and Prestwich, 
2001). This paper was acting to promote an alternative reaction scheme and the 
results here show that although the reaction produced a much lower 
modification than intended a measurable modification was achieved. 
 142 
4.4.2 Complexes with Modified Hyaluronic Acid 
 
Complexes produced with HAM were visually similar to those produced with 
unmodified HA. This was the case at all polymer ratios and physiological salt 
caused only a slight disruption to the complexes. The only visual difference to 
Ch:HA complexes was in the bulk solution, which was more turbid with 
Ch:HAM complexes. The only exception was at 0.9:1 and 1:1 ratios, although 
these ratios showed turbidity on occasion. This turbidity can be explained by 
the formation of small polyelectrolyte particles, which usually occurs in high 
charge solutions. However the formed Ch:HA and Ch:HAM complexes have a 
similar mass. This shows that the increase in smDOO FRPSOH[HV LVQ¶W DW WKH
expense of the precipitated complex. This suggests that these small complexes 
form out of any polymer that was not incorporated into the main complex. This 
may be driven by the ability of the modified HA to form cross-links. 
 
The most significant and unexpected change when HAM was incorporated into 
complexes was a much more rapid complex formation. This was seen in the 
visual study where formation occurred during mixing, with few changes after 
this. It was also apparent through rheology time sweeps which showed that 
gelation occurred before measurements could start and the formation was 
complete after 60 minutes. This compared to Ch:HA complexes which showed 
visual changes over 30 minutes and rheological changes over around 150 
minutes. This rapid formation is of great advantage for this project because 
after administration the complexes need to form before clearance from the joint 
occurs. 
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It is proposed that this increase in the speed of formation is due to the structure 
of complexes becoming locked due to the formation of cross-links. These 
cross-links also act to pull the complexes together more rapidly. The ratio of 
polymers had no effect on the speed of formation of the Ch:HAM complexes. 
This shows further advantages over the Ch:HA complexes where a slower 
formation was found with lower chitosan concentrations. 
 
Investigations were carried out on the effect of physiological conditions on 
Ch:HAM complex formation. These found that physiological salt and the 
presence of unmodified hyaluronic acid caused a slowed complex formation. 
This would suggest that salt causes a slight disruption of complexes as they 
form. It would also suggest that HAM is not exclusively incorporated into the 
complexes when both HA and HAM are present. The incorporation of 
unmodified HA slows Ch:HAM complex formation as it is unable to cross-
link. The kinetics are similar to those of Ch:HAM complexes alone which 
suggests that HAM is preferentially incorporated. This would be expected as 
cross-links can only form between HAM molecules. These results show that 
the formation of complexes with HAM was only slightly affected by the 
presence of synovial fluid constituents. Formation is faster than with 
unmodified HA under these conditions. 
 
Rheology amplitude sweeps showed that HAM caused a significant increase in 
complex resistance to shear stress at ratios between 1:1 and 0.5:1. This was 
expected as the inclusion of covalent cross-links into the complexes should 
increase their stability and gel strength. Covalent bonds are strong bonds and 
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when formed across the entire complex would produce a resilient complex. It 
was also found that there was a greater relative increase in the yield stress 
compared to the *ƍ7KLV LVSRVLWLYHDVLW VXJJHVWV WKDW WKHUHVLVWDQFH WRVKHDU
stress has been increased without increasing the solidity of the complexes as 
much. Therefore these Ch:HAM complexes should be better able to withstand 
the physical challenges of the joint without being too rigid and causing damage 
(Seireg and Arvikar, 1975, Sharma et al., 2007, Gerwin et al., 2006).  
 
,WZDVDOVRIRXQGWKDW&K+$0FRPSOH[HVH[KLELWHGWKHJUHDWHVW*ƍDQG yield 
stress at the 0.9:1 ratio, which suggests that the modification has changed the 
charge ratios of these complexes. The modification of HA on the carboxylate 
group will have removed charges from the polymer. The modification was at a 
low level and so would not be expected to cause a discernible change in the 
complexes. However if there were inaccuracies in the original polymer 
characterisations then the calculated ratios may have been slightly inaccurate. 
Therefore despite the low level of modification the stoichiometry of the 
complexes may have been altered. 
 
Ch:HAM complexes showed a similar degradation profile to Ch:HA 
complexes in ASF buffer. Ch:HAM 1:1 complexes showed a slower initial rate 
of degradation, which was statistically significant to Ch:HA 1:1 complexes at 7 
days. After this time the degradation profile trended back towards that of 
Ch:HA 1:1 complexes and at the end of the study the overall degradation levels 
were very similar. This would suggest that the covalent bonds are able to 
increase the stability of these complexes. 
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The degradation of Ch:HA complexes showed that there was a stable core to 
the complexes. The mass loss observed has been attributed to the loss of 
loosely incorporated polymer chains on the surface. The increase in initial 
stability with Ch:HAM would therefore be due to these loosely incorporated 
polymer chains being more tightly held by covalent bonds which slows their 
release. 
 
HAM did not affect the formation of the complex core and so similar 
degradation levels were seen compared to unmodified HA. Further studies 
under more challenging conditions would be required to see whether HAM was 
able to slow the degradation of this core. Ch:HAM 0.5:1 complexes show some 
evidence of this. They retained a significantly larger mass at 56 days compared 
to Ch:HA complexes. This suggests that HAM may also be able to stabilise the 
core of these complexes. 
 
The stability of these complexes compares well to the degradation of other 
hydrogels produced using modified hyaluronic acids. One system used 
hyaluronic acid linked to Pluronic F127 (Kim and Park, 2002). These 
hydrogels showed an 80% mass loss over 20 days. A system that is more 
comparable to that produced here used hydrogels of covalently linked 
hyaluronic acid and chitosan (Tan et al., 2009). These hydrogels exhibited a 
slow and gradual degradation in PBS over 28 days of study. During this time 
around 20% to 40% of the hydrogel mass was lost depending on the exact 
hydrogel composition.  These are very similar levels and rates of degradation 
to those seen with the Ch:HAM complexes produced here. However the 
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termination of the study after 28 days means that it is not possible to assess 
whether a plateau in degradation would occur as was seen in this study. 
 
The rheology amplitude sweeps that were conducted on degraded samples gave 
further information on the degradation of the complexes. These showed that 
GXULQJ WKH GHJUDGDWLRQ WKHUH ZDV OLWWOH FKDQJH LQ *ƍ YDOXHV DQG D JUDGXDO
decrease in yield stresses. This suggests that the mass lost from these 
complexes did not cause large structural and mechanical changes in complexes. 
The polymer lost is therefore most likely to be loosely associated on the 
surface. 
 
To investigate the degradation of these complexes in more biologically relevant 
conditions a study was conducted where protein was also included. This found 
little change over the first week and then a gradual increase in mass. This 
would be due to protein being adsorbed onto the surface of these complexes. It 
is not surprising that this occurs as proteins are polyelectrolytes meaning that 
they can form electrostatic bonds with the complexes. The adsorption occurs 
gradually and initially replaced the mass loss that was seen in other studies. 
After 28 days there was a divergence in the remaining mass of complex with 
statistically significant differences between samples at 56 days. Ch:HAM 
complexes stabilised over this period which would suggest that a maximum 
protein binding has been reached. The Ch:HA 0.5:1 complexes continued to 
gain mass through this time. These complexes were the least stable in previous 
studies. This would suggest that the degradation in these complexes exposed a 
greater surface area over which protein could adsorb.  
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The production of injectable complexes was an aim of this study. In order to 
achieve this complexation would be prevented by salt. The effect that HAM 
had on complex formation in salt was therefore important. A study found that 
Ch:HAM complexes seemed to be slightly less stable in salt than Ch:HA 
complexes. This may be explained as the modification causes a reduction in the 
charges present on HA. This would reduce the electrostatic bonding between 
complexes meaning they were more easily disrupted. 
 
The reduction in stability was only small and complexes were successfully 
prepared in physiological salt concentrations. It may provide an advantage 
though as a lower salt concentration could be used in the injectable 
formulation. These results suggest that the electrostatic charges drive the initial 
interaction between these two polymers and the covalent bonds form after 
these initial interactions. If covalent bonds played a role in the initial 
interactions Ch:HAM complexes would be expected to show a greater stability 
in salt as these bonds would be less affected by the salt. 
 
The decreased stability of Ch:HAM complexes in salt gave concerns for the 
formation of complexes by the dialysis method. Experiments found that 
Ch:HAM complexes were able to form better than Ch:HA complexes by this 
method. This is particularly clear at the 0.5:1 ratio. Formation was clearly seen 
with Ch:HAM 0.5:1 complexes dialysed against water, and some formation 
was seen in dialysis against ASF. Whereas only a minimal formation was seen 
with Ch:HA 0.5:1 complexes. The formation of Ch:HAM 0.5:1 complexes 
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dialysed against water was confirmed by rheology. Rheology showed that 
formation was slower than for 1:1 ratio complexes. 
 
Complexes with HAM seemed to show a lower stability in salt but gave a 
better formation by the dialysis method, which suggests that the cross-linking 
ability of HAM is still able to promote complex formation. The Ch:HAM 1:1 
complexes showed a rapid precipitation during dialysis against both water and 
ASF. This was followed by contraction into discrete complexes over an hour 
which caused only a small and gradual rheological change. This suggests that 
the contraction does not affect the overall structure and bonding of the 
complexes. Overall these results show that Ch:HAM complexes are able to 
form rapidly by this method. The presence of physiological salt in the dialysis 
media only slightly disrupts and slows formation. 
 
4.5 Conclusions 
 
The results obtained show that the incorporation of HAM into polyelectrolyte 
complexes provides a number of advantages. These changes occurred despite 
the low level of modification achieved. The most striking result was the rapid 
formation of Ch:HAM complexes, which was much faster than observed for 
Ch:HA complexes. The speed of formation was not as obviously increased 
with the dialysis formation method. However there was a clear improvement in 
the overall formation of these complexes by dialysis, which was particularly 
evident in the 0.5:1 ratio complexes. 
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The degradation and resistance to stress also improved through the 
incorporation of HAM. The initial degradation in the 1:1 ratio complexes was 
slowed and the 0.5:1 ratio complexes were stabilised for longer. The rheology 
VKRZHG WKDW&K+$0FRPSOH[HVH[KLELWHGKLJKHU*ƍ DQG \LHOG VWUHVVYDOXHV
with relatively larger increases in the yield stresses. These results suggest that 
the Ch:HAM complexes would be more resilient and long lived in the 
challenging environment of the joint. The positive effects of HAM mean that it 
will continue to be used through the rest of this project. 
 
A number of other considerations arise from the results in this chapter and the 
previous chapter. The dialysis method showed a greater formation of small 
complexes not incorporated into the main complex. The effects of the dialysis 
formation method on the complex properties could therefore be important. The 
properties of complexes formed through this method will be assessed. Also the 
formation in the joint will occur in the presence of physiological salt and so 
dialysis in future studies will be carried out against ASF only. The results with 
reduced chitosan concentrations showed that there was a much worse 
formation below 0.5:1 ratio, therefore for the rest of this project only the 1:1 
and 0.5:1 Ch:HA ratios will be investigated. Finally the results suggest 
interactions between these complexes and plasma proteins. This suggests that 
biological relevance of studies need to be further considered. 
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CHAPTER 5 - SYNTHESIS AND 
CHARACTERISATION OF DRUG LOADED  
PGA NANOPARTICLES 
 
5.1 Introduction 
 
Dexamethasone phosphate was selected as the drug for incorporation into this 
delivery system as it is currently used for the treatment of osteoarthritis by 
intra-articular injection. However its delivery could be improved and there is a 
particular lack of slow release delivery systems. 
 
A composite delivery system of nanoparticles retained within a hydrogel has 
been proposed. A suitable hydrogel has been selected and so the nanoparticle 
component is required. The nanoparticles will be produced using poly(glycerol 
adipate) as this polymer has shown promising results with dexamethasone 
phosphate. These two components are introduced in more detail below. 
 
5.1.1 Dexamethasone Phosphate 
 
Dexamethasone phosphate (DXMP) is a synthetic glucocorticoid steroid and its 
structure is shown in Figure 5-1. Glucocorticoid steroids are used 
therapeutically to treat asthma and many other conditions as they have potent 
anti-inflammatory properties. Glucocorticoids also have immunosuppressive 
properties and are used to treat some autoimmune diseases such as rheumatoid 
arthritis. Due to these potent effects glucocorticoids have a wide range of side 
effects. Delivery systems that provide a sustained release of glucocorticoids are 
desirable as they would reduce the incidence and severity of side effects. 
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Figure 5-1 Chemical structure of dexamethasone phosphate. 
 
Delivery systems for dexamethasone phosphate have included liposomes 
(Anderson et al., 2010) and polymeric particles (Karmouty-Quintana et al., 
2010, Thote et al., 2005). PLGA microparticles of around 100µm were 
prepared by the emulsification solvent evaporation method (Thote et al., 2005). 
These particles had a drug loading of 8% and drug release was complete within 
24 hours but was slowed by surface cross-linking to around 7 days (Thote et 
al., 2005). Calcium pyrophosphate microparticles (5-15 µm) gave a release of 
DXMP over 7 days (Karmouty-Quintana et al., 2010). This study did not look 
into the particle drug loading and so their true potential is hard to judge. 
 
Many more delivery systems have been investigated using dexamethasone. 
Table 5-1 shows the size and drug loading data for a number of dexamethasone 
delivery systems. This form of the drug is only sparingly water soluble and so 
these systems have mainly aimed to improve its immediate delivery. The 
release from these particles was often complete in a day or two (Kim and 
Martin, 2006, Ramesh et al., 1999). Some systems have shown a more gradual 
release over longer periods (Song et al., 1997, Gomez-Gaete et al., 2007) with 
the maximum being 20 days (Wang et al., 2010). The size of particles had no 
relationship to loading levels or drug release. 
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Polymer Preparation 
Method 
Particle 
Size 
 
Drug 
Loading  
(%) 
Encapsulation 
Efficiency  
(%) 
Reference 
PLGA E/S 125nm 
(±39) 
16.0 79.6 (Song et 
al., 1997) 
PLGA E/S 240-
270nm 
11.0 55.0 (Panyam 
et al., 
2004) 
PLGA E/S 400-
600nm 
13 79 (Kim and 
Martin, 
2006) 
PLGA E/S 200nm 0.3 3 (Gomez-
Gaete et 
al., 2007) 
PLGA E/S 200nm 10 50 (Wang et 
al., 2010) 
PLGA E/S 20µm 0.18 0.9 (Dawes et 
al., 2009) 
PLGA E/S 1µm 2.24 11.2 (Dawes et 
al., 2009) 
PDLLA E/S 40-
60µm 
5.2 52 (Ramesh 
et al., 
1999) 
Table 5-1 Physical and drug loading properties of particulate dexamethasone delivery 
systems. 
Summary of key parameters of published polymer based dexamethasone delivery systems. E/S 
in preparation method refers to emulsification solvent evaporation particle formation method.  
 
5.1.2 Poly(glycerol) Adipate 
 
Poly(glycerol) adipate (PGA) is a polyester polymer produced from glycerol 
and adipic acid in a lipase catalysed reaction (Kallinteri et al., 2005). This 
produces a polymer that contains pendant hydroxyl groups and the polymer 
structure is shown in Figure 5-2. The pendant hydroxyl groups allow covalent 
modifications that can alter the polymer properties. 
 
Nanoparticles loaded with dexamethasone phosphate have been prepared using 
PGA modified with acyl groups (Kallinteri et al., 2005, Puri et al., 2008). 
Steroids are known to interact with the acyl chains of fatty acids in cellular 
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membranes. The incorporation of acyl groups into PGA increases drug loading 
(Kallinteri et al., 2005) and improves the drug release profile (Puri et al., 2008). 
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Figure 5-2 Chemical structure of poly(glycerol adipate) (PGA) polymer modified with 18 
carbon acyl chains. 
Structure of PGA polymer showing both the unmodified backbone residue (right) and stearoyl 
modified residue (left). PGA used for this study has 40% of repeating units modified, produced 
as a random co-polymer. 
 
A study investigated various levels of acyl modification and different 
molecular weight PGA polymers (Kallinteri et al., 2005). This found the 
highest drug loading with 12kDa PGA which was 40% modified with stearoyl 
groups. This polymer produced particles of around 200nm with a drug loading 
level of 10% (Kallinteri et al., 2005). A study on PGA modified with octanoyl 
groups found that the interfacial deposition method gave higher drug loading 
levels than the emulsification solvent evaporation method (Puri et al., 2008). 
The higher loading levels gave a better release profile, with a gradual release 
over 14 days achieved (Puri et al., 2008). 
 
5.1.3 Chapter Aims 
 
PGA was chosen as the polymer used for the nanoparticles within this system 
as this polymer has shown high drug loading levels and promising sustained 
release with dexamethasone phosphate. Specifically, 12kDa PGA with 40% of 
its hydroxyl groups modified with C18 acyl (stearoyl) chains was chosen. This 
polymer has shown the highest dexamethasone phosphate loading levels in 
previous studies (Kallinteri et al., 2005). 
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This chapter characterised nanoparticles produced with 40% C18 modified 
12kDa PGA loaded with DXMP. The physiochemical properties, drug loading 
and drug release were assessed. Nanoparticles loaded with rhodamine B 
isothiocyanate (RBITC) as a tracking dye were also synthesised and 
characterised. RBITC loaded PGA nanoparticles have been previously 
synthesised (Meng et al., 2007, Meng et al., 2006) and will be used to monitor 
the nanoparticles within the hydrogels in future studies. 
 
5.2 Materials and Methods 
5.2.1 Materials 
 
The materials used are detailed in section 2.1. 
 
5.2.2 PGA Polymer Modification 
 
PGA polymer was modified with C18 acyl groups and characterised using the 
method described in section 2.5.1. 
 
5.2.3 Nanoparticle Preparation and Characterisation 
5.2.3.1 Nanoparticle preparation 
 
Nanoparticles were prepared using the method in section 2.5.2. Unloaded, 
DXMP and RBITC loaded particles were prepared. 
 
5.2.3.2 Separation of unencapsulated drug 
 
Unencapsulated drug was removed from the prepared nanoparticles using the 
methods described in section 2.5.3. 
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5.2.3.3 Nanoparticle characterisation 
 
The size and zeta potential of the particles were determined using the method 
described in section 2.5.4. 
 
5.2.3.4 Determination of RBITC loading levels 
 
RBITC loading levels were determined using the method in section 2.5.5.1. 
 
5.2.3.5 Method development for DXMP loading levels 
 
The direct method for DXMP loading determination was developed. The 
summary of the methods used is included in section 2.5.5.2. 
 
5.2.3.6 Determination of DXMP loading levels 
 
DXMP loading levels were determined using the indirect and optimised direct 
methods that are detailed in section 2.5.5.3. 
 
5.2.3.7 Analysis of RBITC release 
 
RBITC release from nanoparticles was determined using the method described 
in section 2.5.6.1. 
 
5.2.3.8 Analysis of DXMP release 
 
DXMP release was determined using the method in section 2.5.6.2. 
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5.3 Results 
5.3.1 Polymer Characterisation 
 
40% C18 modified PGA was synthesised as previously described (Kallinteri et 
al., 2005). This polymer was characterised by H
1
-NMR to assess the 
percentage modification, as shown in Figure 5-3. The results of this confirmed 
that the PGA polymer had been successfully modified with 37.6% (standard 
deviation=0.76, n=3) stearoyl groups. This polymer was used for all 
subsequent nanoparticle studies. 
 
5.3.2 Particle Size and Zeta Potential 
 
Nanoparticles were successfully produced using the modified PGA polymer. 
The size and zeta potential of these particles were determined. Particles were 
loaded with dexamethasone phosphate, or the fluorescent label rhodamine B 
isothiocyanate, or were left unloaded as a control. The results of this show that 
all particles produced were less than 200nm in diameter, Table 5-2. The 
particles showed a very low polydispersity, which means that particles of a 
tightly defined size were produced. The particles also showed a small 
variability between batches. Empty nanoparticles were the largest, and a slight 
but significant reduction in diameter was seen when DXMP or RBITC were 
loaded into the particles (P<0.01). 
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Figure 5-3 Assigned H
1
-NMR spectra of PGA polymer and modified derivative. 
Top: Structure of C18 acyl modified PGA polymer with numbered groups corresponding to 
numbered NMR peaks. Middle: Assigned spectra of PGA backbone polymer. Bottom: 
Assigned spectra of C18 acyl modified PGA polymer. 
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The zeta potential of these particles was around -50mV in all cases, which 
would suggest that these particles are relatively stable in solution. Significant 
differences in zeta potential were found between all different nanoparticle 
samples (P<0.001). The empty nanoparticles had the least negative zeta 
potential and the DXMP loaded particles exhibited the most negative zeta 
potential. 
Particle Type Particle Diameter 
(nm) 
Zeta Potential 
(mV) 
Empty 176.9 (2.85) [0.068] -39.8 (2.27) 
DXMP loaded 167.3 (4.64) [0.097] -58.6 (6.63) 
RBITC loaded 164.9 (3.56) [0.136] -49.8 (4.05) 
Table 5-2 Particle size and zeta potential of 40% C18 substituted 12kDa PGA 
nanoparticles. 
For particle diameter standard deviation values are given in round brackets and polydispersity 
values are given in square brackets (N=8). For zeta potential standard deviation values are 
given in round brackets (N=8). 
 
5.3.3 Drug Loading 
5.3.3.1 RBITC 
 
The drug loading of PGA nanoparticles with RBITC was determined by 
fluorescence. The particles were disrupted using a mixture of acetone and 
methanol and the concentration of RBITC released into solution was then 
determined using a fluorescence spectrometer. The results of this found that 
almost 90% of the initially present RBITC was encapsulated into the particles, 
Table 5-3. As the amount of RBITC used was small this translated to low drug 
loading levels. However this is a sufficient loading to fluorescently label these 
nanoparticles and allows them to be used in monitoring the fate of 
nanoparticles within the polyelectrolyte complexes. 
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Encapsulation 
Efficiency 
(%) 
Drug Loading 
 
(%) 
89.0 (1.91) 0.45 (0.01) 
Table 5-3 RBITC loading levels for 40% C18 substituted 12kDa PGA nanoparticles. 
Drug loading levels were determined by a direct method to assay the drug recovered from 
nanoparticles. RBITC concentrations were determined using fluorimetry. Standard deviations 
values are given in brackets (N=6). 
 
5.3.3.2 DXMP method development  
 
The drug loading of PGA nanoparticles with DXMP has previously been 
estimated using an indirect method (Kallinteri et al., 2005). It is desirable to 
use a direct method for this analysis to give a greater accuracy of results. A 
direct method involves the disruption of purified nanoparticles and measuring 
the recovered drug. The most common methods for direct drug loading 
determination use a solvent that solubilises both the polymer and the drug. 
Acetonitrile is a very common solvent for these methods (Thote et al., 2005, 
Gomez-Gaete et al., 2007). In the case of PGA this has not proven possible due 
to the limited solubility of this polymer. PGA is soluble in acetone, chloroform 
and few other solvents, and DXMP is not soluble in these solvents. 
 
An alternative approach was therefore necessary, and a number of approaches 
were investigated with the results presented in Table 5-4. As PGA is a 
polyester it is susceptible to degradation by sodium hydroxide. DXMP is water 
soluble and therefore would be released into solution as the polymer is 
degraded. Treatment with sodium hydroxide visually appeared to disrupt the 
nanoparticles, and a pH corrected sample was analysed by HPLC to determine 
the DXMP concentration. 
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For this analysis nanoparticle samples containing a known amount of drug 
were required. These were produced by synthesising blank nanoparticles which 
were freeze dried and then spiked with a known amount of DXMP. The 
analysis of this reference sample found that this method was only able to 
recover 21.3% of the loaded drug. However 100% of a control sample of 
DXMP alone was recovered after this treatment. It is believed that the 
explanation for this maybe that the released fatty acids bind the steroid drug. 
To remove these fatty acids a hexane washing step was included. The same 
samples as before were used. This found that 33.9% of the drug in the spiked 
nanoparticle sample was recovered. 
 
The failure of this approach led to the investigation of a biphasic system. This 
would be composed of one phase that was able to dissolve PGA and a second 
phase able to solubilise DXMP. The solvent for DXMP was chosen to be water 
and the solvent to dissolve PGA was to be either chloroform or 
dichloromethane. DXMP is unstable and will readily degrade in solution to 
dexamethasone. Dexamethasone is only sparing soluble in water and so the 
ability of this method to recover dexamethasone as well is essential for a fully 
accurate determination of drug loading. Results of this biphasic method found a 
good recovery of DXMP, which was 89% and above in all cases. The recovery 
of dexamethasone was less encouraging as it was under 5%. The recovery was 
similar with and without PGA present suggesting that dexamethasone is 
becoming partitioned into the organic phase of this system. 
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Extraction 
Method 
Drug Sample Drug Recovery 
(%) 
NaOH DXMP Drug alone 100.1 
DXMP Blank NPs spiked 
with drug 
21.3 
NaOH/Hexane DXMP Blank NPs spiked 
with drug 
33.9 
DCM/water DXMP Drug alone 92.5 
Dex Drug alone 1.56 
DXMP Blank NPs spiked 
with drug 
98.3 
Dex Blank NPs spiked 
with drug 
1.65 
Chloroform/water DXMP Drug alone 89.0 
Dex Drug alone 4.77 
DXMP Blank NPs spiked 
with drug 
108.0 
Dex Blank NPs spiked 
with drug 
3.00 
DCM/water with 
analysis of DCM 
 
DXMP Blank NPs spiked 
with drug 
95.4 (1.40) 
Dex Blank NPs spiked 
with drug 
99.0 (1.48) 
Table 5-4 Method development for the extraction of DXMP from PGA nanoparticles. 
Drug recovery percentages using the methods trialled for extraction of DXMP and 
dexamethasone (Dex) from nanoparticles. Drug concentration was determined using HPLC. 
NaOH method used NaOH to degrade PGA, which was also combined with a hexane defatting. 
Direct extraction using DCM or chloroform and water was used, with the final method 
including analysis of DCM. For optimised method standard deviations are given in round 
brackets (N=3). 
 
In order to overcome this problem the organic solvent phase could be analysed. 
These solvents are not considered to be water miscible and water miscibility is 
essential to allow the analysis by HPLC. Small quantities of dichloromethane 
diluted with methanol were found to be sufficiently water miscible to allow 
HPLC analysis. Therefore this solvent was utilised for further studies where the 
organic solvent was also analysed. The results of this found that 95.4% DXMP 
and 99.0% dexamethasone were recovered from drug spiked nanoparticle 
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samples. The high and repeatable recoveries make this method suitable for the 
determination of drug loading of nanoparticles and it will be therefore continue 
to be used for this purpose. 
 
5.3.3.3 DXMP 
 
The direct method, as developed above, was used along with a previously 
reported indirect method (Kallinteri et al., 2005) to determine drug loading 
levels. The indirect method collected and analysed the unencapsulated drug 
that was separated from loaded nanoparticles. Inaccuracies with this method 
are likely to occur if the free drug is not fully recovered from the column. In 
order to correct for this known drug concentrations were run through the 
column and the percentage recovery was determined. It was found that 80.1% 
(standard deviation=2.54, n=3) of free DXMP was recovered after passing 
through the column. This retention was corrected for and the drug loading was 
calculated using this method. 
 
The results using the indirect method, Table 5-5, show an estimated drug 
loading of 8.98%. This value is much higher than was found when the direct 
method was used. The direct method showed a drug loading of 1.69% was 
achieved, which corresponds to an encapsulation efficiency of 4.29%. These 
lower values represent a more accurate estimation of the drug loading due to 
the fact that they used a validated direct method. The improved accuracy of the 
direct method can be seen by the smaller standard deviations. 
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Method Encapsulation 
Efficiency 
(%) 
Drug Loading 
 
(%) 
Indirect 18.5 (3.99) 8.98 (1.94) 
Direct 4.29 (0.52) 1.69 (0.24) 
Table 5-5 DXMP drug loading levels for 40% C18 substituted 12kDa PGA nanoparticles. 
Drug loading levels were determined by an indirect method using drug recovered during 
particle purification or by a direct method on the drug recovered from formed particles. Drug 
concentrations were determined using HPLC. Standard deviation values are given in round 
brackets (for indirect method N=3; for direct method N=6). 
 
5.3.4 Drug Release 
5.3.4.1 RBITC 
 
The RBITC loaded nanoparticles were needed for monitoring the fate of 
particles within complexes. To enable this, a low release of the fluorescent 
label was desirable to allow monitoring of the particles over extended time 
periods. A drug release study was therefore carried out on the RBITC loaded 
particles and the results of this study are shown in Figure 5-4. These results 
show that around 20% of the loaded RBITC is released over 14 days, and after 
this time a minimal RBITC release occurred. The level and speed of release 
was the same with and without serum proteins present. In contrast the release 
of free RBITC from the dialysis membrane occurred very rapidly and over 
90% of RBITC escaped from the dialysis membrane within 2 days. The 
remaining RBITC was recovered from within the dialysis membrane. 
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Figure 5-4 RBITC release from 40% C18 substituted 12kDa PGA nanoparticles. 
RBITC release from nanoparticles was determined using a dialysis membrane to retain the 
nanoparticles. RBITC concentration was determined by fluorimetry. Blue- Release of free 
RBITC from dialysis membrane (N=3); Red- Release of RBITC loaded nanoparticles in ASF 
(N=3); Green- Release of RBITC loaded nanoparticles with serum in ASF (N=3). 
 
5.3.4.2 DXMP 
 
A sustained dexamethasone phosphate release from particles was an essential 
part of the proposed delivery system. The release of drug from 40% C18 
modified 12kDa PGA nanoparticles was therefore determined. The results of 
the release experiment are shown in Figure 5-5. This found that these particles 
were able to give a gradual and sustained release over 28 days, and after this 
time 83.9% of the loaded drug had been released. This compared to the release 
of free DXMP from a dialysis membrane which was complete in less than 5 
days, with most of this occurring within 1 day. These results show that PGA 
nanoparticles are able to retain DXMP and provide a sustained drug release. 
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Figure 5-5 DXMP release from 40% C18 substituted 12kDa PGA nanoparticles. 
DXMP release from nanoparticles was determined using a dialysis membrane to retain the 
nanoparticles. Drug concentrations were determined using HPLC. Blue- Release of free DXMP 
from dialysis membrane (N=3); Red- Release of DXMP loaded nanoparticles (N=4). 
 
5.4 Discussion 
5.4.1 Physical Properties of Nanoparticles 
5.4.1.1 Size 
 
Nanoparticles were prepared using 12kDa PGA which was 40% modified with 
stearoyl groups. In all cases these particles were found to be smaller than 
200nm in diameter with a low polydispersity. Low polydispersity shows the 
particles have a tightly defined size range. There was also a low variability 
between nanoparticle batches, which shows a good reproducibility in the 
production of these particles. This is desirable as the physical properties can 
affect the other properties such as the drug release. Therefore a reproducible 
production of particles will give more accurate results in further studies. 
 
The size of nanoparticles varied when different compounds were loaded into 
them. Empty nanoparticles were the largest (176nm) and a slight, but 
significant, reduction in diameter was seen when DXMP or RBITC were 
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loaded into the particles (167nm and 164nm respectively). This size change is 
likely to be due to interactions occurring between the drugs and the polymer, 
which cause a tighter binding within the particles and thus reduce their size 
(Puri et al., 2008). It is also possible that the drugs may be having an effect on 
the water and solvent interface causing a reduction in particle size (Puri et al., 
2008). 
 
The particle size is similar to previous reports of nanoparticles produced with 
40% C18 modified 12kDa PGA. However the particles produced here are 
consistently slightly smaller than previous results. One previous study 
produced unloaded particles using 40% C18 modified 12kDa PGA and found 
them to have a size of 212nm (Kallinteri et al., 2005), this compares to 177nm 
for similar nanoparticles in this study. The same published study found that 
particles loaded with DXMP showed no size difference to unloaded particles 
(Kallinteri et al., 2005). However another study on PGA polymers with 
octanoyl substitutions found that DXMP loaded particles were consistently 
smaller than unloaded particles (Puri et al., 2008), as was found here. 
 
RBITC loaded particles produced using 40% C18 modified 12kDa PGA have 
been reported with a size of 176nm (Meng et al., 2006), which again is slightly 
larger than produced here. The size differences to the particles produced in this 
project are small. They could be explained by small differences in polymer 
batches or by the different machine used to size the particles in this project. 
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5.4.1.2 Zeta potential 
 
The PGA nanoparticles exhibited zeta potentials of around -50mV. A zeta 
potential in this range is considered to show that particles are relatively stable 
in solution. This is because a high surface charge prevents flocculation as it 
acts to repel particles from one another and thus reduces aggregation. The zeta 
potential became significantly more negative from empty nanoparticles, to 
RBITC loaded particles to DXMP loaded particles. 
 
The charge on unloaded nanoparticles is likely to be due to the terminal 
carboxylate groups on the PGA polymer (Puri, 2007). Within particles the 
hydrophobic stearoyl groups will be shielded from the external aqueous 
environment. This will lead to the hydrophilic pendant hydroxyl groups and 
terminal carboxylate groups being orientated to the surface of the particles and 
thus produce a negative zeta potential. 
 
The more negative zeta potential with DXMP incorporated into nanoparticles is 
likely to be due to the negative charge of this compound. The random 
incorporation of a negatively charged compound into nanoparticles would 
increase the negative charges present on the particle surface. However due to 
the hydrophobicity of the particle core it is unlikely that this incorporation 
would be random, and most likely occurs in the surface layers. RBITC is not 
negatively charged and so the more negative zeta potential when this 
compound is loaded must have an alternative explanation. The most likely 
cause is that the incorporation of RBITC causes a rearrangement of the 
polymer chains leading to an increase in the terminal carboxylate groups 
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exposed at the surface. The increase in carboxylate groups at the surface causes 
the increased negativity of the zeta potential. 
 
The zeta potential values agree well with previous reports. The published study 
conducted using 40% C18 modified 12kDa PGA found that unloaded particles 
had a zeta potential of -25.9mV and DXMP loaded particles had a zeta 
potential -34.5mV (Kallinteri et al., 2005). Similar values were also found for 
unloaded and DXMP loaded particles using PGA with different substitutions 
(Puri et al., 2008). The values produced here were more negative with a zeta 
potential of -39.8mV for unloaded particles and -58.6mV for DXMP loaded 
particles. A study investigating 40% C18 modified 12kDa PGA nanoparticles 
loaded with RBITC found particles to have a zeta potential of -52.2mV (Meng 
et al., 2006). This is very similar to the value of -49.8mV which was obtained 
in this study. 
 
The difference between loaded and unloaded particles is similar for the 
samples produced here and previous reports (Kallinteri et al., 2005). The 
differences would therefore seem to due slight differences in the polymer used 
for this study. Alternatively the production conditions for these particles have 
caused a greater proportion of the polymer carboxylate groups to become 
localised to the surface. 
 
5.4.2 Drug Loading 
 
The drug loading of nanoparticles is much more accurately determined using a 
direct method, which extracts the drug from the particles and then quantifie
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this extracted drug. This contrasts to an indirect method where the 
unencapsulated drug is measured and the difference to the initial amount of 
drug added is assumed to be the drug loading. A direct method requires the 
disruption of particles to allow recovery of the drug. No method to do this was 
available for DXMP loaded PGA particles, so a method had to be developed. 
This extraction was not straightforward as there is no common solvent which 
would dissolve both the polymer and the drug. A more complex extraction than 
used for most nanoparticle systems was therefore required. 
 
Two main approaches were investigated, which were a sodium hydroxide 
degradation of PGA and a biphasic extraction. The sodium hydroxide 
degradation was successful at disrupting PGA nanoparticles but did not give a 
good drug recovery. It was thought that this low recovery may be due to the 
stearoyl groups present in the polymer as these are known to bind steroid drugs 
such as DXMP (Puri, 2007). A hexane wash to remove the stearoyl groups 
only produced a small increase in drug recovery. This result suggests that 
DXMP remains associated with the stearoyl groups even when they are 
removed into the hexane layer. 
 
The biphasic extraction used a solvent which dissolved PGA to disrupt the 
particles and water to solubilise the drug. To give a full analysis of the loading 
both DXMP and dexamethasone need to be quantified. Dexamethasone is more 
hydrophobic and the low recovery of this drug suggests that it is preferentially 
sequestered within the solvent phase of the system. The use of alternative 
solvents is not possible due to the limited solubility of PGA. Analysis of the 
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organic solvent was therefore needed and it was found that the small volumes 
of dichloromethane required were miscible in the HPLC mobile phase when 
diluted in methanol. 
 
The biphasic extraction with analysis of dichloromethane and water provided 
an excellent recovery of both drugs. This method also gave consistent results 
with different samples. This validated method was therefore used for the 
determination of DXMP drug loading of PGA nanoparticles through the rest of 
this study. 
 
The drug loading of DXMP was determined by both the developed direct 
method and a previously used indirect method (Kallinteri et al., 2005). With 
the indirect method the results obtained here (9% drug loading) were broadly 
similar to previous reports (10% drug loading) (Kallinteri et al., 2005). These 
results did not agree with the results obtained using the direct method, which 
found the loading to be around 1.7%. The direct method is a much more 
accurate method for determining the drug loading as the loaded drug is 
recovered from the particles. The direct method is only less accurate if the drug 
is not fully liberated from the particles as this would mean that it is unavailable 
for analysis. The direct method that was used here was validated using freeze 
dried nanoparticles spiked with known concentrations of drug and is therefore 
known to be accurate. 
 
There is also the possibility that the direct method is providing an 
underestimate of the true drug loading. This could occur if there is an 
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incomplete release of the drug from the degraded nanoparticles. The 
incomplete release could be caused by the DXMP remaining associated with 
the solubilised PGA or it could become sequestered at the organic/aqueous 
phase boundary due to its amphipathic nature. Any drug that is not completely 
released would not be detected by the HPLC and so would lead to an 
underestimation of the drug loading. The validation studies run using dried 
nanoparticles spiked with known concentrations of drug were included to 
attempt to show that the losses by these causes were negligible. 
 
The indirect method is likely to have errors due to the drug not being recovered 
from the column. This study attempted to correct for this by measuring the 
recovery of a known amount of DXMP from the complexes, but despite this 
the results did not agree with the direct method. The cause for this may be due 
to the drug binding to aggregated polymer present when the particles were 
synthesised, or drug binding strongly to the column so that it is not eluted. 
Aggregated particles were removed by filtration but visually appeared to be of 
small quantities. Also the concentration of free drug in the nanoparticle 
samples is not known. Therefore the correction applied from the recovery of 
the known DXMP concentration may also be causing an over or 
underestimation of the actual concentration. This would occur if the column 
retention was not varying linearly with the concentration applied. Overall it is 
not entirely clear why there were quite such inaccuracies with the indirect 
method. 
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The DXMP drug loading found was lower than expected. Other nanoparticle 
systems have managed higher dexamethasone phosphate loading levels. One 
study produced PLGA microparticles of around 250nm by the emulsification 
solvent evaporation method that had a drug loading level of 11% (Panyam et 
al., 2004, Thote et al., 2005). The interfacial deposition method is known to 
give poor loading levels of hydrophilic drugs due to the accessible aqueous 
phase present during formation. However PGA showed better DXMP loading 
using the interfacial deposition compared to the emulsification solvent 
evaporation method (Puri, 2007). Although the DXMP loadings achieved here 
are lower than previous reports with PGA and PLGA, they are still a good 
loading compared to many steroid loaded particles. 
 
The encapsulation efficiency of RBITC into nanoparticles was very high with 
around 90% of the available drug loaded into particles. This high efficiency is 
due to the hydrophobicity of this drug and to the small amount of drug used in 
the encapsulation process. As RBITC is hydrophobic it is favourable for it to 
become encapsulated within the hydrophobic polymer matrix. Only a low drug 
loading of RBITC in the particles was required as the drug was intended as a 
fluorescent label for tracking the nanoparticles. 
 
5.4.3 Drug Release 
 
Drug release from nanoparticles can be assessed by a number of methods. The 
main challenge for assessing drug release from particles is the separation of 
particles from the release medium. The most commonly used methods are to 
retain particles within a dialysis bag or to separate release medium from the 
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particles. Ultrafiltration methods utilising pressurised ultrafiltration cells and 
centrifugal ultrafiltration cells have also been used. Each of these methods has 
its own advantages and disadvantages. 
 
The use of a dialysis membrane adds a barrier into the system which means 
that the measured release is also dependent on the diffusion of drug across the 
membrane. Such a method also maintains a high concentration of particles 
within the membrane which may affect the partitioning of drug between 
polymer and solution (Washington, 1990, Redhead, 1997). This can alter the 
concentration gradient which drives the movement of drug across the dialysis 
membrane. 
 
Separation methods use filtration or centrifugation to separate release medium 
from the particles. This method becomes more difficult with smaller particles 
as separation becomes more difficult and can take longer. Ultrafiltration 
involves additional forces to facilitate the separation. These methods again 
struggle with small particles as fine filters require greater pressure to achieve 
filtration. They also risk clogging of the filter and loosing particles onto the 
membrane which will have major effects on the quality of any data produced 
by this method. 
 
For this project the dialysis membrane method was chosen. With the 
nanoparticles used in this project it was the easiest method to use. The 
problems associated with diffusion across the dialysis membrane can be 
minimised by using a control sample of free drug for comparison. This can 
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reveal whether effects seen are due to release from the particles or due to a 
delayed diffusion across the membrane. Also the remaining solutions at the end 
of the studies can be analysed to ensure that 100% of the drug present is 
recovered, identifying any problems of drug binding to the dialysis membrane. 
 
The RBITC loaded particles were to be used as fluorescently labelled particles 
for monitoring the fate of particles incorporated into hydrogels. It was therefore 
desired that the particles exhibited a low release so that the label remained 
within the particles. The release was found to be low with only 20% of the 
loaded RBITC released during the study period. The majority of this release 
occurred rapidly within the first 7 days. 96.1% of the original loaded RBITC 
was recovered at the end of the study; this includes both the released drug and 
that recovered from the particles. This release is similar to that previously seen 
for PGA particles loaded with RBITC (Meng et al., 2006). 
 
An alternative strategy would have been to covalently attach RBITC to PGA. 
With the pendant hydroxyl groups present in PGA this would have been 
possible and would have almost eliminated the release of the label from 
particles. However no method had been developed for this modification. As the 
release of RBITC from particles was low it was decided that these particles 
would be used to allow more work to be carried out on the combined delivery 
system. Also a fluorescently modified PGA polymer would have altered the 
particles physiochemical properties and thus the behaviour of the particles 
produced. 
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Previous investigations with different modified PGA polymers have shown that 
the 40% stearoyl modified 12kDa polymer should have the best sustained 
release profile with DXMP (Kallinteri et al., 2005, Puri et al., 2008). The 
previous results suggested that this polymer should give a release over around 
30 days (Puri et al., 2008). It was found in the present study that these particles 
gave a gradual release of 80% of loaded drug over 28 days. This is a very good 
slow release for dexamethasone phosphate from nanoparticles. 
 
This length of release is far in excess of all previous systems, with a release 
over 7 days being the longest achieved (Karmouty-Quintana et al., 2010, Thote 
et al., 2005). Other steroid drugs have rarely shown release over such an 
extended period. The maximum period of release that has been achieved with 
dexamethasone is 20 days (Wang et al., 2010). This slow release from PGA has 
been attributed to the acyl groups within the modified polymer having a high 
affinity for steroid drugs (Puri, 2007). The strong retention of DXMP allows 
the extended and gradual drug release observed. 
 
5.5 Conclusions 
 
Nanoparticles have been produced using 40% C18 modified 12kDa PGA that 
have promising properties for the intended application. The particles have a 
well defined and reproducible size just under 200nm. Particles with a well 
defined size were desired as they will give a better characterisation of the 
combined hydrogel and nanoparticle system. The actual size was not an 
essential property for the particles in this system. Particles were desired that 
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would be taken up by phagocytosis if they were released from the hydrogels, 
which gives a maximum size for particles of around 15µm. 
 
The loading of DXMP was lower than has previously been observed. However 
the development and use of a direct method for the loading determination gives 
confidence in the accuracy of the results. The release of DXMP was as 
expected from previous reports and occurred over 28 days as a slow, sustained 
release with no initial burst. This period of release exceeds all other published 
nanoparticle delivery systems for dexamethasone and dexamethasone 
phosphate. With the aims of this project, although a high drug loading is 
desirable, a good sustained release profile is extremely important. Therefore 
these PGA particles show good promise for this delivery system. 
 
In general it is expected that larger particles will give a longer release. Using 
larger particles or improving the drug loading of the particles may well provide 
benefits to this delivery system. At this stage it was desired to produce a 
system which proves the concept of a delivery system with a hydrogel retaining 
nanoparticles. It was not desired to do a large amount of work to optimise the 
particles and the nanoparticles produced already give a better release than any 
other system. The use of nanoparticles also ensures that any released particles 
will be taken up by synovial macrophages and deliver drug to where it is 
needed. But this does leave this portion of the delivery system as an area for 
potential future improvements. 
 
 
 
 
 177 
CHAPTER 6 - EVALUATION OF NANOPARTICLE 
LOADED POLYELECTROLYTE COMPLEXES AS 
COMPOSITE DELIVERY SYSTEM 
 
6.1 Introduction to Composite Delivery Systems 
 
Generally drug delivery systems are designed to be as simple as possible. This 
is because a simple system has many advantages. A simple system will be 
easier to produce, characterise and manufacture. Also when there are many 
interacting elements there is a possibility of unexpected properties being 
exhibited in vivo that were not identified during in vitro testing. However even 
in a simple system this risk remains. Perhaps the biggest reason for producing a 
simple delivery system is that it is easier and more likely for regulatory 
approval to be obtained. 
 
Due to these advantages for simple drug delivery systems there have been very 
few systems that have combined a hydrogel and nanoparticles. A simpler 
system is the directly loading of a hydrogel with drug, and a number of such 
systems have been produced (Van Tomme et al., 2008). These approaches are 
briefly reviewed below. 
 
6.1.1 Hydrogel Delivery Systems 
 
Hydrogels contain large volumes of water entrapped within their structure and 
in general also have large internal pores (Hamidi et al., 2008). This means that 
small molecules are unlikely to be well retained within a hydrogel by physical 
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entrapment alone. However larger molecules such as proteins are more likely 
to be retained. 
 
The success of loading a protein into a hydrogel can be seen where human 
growth hormone was incorporated into hydrogels produced from hyaluronic 
acid and Pluronic F127 (Kim and Park, 2002). The release of this protein 
showed an initial burst over the first 24 hours, and was followed by a sustained 
release over the next 10 days. During this period over 60% of the hydrogel 
mass was lost suggesting that drug release was driven by hydrogel degradation. 
 
Hydrogel systems containing small molecule drugs have also been produced, 
including a system loaded with dexamethasone (Kim et al., 2011). Kim et al. 
used a hydrogel produced by the action of horseradish peroxidise on a HA 
modified with tyramine. This system gave a sustained in vitro drug release over 
30 days, and a similar release in vivo. Another delivery system used PEG based 
hydrogels to give a sustained release of paclitaxel over 50 days with very small 
initial burst (Zentner et al., 2001). However when this system was loaded with 
protein a much faster release over 10 days was observed. This observation 
suggests molecular weight was not the most important factor and that 
paclitaxel was interacting with the hydrogel to give the slower release seen. 
 
The differences between drugs show that ability to directly load a drug into a 
hydrogel depends on the specific properties of both components. The release 
rate of the drug from the hydrogel will also be affected by these properties. 
Therefore a system using drug directly loaded into a hydrogel has less 
 179 
flexibility for use with new drugs as the properties cannot be accurately 
predicted and need to be checked with any new drug that is loaded. 
 
6.1.2 Hydrogel Composite Delivery Systems 
 
Hydrogels can be synthesised to hold and retain many different things other 
than drugs and proteins. For tissue engineering applications hydrogels are often 
utilised to produce cell scaffolds and so are loaded with cells (Tan et al., 2009, 
Chen and Cheng, 2009). Colloidal drug delivery systems can also be loaded 
into hydrogels, and this includes nanoparticles as well as other systems such as 
liposomes. One system used liposomes incorporated into hydrogels composed 
of chitosan-ȕ-glycerophosphate (Ruel-Gariepy et al., 2002). This temperature 
sensitive polymer had been previously found to produce hydrogels unsuitable 
for the direct loading of drug (Ruel-Gariepy et al., 2000). The combined 
liposome and hydrogel system gave a slow drug release of between 50% and 
70% of loaded drug over 14 days (Ruel-Gariepy et al., 2002). 
 
Relatively few drug delivery systems have investigated the incorporation of 
nanoparticles into a hydrogel. There are such systems that have been loaded 
with dexamethasone (Cascone et al., 2002, Kim and Martin, 2006). The first of 
these systems used poly(vinyl alcohol) hydrogels to retain PLGA nanoparticles 
(Cascone et al., 2002). PLGA nanoparticles loaded into poly(vinyl alcohol) 
hydrogels showed a slower drug release than free nanoparticles. There was an 
almost complete drug release in 21 days but a significant initial burst release 
occurred. Another composite system for dexamethasone retained PLGA 
nanoparticles within an alginate hydrogel (Kim and Martin, 2006). This system 
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was able to provide a sustained release over 15 days, but the release from free 
nanoparticles was found to be only slightly more rapid. 
 
Another study used a very different approach that resulted in a similar system. 
This used aggregating nanoparticles which formed a system with similar 
characteristics to one where nanoparticles were retained within a hydrogel 
(Wang et al., 2010). Two different surface modified PLGA nanoparticles were 
used to achieve this. This system gave a sustained release of dexamethasone 
over 60 days (Wang et al., 2010). This is an impressive length of release and 
exceeds that achieved with nanoparticles retained in a hydrogel. The free 
particles were also found to give a significantly faster release. 
 
6.1.3 Chapter Aims 
 
This chapter investigated the incorporation of nanoparticles into polyelectrolyte 
complexes composed of hyaluronic acid and chitosan. The incorporation and 
release of particles was investigated. The properties of the complexes that have 
previously been measured were also assessed. This allowed the identification 
of any effects that the incorporation of nanoparticles had on the complex 
properties. It was hoped that no negative effects would be found and that 
nanoparticles may further stabilise the system. 
 
It was also important to assess the properties of complexes produced by the 
dialysis method. This chapter also investigated the properties of dialysis 
formed composites to ensure that this formation method produced complexes 
with the required properties. 
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Finally this chapter investigated the drug release from these composites. It was 
hoped that a delivery of three months could be achieved with this system. 
However a release greater than 1 month would give an improvement over 
currently available therapies. The release from complexes loaded with 
dexamethasone crystals was also investigated to assess the necessity of the 
nanoparticle portion of this delivery system. 
 
6.2 Materials and Methods 
6.2.1 Materials 
 
The materials used are detailed in section 2.1. 
 
6.2.2 Composite Preparation and Characterisation 
6.2.2.1 Composite preparation 
 
Composites were prepared and the formation characterised using the methods 
described in section 2.6.1. 
 
6.2.2.2 Determination of nanoparticle incorporation into composites 
 
The level of incorporation of nanoparticles into complexes was determined 
using the method detailed in section 2.6.3. 
 
6.2.2.3 Rheology amplitude sweeps on composites 
 
Rheology amplitude sweeps on composites were carried out as described in 
section 2.6.2. 
 
 182 
6.2.2.4 Composite degradation 
 
Composite degradation was determined using the method described in section 
2.6.2. 
 
6.2.2.5 Nanoparticle release from composites 
 
Nanoparticle release from composites was determined using the method 
detailed in section 2.6.5. 
 
6.2.2.6 Enzyme degradation of composites 
 
Nanoparticle release from composites incubated with hyaluronidase was 
determined using the method described in section 2.6.6. 
 
6.2.2.7 Effect on salt on composite formation 
 
The effect of salt on the formation of composites was analysed using the 
method described in section 2.6.7. 
 
6.2.2.8 Composite formation by dialysis 
 
Composites were prepared by the dialysis method described in section 2.6.8.1 
and their formation of these complexes was analysed using the methods 
detailed in section 2.6.8.1. 
 
6.2.2.9 Characterisation of composites formed by dialysis 
 
Formed composites prepared by the dialysis formation method were 
characterised using the same methods as used for bulk formed composites, as 
described in section 2.6.8.2. 
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6.2.3 Analysis of Drug Release from Composites 
6.2.3.1 DXMP release from drug loaded composites 
 
Dexamethasone phosphate release from composites was determined using the 
method in section 2.7.1. 
 
6.2.3.2 Dexamethasone crystal preparation and characterisation 
 
Dexamethasone crystal suspensions were prepared and characterised using the 
methods detailed in section 2.7.2.1. 
 
6.2.3.3 Drug release from dexamethasone loaded complexes 
 
Dexamethasone release from complexes was determined using the method 
described in section 2.7.2.2. 
 
6.3 Results 
6.3.1 Characterisation of Composites 
6.3.1.1 Composite formation 
 
To initially investigate the formation of nanoparticle loaded complexes a 
photographic study was undertaken and the results of this study are presented 
in Figure 6-1. Complex formation appeared to be similar to that observed when 
nanoparticles were not present. Ch:HA complexes showed a rapid initial 
precipitation followed by a rearrangement into a tight complex over around 30 
minutes, which is identical to the observations on Ch:HA complexes without 
nanoparticles. The formation of Ch:HAM complexes was also unaffected by 
the presence of nanoparticles and showed an instantaneous precipitation and 
complex formation with little change over the study period. 
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0 minutes           10 minutes             30 minutes            60 minutes  
Ch:HA 1:1 complexes 
 
0 minutes            10 minutes          30 minutes             60 minutes 
 Ch:HA 0.5:1 complexes 
 
0 minutes            10 minutes           30 minutes             60 minutes 
Ch:HAM 1:1 complexes 
 
0 minutes              10 minutes          30 minutes             60 minutes  
Ch:HAM 0.5:1 complexes  
Figure 6-1 Photographs showing the formation of different polymer ratio Ch:HA and 
Ch:HAM complexes loaded with RBITC nanoparticles in water. 
Chitosan, HA/HAM and nanoparticles were mixed at the indicated ratio and incubated at 37°C. 
Photographs were taken at the indicated times. 
 
This initial photographic study was conducted using RBITC loaded particles. It 
was hoped that the pink colour of these particles would provide an indication to 
the distribution of particles within the complexes. This showed that the 
particles appeared to be quite evenly distributed within the complexes as they 
had a relatively even colouring. It appeared that Ch:HA complexes in particular 
exhibited a lower concentrations of particles near the surface as less coloured 
areas were visible. However this macroscopic inspection only provided an 
indication of the distribution and further studies would be necessary to 
determine the true particle distribution. 
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These complexes will form after injection into the joint and therefore in the 
presence of a physiological salt concentration. Therefore it was important to 
check that the composites were able to form under these conditions. The results 
of a qualitative study to assess this are presented in Figure 6-2. These results 
show that salt seemed to cause a slight disruption to the nanoparticle loaded 
complexes. The complexes produced have a more fibrous and less compact 
appearance, however complexes were still able to form in all cases. 
 
  Ch:HA 1:1          Ch:HA 0.5:1         Ch:HAM 1:1      Ch:HAM 0.5:1 
Figure 6-2 Photographs showing Ch:HA and Ch:HAM complexes at different polymer 
ratios loaded with RBITC nanoparticles prepared in ASF. 
Chitosan, HA/HAM and nanoparticles were mixed at the indicated ratio and incubated at 37°C. 
Photographs were taken after 60 minutes. 
 
To further analyse the kinetics of composite formation rheology time sweeps 
were carried out on Ch:HA and Ch:HAM complexes at the 1:1 ratio. The 
results of these investigations are presented in Figures 6-3 and 6-4. The Ch:HA 
1:1 ratio complexes showed that the presence of nanoparticles slightly slowed 
initial complex formation, Figure 6-3. The cross-RYHU SRLQW RI *ƍ DQG *ƍƍ LV
delayed from around 20 minutes without nanoparticles to around 60 minutes 
ZKHQ QDQRSDUWLFOHV ZHUH SUHVHQW :KHQ WKH SKDVH DQJOH į YDOXHV DUH
examined further differences become evident. The phase angle of the Ch:HA 
sample without nanoparticles became steady after 150 minutes which suggests 
that the complexes were undergoing very little change after this point. In the 
sample containing nanoparticles the phase angle did not stabilise after 150 
minutes which suggests that formation continued for longer in this sample. 
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Figure 6-3 Rheology time sweeps showing the formation kinetics of Ch:HA complexes 
loaded with nanoparticles. 
Rheology time sweeps were conducted at 37°C on Ch:HA 1:1 complexes. Chitosan, HA and 
PGA nanoparticles were mixed on the plate of the rheometer and measurements were started as 
VRRQDVSRVVLEOHDIWHUZDUGV*ƍVTXDUHVDQG*ƍƍWULDQJOHVDUHSORWWHGRQWKHSULPDU\\-axis; 
SKDVHDQJOHį- diamonds) is plotted on the secondary axis. 
 
The results obtained with Ch:HAM 1:1 ratio complexes showed that for these 
samples the addition of nanoparticles had very little effect on the speed of 
formation, Figure 6-4. The formation remained extremely rapid with an 
instantaneous gelation and no change after 20 minutes. The formation was also 
unaffected by different amounts of nanoparticles. Increasing nanoparticle 
OHYHOVFDQEHVHHQWRLQFUHDVHWKH*ƍYDOXHRIWKHFRPSOH[HVVXJJHVWLQJWKDWWKLV
addition is strengthening the complexes. Further examination reveals that the 
final phase angle of these samples remains constant. This implies that the 
presence of nanoparticles may be increasing the strength of the complexes but 
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without affecting the overall solidity of the complexHVERWKWKH*ƍDQG*ƍƍDUH
being increased proportionally. 
 
Figure 6-4 Rheology time sweeps showing the formation kinetics of Ch:HAM complexes 
loaded with nanoparticles. 
Rheology time sweeps were conducted at 37°C on Ch:HAM 1:1 complexes. Chitosan, HAM 
and PGA nanoparticles were mixed on the plate of the rheometer and measurements were 
VWDUWHG DV VRRQ DV SRVVLEOH DIWHUZDUGV *ƍ VTXDUHV DQG *ƍƍ WULDQJOHV DUH SORWWHG RQ WKH
primary y-D[LVSKDVHDQJOHį- diamonds) is plotted on the secondary axis. 
 
6.3.1.2 Nanoparticle incorporation levels 
 
The incorporation of nanoparticles into the polyelectrolyte complexes was an 
important part of this delivery system. In order for a sustained drug release to 
occur a high proportion of the nanoparticles added need to be incorporated into 
the complexes. No specific mechanism was used with these nanoparticles to 
ensure their uptake. However as the particles have been shown to have high 
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zeta potentials it was hoped that the surface charge would be sufficient to cause 
incorporation of particles into the complexes. It was therefore very important to 
analyse the particle incorporation to and the fluorescent labelled nanoparticles 
were used to allow this measurement to be carried out more easily. 
 
RBITC loaded particles were included in the preparation of complexes. After 
formation had occurred the composites were separated using nylon mesh filters 
of 30µm pore size. This size was chosen as it is closest to the size limit for 
phagocytosis (Greis et al., 1994) which means that any particles or complex 
material which passed through these filters would be likely taken up by the 
phagocytes present within the joint. The solution that passed through the filter 
was analysed using a fluorimeter, to allow the quantification of the particles 
present and the calculation of the incorporated particles. The results of this 
study are shown in Figure 6-5. 
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Figure 6-5 Graphs showing nanoparticle incorporation levels into Ch:HA and Ch:HAM 
complexes. 
Chitosan, HA/HAM and RBITC loaded nanoparticles (NP) were mixed together and incubated 
at 37°C in a water bath for 60 minutes. Complexes were removed and the remaining solution 
was analysed using a fluorimeter to estimate the nanoparticle incorporation into complexes. 
Ch:HA 1:1- blue; Ch:HA 0.5:1- red; Ch:HAM 1:1- grey; Ch:HAM 0.5:1- green. 
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These results show that in all cases very high nanoparticle incorporations were 
achieved. All complex types and all nanoparticle loading levels studied gave an 
incorporation of over 80%, and even at high nanoparticle levels no decrease in 
incorporation was seen. Statistical analysis of the results revealed no 
significant differences between complexes of the same type with different 
nanoparticle loading levels. Comparing different complex types at the same 
loading levels revealed a number of significant differences. The most relevant 
were between Ch:HAM 0.5:1 ratio samples and all other samples when an 
initial amount of nanoparticles between 4mg and 6mg was used (P<0.01). Also 
Ch:HA 0.5:1 ratio samples showed significant differences to both 1:1 ratio 
samples with 6mg or 8mg initial nanoparticles (P<0.05). With the 1mg initial 
loading significant differences were found between the Ch:HA 0.5:1 ratio 
samples and all other samples (P<0.05). 
 
To better understand the incorporation of nanoparticles into the complexes it 
was desired to use an imaging technique to provide a visualisation of the 
particles within the complexes. Cryo-SEM (scanning electron microscopy) was 
utilised as it is a technique that allows the internal structure of samples to be 
imaged. However it proved very difficult to produce reproducible and accurate 
images of these complexes. The images produced (data not shown) seem to 
show that the nanoparticles were not as evenly distributed as it appeared from 
visual inspection. This was supported by fluorescent microscopy studies 
carried out on complexes loaded with fluorescently labelled nanoparticles. 
These showed an uneven distribution of particles within the complexes (data 
not shown), however no clear images were produced with this technique. 
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6.3.1.3 Complex integrity 
 
Rheology amplitude sweeps were conducted to assess the complex strength. 
From the raw data WKH*ƍDQG\LHOGVWUHVVYDOXHVwere extracted and these are 
presented in Figure 6-6. Samples of 0.7:1 ratio were run in addition to help 
show any trends with changing chitosan concentration. The results show that in 
almost all cases nanoparticles act to increase the complex strength. It is also 
interesting to note that the complex strength increases in the order: unloaded 
complexes; RBITC loaded composites; DXMP loaded composites. In the 
majority of cases, as shown in Table 6-1, the differences between these 
different complex types were statistically significant (P<0.05). 
 
Complex Type No NP v RBITC No NP v DXMP RBITC v DXMP 
Ch:HA 1:1 ¥/¥ ¥/¥ ¥/¥ 
Ch:HA 0.7:1 ¥/¥ ¥/¥ ¥/X 
Ch:HA 0.5:1 X/¥ ¥/¥ ¥/¥ 
Ch:HAM 1:1 ¥/¥ ¥/¥ ¥/X 
Ch:HAM 0.7:1 ¥/X ¥/¥ ¥/¥ 
Ch:HAM 0.5:1 ¥/X ¥/X X/X 
Table 6-1 Table showing significant differences in rheology results between nanoparticle 
loaded complexes. 
Significant differences (P<0.05) between rheology results different nanoparticle loaded 
FRPSOH[HV)LUVWYDOXHUHIHUVWR*ƍYDOXHDQGVHFRQGYDOXHWR\LHOGVWUHVVYDOXH¥LQGLFDWHVD
significant difference and X indicates that difference was not significant. 
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Figure 6-6 *UDSKV VKRZLQJ *ƍ DQG \LHOG VWUHVV YDOXHV IRU &K+$ DQG &K+$0
complexes loaded with nanoparticles. 
*ƍDQG\LHOGVWUHVVYDOXHVwere extracted from rheology amplitude sweeps carried out at 37°C 
on complexes loaded with nanoparticles ZKHUHLQGLFDWHG7RS*ƍYDOXHLQ/95ERWWRP yield 
stress value. For both graphs: Ch:HA- blue; Ch:HA with RBITC loaded NP- red; Ch:HA with 
DXMP loaded NP- grey; Ch:HAM- green; Ch:HAM with RBITC loaded NP- black; Ch:HAM 
with DXMP loaded NP- white. 
The presence of nanoparticles seemed to have a greater effect on the strength 
of Ch:HA complexes compared to Ch:HAM complexes. The Ch:HAM 0.5:1 
ratio samples were the least affected by the addition of nanoparticles with no 
VLJQLILFDQW GLIIHUHQFHV EHWZHHQ WKH \LHOG VWUHVVHV 7KH *ƍ DQG \LHOG VWUHVV
values for the Ch:HAM 0.5:1 samples still exceeded the highest values for 
Ch:HA 0.5:1 samples. This shows that the use of HAM rather than HA in the 
complexes gives a higher strength than the addition of nanoparticles. 
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6.3.1.4 Composite degradation 
 
In order for this delivery system to be useful for a sustained drug release, long 
term stability of the composites was required. The degradation of nanoparticle 
loaded complexes was therefore assessed using a mass degradation method. 
The results of studies in both ASF and ASFP are presented in Figure 6-7. 
 
The degradation in ASF was found to be slower and more gradual with 
nanoparticles present. The degradation of complexes without nanoparticles, 
Figure 4-8, showed a rapid initial mass loss over 14 days followed by a plateau. 
The nanoparticle loaded complexes showed no rapid initial degradation, only a 
gradual mass loss throughout the study period. A higher mass of complex 
remained at the end of the study than with unloaded complexes, around 75% 
compared to between 45% and 60% for complexes alone. The difference was 
statistically significant (P<0.05) for all complex types except Ch:HAM 1:1 
complexes. 
 
In ASFP the degradation of 0.5:1 ratio samples showed a gradual degradation 
to a level similar to that seen with ASF, Figure 6-7. However without 
nanoparticles these samples showed a steady increase in mass, Figure 4-10. 
The 1:1 ratio samples both showed a similar degradation profile in ASFP to 
that seen without nanoparticles. Smaller increases in mass were observed, with 
a significant difference (P<0.01) in the Ch:HA 1:1 samples at 56 days. Overall 
it seems that the addition of nanoparticles increased the degradation in ASFP as 
lower final masses remained. Extensive adsorption of protein was seen in the 
complexes without nanoparticles. Therefore the decreases in mass seen may be 
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due to a reduction in protein adsorption. These results highlight the effects that 
protein can have on these complexes. The use of ASFP increases the deviation 
in the results showing that a more diverse response occurs when protein is 
present. 
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Figure 6-7 Mass degradation profiles of Ch:HA and Ch:HAM complexes loaded with 
nanoparticles. 
Ch:HA and Ch:HAM complexes loaded with PGA nanoparticles were prepared and then 
incubated in buffer at 37°C. Buffer was regularly changed and at each time point complexes 
were extracted, dried and weighed. Buffer and complex type used are detailed in the legend. 
 
The mass loss from the complexes is not the only important factor during their 
degradation. The integrity and strength of the complexes must be retained to 
allow the complexes to withstand the forces that occur within joints. Rheology 
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amplitude sweeps were carried out on samples degraded in ASF to assess the 
integrity and strength of the complexes during degradation and the results are 
presented in Figure 6-8. 
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Figure 6-8 *ƍ DQd yield stress values for Ch:HA and Ch:HAM complexes loaded with 
nanoparticles during degradation in ASF. 
*ƍDQG\LHOGVWUHVVYDOXHVwere extracted from rheology amplitude sweeps carried out on ASF 
degraded complexes loaded with nanoparticles at 37°C. Top: *ƍYDOXH LQ/95ERWWRP: yield 
stress value. For both graphs, time of degradation: 0 days- blue; 28 days- red; 56 days- grey. 
 
The results were very similar to those obtained from complexes without 
nanoparticles, Figure 4-9. A small increase is observed iQ*ƍYDOXHVLQWKHILUVW
28 days, which is followed by a slight decrease after 56 days. The yield stress 
values show a gradual but larger decrease over the study period. This shows 
that there is a gradual loss of resistance to shear stress whilst the overall 
structure and strength of the complexes is minimally affected. 
 
 195 
6.3.1.5 Nanoparticle release 
 
This composite delivery system is designed to retain nanoparticles within the 
joint and therefore the nanoparticles need to be retained within the complexes. 
To ensure that this was the case the release of nanoparticles from the 
complexes was investigated. This was carried out using the fluorescently 
labelled nanoparticles as this allowed easy quantification of released particles. 
The results of this study are presented in Figure 6-9. 
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Figure 6-9 Release profiles of nanoparticles from composites incubated in buffer. 
Ch:HA and Ch:HAM complexes loaded with nanoparticles (NP) containing RBITC were 
prepared and then incubated in buffer at 37°C. Buffer was regularly changed and release of 
nanoparticles was determined by fluorimetery. Buffer and complex type used are detailed in 
the legend. 
 
It was found that only a low release of particles occurred from the complexes. 
This release occurred rapidly and after 7 days minimal further release occurred. 
In all samples a maximum of 25% of the loaded nanoparticles were released 
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during the 56 days of the study. Significant differences were found between 
release in ASF and ASFP (P<0.01), with a higher release occurring in the 
presence of protein. A significantly higher release was also found in 0.5:1 ratio 
samples compared to 1:1 ratio samples (P<0.01). 
 
6.3.1.6 Enzymatic degradation of complexes 
 
In the osteoarthritic joint a number of catabolic enzymes are present. Many of 
these enzymes are proteinases and would not be expected to have any effect on 
the carbohydrate based polymers used in these complexes. Hyaluronic acid is a 
component of synovial fluid and so is naturally degraded by the enzyme 
hyaluronidase (HAase). There is no consensus as to whether this enzyme is 
present within the joint. However HAase can be used to give more challenging 
degradation conditions to allow the potential of these complexes to be assessed. 
The complexes were incubated in the presence of HAase and the particle 
release was monitored to show the enzyme degradation. The results of this 
investigation are shown in Figure 6-10. 
 
A formate buffer of pH 4.5 was used for this investigation as this is the optimal 
pH for HAase activity. The particle release with formate buffer is very similar 
to that seen with ASF. A significantly greater degradation and particle release 
occurred in the presence of enzyme (P<0.01). The composites incubated with 
enzyme showed an initial phase of between 7 and 21 days where the particle 
release was no different to samples incubated in buffer. After this initial lag the 
1:1 ratio complexes showed a gradual and sustained degradation. The 
complexes prepared with HAM showed a longer lag period and lower 
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degradation than HA samples, however the differences were not statistically 
significant. After 56 days at the end of the study the complexes were disrupted 
using a high concentration of hyaluronidase leading to the recovery of around 
20% to 30% of the loaded nanoparticles from the 1:1 ratio complexes. These 
results show that even under challenging conditions these complexes show a 
high level of stability. 
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Figure 6-10 Release profile of nanoparticles from composites during hyaluronidase 
degradation. 
Ch:HA and Ch:HAM complexes loaded with nanoparticles (NP) containing RBITC were 
prepared and then incubated in formate buffer (pH 4.5) at 37°C. In indicated samples 3U of 
HAase (0.6 U/ml) was also included in the buffer. Buffer was regularly changed and release of 
nanoparticles was determined by fluorimetery. Complex type used is detailed in the legend. 
 
The 0.5:1 ratio complexes showed a faster degradation in the presence of 
enzyme than the 1:1 ratio complexes, Figure 6-10. There was only a significant 
difference in the degradation level between 35 and 56 days (P<0.01). At this 
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polymer ratio the complexes containing HAM showed a faster degradation than 
occurred with complexes containing HA; however the differences were not 
significant. The 0.5:1 ratio complexes also showed a more complete 
degradation with only 5% to 10% of the loaded nanoparticles being recovered 
at the end of the study. 
 
6.3.2 Evaluation of Injectable Formulation 
6.3.2.1 Stability in salt 
 
In order to produce an injectable formulation for this delivery system 
complexation will be prevented by salt. The effect that nanoparticles have on 
the complex stability in salt is therefore important and was investigated using 
photography of the composites formed in increasing salt concentrations. 
Fluorescently labelled nanoparticles were used to give a visual indication of the 
nanoparticle incorporation and distribution. The results of this study are 
presented in Figure 6-11. At the 1:1 ratio discrete compact complexes were 
formed in 0.2M NaCl and below. At 0.3M and 0.4M salt a diffuse precipitated 
complex was produced, and a full disruption occurred with 0.5M NaCl. 
 
For the 0.5:1 ratio a complete complex disruption occurred in a salt 
concentration of 0.3M and above. Composites prepared using HA formed into 
discrete compact complexes in 0.2M NaCl and below, whereas HAM produced 
discrete compact complexes in NaCl concentrations of 0.1M and below. 
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Ch:HA 1:1 complexes 
 
0M              0.1M             0.2M            0.3M             0.4M            0.5M  
Ch:HA 0.5:1 complexes 
 
0M              0.1M            0.2M            0.3M             0.4M             0.5M  
Ch:HAM 1:1 complexes 
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Ch:HAM 0.5:1 complexes 
Figure 6-11 Photographs showing the effect of salt on composite formation. 
Complexes including RBITC loaded nanoparticles were prepared in the presence of the 
indicated concentration of NaCl. Mixtures were incubated at 37°C for 60 minutes to allow 
complex formation to occur before photographs were taken. 
 
6.3.2.2 Composite formation by dialysis 
 
From the mixtures prepared in 0.5M NaCl a dialysis formation method was 
utilised to form complexes. This method mimicked the reduction in salt that 
would occur in vivo through diffusion. The formation of composites by this 
method were analysed by photography and rheology amplitude sweeps. 
 
The results of the photographic study are presented in Figure 6-12, and show 
that this method was able to produce a visible complex formation in all cases. 
Ch:HA 1:1 samples showed the best visible formation with a rapid 
precipitation within 15 minutes, followed by a contraction and aggregation of 
the complex over 60 minutes. There appeared to be an even distribution of 
nanoparticles in these samples. 
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Figure 6-12 Photographs showing formation of composites by dialysis. 
Solutions containing composite components (including RBITC loaded nanoparticles) were 
prepared in 0.5M NaCl. These mixtures were dialysed against ASF at 37°C with the buffer 
replaced every 15 minutes. Photographs were taken at each buffer change. 
 
Ch:HAM 1:1 ratio samples also showed a good visual formation, which 
occurred into small discrete complexes, Figure 6-12. After an initial rapid 
precipitation very little rearrangement occurred. In these samples there 
appeared to be a less even distribution of particles with a small number of 
complexes appearing to be enriched with nanoparticles. 
 
The samples at the 0.5:1 ratio showed an impaired formation by this method, 
but a rapid precipitation still occurred, Figure 6-12. For the Ch:HA 0.5:1 
complexes this was followed by a much slower rearrangement over the course 
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of 120 minutes into small discrete complexes. The Ch:HAM 0.5:1 complexes 
showed no changes after 30 minutes, and formed a number of small discrete 
complexes. 
 
The results of the rheology time sweeps are presented in Figure 6-13. These 
back up the visual observations. They found that in all samples except Ch:HA 
0.5:1 a detectable formation occurred. Ch:HAM 1:1 ratio composites showed 
the most rapid formation, with complex detectable after 15 minutes. Despite 
the lack of visual changes after this point, the rheology revealed a gradual 
strengthening. Complexation was detected in Ch:HA 1:1 ratio composites after 
30 minutes, with a gradual increase in complex strength after this time. The 
Ch:HAM 0.5:1 ratio composites showed a slower formation, with complex 
detected after 60 minutes. 
 
To ensure that formation was not differently affected by drug loaded 
nanoparticles a further study was undertaken using these particles and the 
results of this photographic study are presented in Figure 6-14. These 
photographs show that the DXMP loaded nanoparticles do not cause any 
visible changes. The Ch:HA 1:1 ratio samples still produced the largest 
complexes. The other samples produced similar small discrete complexes.  
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Figure 6-13 Rheology amplitude sweeps showing composite formation by dialysis. 
Solutions containing composite components were prepared in 0.5M NaCl. These were dialysed 
against ASF at 37°C with the buffer replaced every 15 minutes. Rheology amplitude sweeps 
were carrieGRXWRQWKHUHFRYHUHGPL[WXUHVDW&*ƍVTXDUHVDQG*ƍƍWULDQJOHVDUHSORWWHG
against shear stress. Top left: Ch:HA 1:1; Top right: Ch:HAM 1:1; Bottom: Ch:HAM 0.5:1. 
The time of dialysis is shown in the legend and is the same for all graphs. 
 
 
 
 
Ch:HA 1:1          Ch:HA 0.5:1         Ch:HAM 1:1        Ch:HAM 0.5:1 
Figure 6-14 Photographs showing formation of drug loaded composites by dialysis. 
Solutions containing complex components (including DXMP loaded nanoparticles) were 
prepared in 0.5M NaCl. These mixtures were dialysed against ASF at 37°C with the buffer 
replaced every 15 minutes. After 60 minutes of dialysis photographs were taken. 
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6.3.2.3 Nanoparticle incorporation levels 
 
The studies conducted into the dialysis formation method have shown that the 
complexes appear different to the bulk formed complexes. The effect that the 
dialysis formation method had on the other properties of the complexes was 
therefore investigated. The incorporation of nanoparticles is an essential 
property and so the incorporation study was repeated using dialysis formed 
samples. The results of this study are presented in Figure 6-15. 
0
20
40
60
80
100
1 2 4 6 8
Initial NP Amount (mg)
%
 N
P
 i
n
c
o
rp
o
ra
ti
o
n
 
Figure 6-15 Graph showing nanoparticle incorporation levels into Ch:HA and Ch:HAM 
complexes formed by dialysis. 
Solutions containing complex components (including RBITC loaded nanoparticles (NP)) were 
prepared in 0.5M NaCl. These mixtures were dialysed for 60 minutes against ASF at 37°C with 
the buffer replaced every 15 minutes. Complexes were removed and remaining solution was 
analysed using a fluorimeter to estimate the nanoparticle incorporation into complexes. Ch:HA 
1:1- blue; Ch:HA 0.5:1- red; Ch:HAM 1:1- grey; Ch:HAM 0.5:1- green. 
 
The results show that high levels of incorporation occurred with this formation 
method. The loading levels were over 70% for 0.5:1 ratio samples and over 
85% for the 1:1 ratio complexes. For the majority of samples there was no 
significant difference between the bulk formed complexes and the dialysis 
formed complexes. The exception was the Ch:HA 0.5:1 samples which showed 
a significant difference in loading at loading levels of 1, 2 and 6mg (P<0.05). 
Incorporation levels were consistently lower with the dialysis formation 
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method. Comparing different complex types only found significant differences 
between the Ch:HA 0.5:1 ratio samples and both 1:1 ratio samples.  
 
6.3.2.4 Complex integrity 
 
The visual differences in the complexes produced by the dialysis method meant 
it was important to assess the strength of these complexes. This was done 
through rheology amplitude sweeps on dialysis formed complexes and the 
results of this study are presented in Figure 6-16. These results show that 1:1 
ratio complexes exhibited a slightO\LQFUHDVHG*ƍDQG\LHOGVWUHQJWKFRPSDUHG
to the bulk formed complexes. In contrast the 0.5:1 ratio complexes show a 
decreased *ƍDQG\LHOGVWUHQJWKYDOXHVFRPSDUHGWREXONIRUPHGFRPSOH[HV,Q
the case of Ch:HAM 0.5:1 these values are reduced dramatically. These results 
suggest that the 1:1 ratio complexes are stronger when produced by the dialysis 
method, whereas the 0.5:1 ratio produced weaker complexes. 
 
6.3.2.5 Degradation 
 
The long term stability of these composites in ASF was assessed using a mass 
degradation method and the results of this study are presented in Figure 6-17. 
The dialysis formed complexes exhibited a gradual degradation over the 56 day 
study period, which is an identical response to that seen with bulk formed 
complexes. The mass remaining at the end of the study in complexes produced 
by dialysis (between 50% and 70%) was slightly lower than for bulk formed 
complexes (between 70% and 75%). The only statistically significant 
difference in the degradation between bulk formed and dialysis formed 
complexes was in Ch:HA 0.5:1 ratio samples beyond 14 days (P<0.01). 
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Figure 6-16 *ƍDQG\LHOGVWUHVVYDOXHV IRU&K+$DQG&K+$0FRPSOH[HV ORDGHGZLWK
nanoparticles prepared by dialysis. 
*ƍDQG\LHOG VWUHVVYDOXHV were extracted from rheology amplitude sweeps carried out on 1:1 
ratio composites at 37°C. Top: *ƍYDOXH LQ/95ERWWRP: yield stress value. For both graphs: 
bulk formation method- blue; dialysis formation method- red. 
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Figure 6-17 Mass degradation profiles in ASF of Ch:HA and Ch:HAM composites 
formed by the dialysis method. 
Ch:HA and Ch:HAM complexes loaded with PGA nanoparticles were prepared by the dialysis 
method and then incubated in ASF buffer at 37°C. Buffer was regularly changed and at each 
time point complexes were extracted, dried and weighed. 
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6.3.2.6 Particle release 
 
The particle release from the dialysis formed composites was analysed using 
fluorescently labelled nanoparticles. This study found that only a very small 
amount of nanoparticles were released from the complexes during the 56 day 
study, Figure 6-18. The release was lower than that seen for bulk formed 
complexes, and significant differences in the particle release were found for all 
complex types except Ch:HAM at the 1:1 ratio (P<0.01). Ch:HA 1:1 
complexes showed a significant difference after 9 days until the end of the 
study (P<0.01), Ch:HA 0.5:1 complexes after 5 days (P<0.001), and Ch:HAM 
0.5:1 complexes after 7 days (P<0.001). 
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Figure 6-18 Release profiles of nanoparticles from composites prepared by dialysis. 
Ch:HA and Ch:HAM complexes loaded with PGA nanoparticles (NP) were prepared by 
dialysis and then incubated in ASF buffer at 37°C. Buffer was regularly changed and release of 
nanoparticles was determined by fluorimetery. 
 
6.3.2.7 Enzymatic degradation of composites 
 
As well as the degradation in biologically relevant buffer it was desired to test 
the composites under more challenging conditions as the conditions 
experienced within the joint are likely to be quite challenging. A high 
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concentration of hyaluronidase was chosen to provide a challenging test of the 
stability of these complexes. The enzymatic degradation was monitored by the 
release of fluorescently labelled nanoparticles from the complexes. The results 
of this study are shown in Figure 6-19. 
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Figure 6-19 Release profile of nanoparticles from composites prepared by dialysis during 
hyaluronidase degradation. 
Ch:HA and Ch:HAM complexes loaded with PGA nanoparticles (NP) were prepared by 
dialysis and then incubated in formate buffer (pH 4.5) containing HAase (3U) at 37°C. Buffer 
was regularly changed and release of nanoparticles was determined by fluorimetery. 
 
In the bulk formed complexes there was an initial phase where the release was 
the same as composites incubated in buffer alone. For the dialysis formed 
samples this initial phase of low degradation was not seen, Figure 6-19. The 
1:1 ratio composites exhibited a constant degradation throughout the study 
period. The Ch:HA 1:1 exhibited a slightly slower initial degradation rate 
compared to Ch:HAM 1:1 ratio complexes, but this difference was not 
significant. A slight increase in the degradation rate of Ch:HA 1:1 complexes 
occurred after 35 days. This caused the degradation of this sample to trend 
back towards the degradation profile of Ch:HAM 1:1 complexes. At the end of 
the study around 30% of the loaded nanoparticles were recovered from the 1:1 
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ratio composites. In the 1:1 ratio samples there was no significant differences 
between the dialysis formed composites and the bulk formed composites. 
 
The 0.5:1 ratio composites showed a rapid initial degradation and around 60% 
of loaded particles were released in 7 days, Figure 6-19. After this the 
degradation slowed and a gradual release occurred for the rest of the study 
period. At the end of the study around 10% of the loaded nanoparticles were 
recovered from these complexes. The 0.5:1 ratio samples did show a 
significantly faster initial degradation rate compared to the bulk formed 
composites. The Ch:HA 0.5:1 samples showed a significant difference between 
5 and 23 days (P<0.001) and for Ch:HAM 0.5:1 samples a significant 
difference occurred between 5 and 9 days (P<0.001). 
 
6.3.3 Drug Release from Composite Delivery System 
6.3.3.1 Dexamethasone phosphate 
 
The proposed delivery system aims to give a sustained release of 
dexamethasone phosphate over a period of up to three months. This length of 
sustained delivery was required to allow drug release to occur for the minimum 
recommended period between intra articular administrations of steroids. Any 
drug release of over 1 month would provide an improvement on currently 
available treatments. The drug release from the nanoparticle and 
polyelectrolyte composite system was an essential property of the system and 
was therefore investigated. 
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This experiment investigated complexes incubated directly in buffer; there was 
no need for a dialysis membrane with the large complexes. The buffer removed 
at each time point was filtered through a 30µm filter to allow any large 
particles to be returned to the release medium. The type A synovial lining cells 
within the joint have a macrophage like activity. The size limit for uptake by 
these cells means that any particles under 30µm can be considered to have been 
released as they will be cleared from the joint. The dexamethasone phosphate 
concentration in the release medium was analysed using the protocol used for 
the determination of DXMP nanoparticle loading. This resulted in the recovery 
of all drug whether free or from intact released nanoparticles. 
 
The results of this study are presented in Figure 6-20 and Table 6-2. Figure 6-
20 shows the result of a number of control experiments that were carried out. 
These include the release of DXMP from a dialysis membrane and from PGA 
nanoparticles, which was determined in chapter 5. The release of free DXMP 
from the polyelectrolyte complexes was also determined. These results show 
that the release of free drug from the complexes was extremely rapid with over 
90% released within 7 days in all cases. Rate of DXMP release from 
polyelectrolyte complexes was thus only slightly slower rate of release than 
was observed for free DXMP from a dialysis membrane. 
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Figure 6-20 Drug release profiles for dexamethasone phosphate from PGA nanoparticles 
and polyelectrolyte complexes. 
Release of dexamethasone phosphate from various formulations in ASF at 37°C. DXMP 
concentrations were determined by HPLC. The samples used were: free DXMP in dialysis 
membrane; PGA nanoparticles in dialysis membrane; free DXMP in Ch:HA and Ch:HAM 
complexes; PGA nanoparticles retained in Ch:HAM 1:1 complexes. 
 
Complex Type Unincorporated 
Recovery 
(%) 
Release 
after 7 Days 
(%) 
Recovery at 
56 Days 
(%) 
Total 
Recovery  
(%) 
Ch:HA 1:1 18.4 (2.8) 3.26 (0.57) 58.3 (4.3) 80.0 (7.2) 
Ch:HA 0.5:1 16.5 (3.5) 0.0 (0.0) 62.1 (6.5) 78.7 (3.7) 
Ch:HAM 1:1 17.5 (3.8) 4.38 (1.05) 61.2 (5.8) 83.1 (10.5) 
Ch:HAM 0.5:1 12.4 (0.62) 0.0 (0.0) 60.9 (6.0) 73.3 (6.0) 
Ch:HA 1:1 
Dialysis 
17.6 (1.0) 0.0 (0.0) 60.8 (5.9) 78.4 (4.9) 
Ch:HA 0.5:1 
Dialysis 
19.2 (1.5) 0.0 (0.0) 59.7 (3.8) 78.9 (4.6) 
Ch:HAM 1:1 
Dialysis 
16.8 (1.9) 0.0 (0.0) 58.2 (3.3) 75.0 (5.0) 
Ch:HAM 0.5:1 
Dialysis 
15.3 (3.5) 0.0 (0.0) 61.6 (6.8) 77.7 ( 3.3) 
Table 6-2 Dexamethasone phosphate release and recovery from PGA nanoparticles 
loaded into polyelectrolyte complexes. 
Release of dexamethasone phosphate from composites incubated in ASF at 37°C. DXMP 
FRQFHQWUDWLRQV ZHUH GHWHUPLQHG XVLQJ +3/& µ'LDO\VLV¶ LQ FRPSOH[ W\SH indicates that 
complex was produced using the dialysis formation method. 
 
Figure 6-20 and Table 6-2 show the results for DXMP release from 
nanoparticle and polyelectrolyte composites. Firstly these results show that the 
incorporation levels of DXMP loaded nanoparticles were similar to those 
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observed with RBITC loaded nanoparticles. In all cases an incorporation of 
over 80% was seen. Drug release was only detected from two samples which 
were the two 1:1 ratio samples produced by the bulk formation method, shown 
in Figure 6-20. After the release study had been conducted for 56 days the 
remaining complexes were disrupted using hyaluronidase to allow the recovery 
of any unreleased drug. This found that around 55% to 60% of the initially 
loaded drug was recovered from the delivery system.  
 
6.3.3.2 Dexamethasone crystals 
 
To determine whether it was necessary to incorporate a nanoparticle 
component into the delivery system the direct incorporation of dexamethasone 
crystals into complexes was assessed. These crystals were composed of the 
sparingly soluble steroid dexamethasone rather than the water soluble DXMP 
used in the nanoparticles in this study. It was first necessary to size the crystals 
in a dexamethasone suspension as large crystals have been shown to cause 
irritation in the joint. Intra articularly delivered steroid crystal formulations 
therefore have a tightly defined size of under 20µm (Derby et al., 2008). As the 
crystals produced were expected to be in the micrometre range a Coulter 
counter was used to size the crystals. 
 
Representative results of the dexamethasone crystal sizing are presented in 
Figure 6-21. The crystals produced had a mean size of 13.4µm and a median of 
9.93µm. Only a few particles were larger than 20µm, and a larger proportion 
were 5µm or smaller. 
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Figure 6-21 Size distribution of dexamethasone crystals determined by Coulter counter. 
Dexamethasone suspension was prepared in water and crystal size was determined using a 
Coulter counter.  
 
These crystals were incorporated into polyelectrolyte complexes in the same 
manner and amount as nanoparticles and the release was determined. The 
results of this release study are shown in Figure 6-22 and show that the crystal 
loaded complexes provided a gradual and sustained drug release over around 
90 days. No initial burst was observed and the release rate was consistent until 
it slowed as a complete release was reached. 
 
It was necessary to ensure that this result was not simply an effect of the 
limited solubility of dexamethasone in water. In order to accomplish this, a 
control sample of dexamethasone crystals retained within dialysis membrane 
was utilised. The results of this showed that the dexamethasone release by 
dissolution alone occurred within 28 days and was significantly different 
(P<0.001) to the release from complexes. A further control sample was 
analysed to ensure that the effect seen was not due to dexamethasone binding 
to hyaluronic acid. This sample consisted of dexamethasone crystals and 
hyaluronic acid retained within a dialysis membrane. The release from this 
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sample was identical to that seen with dexamethasone crystals alone and was 
significantly different (P<0.001) to the release from complexes. 
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Figure 6-22 Drug release profiles of dexamethasone from polyelectrolyte complexes. 
Release of dexamethasone (Dex) crystals from various formulations in ASF at 37°C. 
Dexamethasone concentrations were determined by HPLC. Samples used were: free Dex in 
dialysis membrane; free Dex and HA in dialysis membrane; free Dex in Ch:HA and Ch:HAM 
complexes. 
 
6.4 Discussion 
6.4.1 Composite Properties 
 
Complexes loaded with nanoparticles were synthesised and the properties of 
these composites were investigated. The incorporation of nanoparticles had few 
effects on the properties of the complexes. It was also found that the complexes 
were able to hold and retain high levels of nanoparticles showing the potential 
of chitosan and HA complexes as a drug delivery system. 
 
The formation of complexes was not visually affected by the presence of 
nanoparticles. In the photographic study no differences were observed between 
complexes prepared in the presence or absence of nanoparticles. The formation 
of nanoparticle loaded complexes was largely unaffected by the presence of a 
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physiological salt concentration. A slight disruption was observed in salt as the 
composites took on a more fibrous and less compact appearance. However the 
complexes were still able to form into the discrete precipitated complexes that 
are desired. 
 
The formation kinetics were slightly altered by the presence of nanoparticles 
and different effects were seen between complexes containing HA and HAM. 
For Ch:HA 1:1 ratio complexes the nanoparticles slowed formation. The 
JHODWLRQRIWKHV\VWHPZKLFKLVWKHSRLQWZKHUH*ƍDQG*ƍƍFURVV-over so that 
*ƍEHFRPHVWKHODUJHUYDOXHZDVGHOD\HGIURPDURXQGPLQXWHVWRDURXQG
minutes. The phase angle also revealed that the samples prepared with 
nanoparticles continued to form for longer than the 150 minutes that samples 
without nanoparticles took. 
 
The kinetics of formation with Ch:HAM complexes showed very little 
difference when nanoparticles were included. The formation remained 
extremely rapid and the only difference ZDVDQLQFUHDVHLQWKHILQDO*ƍYDOXHRI
the complexes. This value also increased with higher nanoparticle loading 
levels suggesting that nanoparticles act to strengthen the composites, and this 
was found to be the case through rheology amplitude sweeps. 
 
The reason for this difference in formation between the two types of hyaluronic 
acid is unclear. The most likely explanation would be that the nanoparticles do 
disrupt formation slightly. HAM has been shown to have positive effects on 
formation which were attributed to the formation of covalent bonds. Therefore 
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composites prepared with HA showed some disruption due to the disruptive 
effect of nanoparticles. However the positive effects of HAM outweighed the 
disruptive effects of the nanoparticles giving the better formation observed. 
 
The successful incorporation of nanoparticles into the polyelectrolyte 
complexes was important for the use of these complexes as a delivery system. 
It was found that in all cases very high nanoparticle incorporations (over 80%) 
were achieved. Significant differences in incorporation were found between 
0.5:1 and 1:1 ratio samples which shows that the polymer ratio can have effects 
on the complex properties and the 1:1 ratio provided the optimal properties for 
this system.  
 
The high incorporation levels show that the surface charge of the nanoparticles 
was sufficient to ensure their incorporation into complexes. The nanoparticle 
surface charge interacts with the charges on the polyelectrolyte polymers and 
drives their incorporation into complexes. No other studies have looked at the 
incorporation level of nanoparticles into hydrogels as most systems gel entirely 
ensuring the incorporation of all included nanoparticles. The precipitation of 
the complexes used here therefore could have been a drawback, but the high 
particle incorporations prove that this is not the case. 
 
An interesting observation from the nanoparticle incorporation study was that 
no decrease in incorporation was seen at high nanoparticle levels. At the 
highest loading levels studied the mass of nanoparticles approached 50% of the 
mass of the complex. At this level it may well be expected that nanoparticle 
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loading would affect the structure of the complexes and reduce the 
incorporation. The loading of nanoparticles is mainly a packing phenomenon 
and therefore the volume ratios are more important. To investigate this further 
it was decided to measure the volume of the complexes formed and calculate 
the percentage volume that nanoparticles take up. 
 
The results of these volume calculations are shown in Table 6-3 and show that 
despite approaching a high percentage of the complex mass, the volume of the 
nanoparticles is much lower. The highest value occurs with the smaller 0.5:1 
complexes with 8mg of nanoparticles where the nanoparticles take up 31% of 
the complex volume, rather than 55% of the complex mass. These lower values 
explain why the complexes are able to hold such high masses of nanoparticles 
efficiently and seems to confirm that the complex nanoparticle holding 
capacity is limited by space filling concerns. This theory could be investigated 
further by producing complexes loaded with higher nanoparticle levels to find 
the maximum loading that can be achieved. 
Table 6-3 Volume ratios of nanoparticles to polyelectrolyte complexes. 
Theoretical percentage volume that various amounts of nanoparticles occupy compared to 
polyelectrolyte complex volume. Polyelectrolyte complex volume was measured using a 1ml 
syringe. 
 
The method used to estimate nanoparticle incorporation used RBITC loaded 
particles. The solution that remained after complex formation was analysed 
using a fluorimeter to quantify the particles present and allow the calculation of 
Initial Loading 
Level  
(mg) 
Particle volume as 
percentage of 1:1 
complex volume 
Particle volume as 
percentage of 0.5:1 
complex volume 
2 3.85 7.69 
4 7.69 15.38 
6 11.54 23.08 
8 15.38 30.77 
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incorporated particles. This method does not directly measure the incorporated 
nanoparticles and so does have the potential for inaccuracy. The resilience of 
the polyelectrolyte complexes prevented the development of a direct method 
for nanoparticle incorporation determination. Measuring the fluorescence 
whilst the label is still incorporated into nanoparticles could also introduce 
errors into the results, because the binding of the label into the nanoparticles 
may cause some quenching of the fluorescence. To reduce this error a standard 
curve of fluorescence against nanoparticle concentration was produced and 
used for this study. The standard deviations of these results show that despite 
the limitations of the method used the results showed a good reproducibility. 
 
The distribution of nanoparticles within complexes appeared, on visual 
inspection, to be even throughout when using RBITC loaded nanoparticles, 
which have a pink colour. It appeared that Ch:HA complexes exhibited lower 
concentrations of particles near the surface. However this macroscopic 
inspection could only provide an indication of the particle distribution. To 
investigate this further cryo-SEM and fluorescence microscopy were used in an 
attempt to reveal the true distribution of the nanoparticles. Unfortunately 
neither of these methods was able to produce clear and definitive images. They 
did give an indication that the nanoparticles were not evenly distributed 
through the complexes, but they remained separate and not aggregated even 
when densely packed. Aggregation is not desired as it would cause 
uncontrolled increases in particle size which could lead to large aggregates 
which may reduce the tolerability in vivo. The failure to produce clear images 
means that further work would be required to confirm this. 
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It was also found that the addition of nanoparticles caused an increase in 
complex strength through rheology amplitude sweeps on composites. 
Nanoparticles gave a greater increase in strength with Ch:HA complexes 
compared to Ch:HAM complexes. This result conflicts with those of the 
rheology time sweep studies which suggested that the Ch:HA complexes were 
slightly disrupted by the presence of nanoparticles. As the amplitude sweeps 
were carried out on formed complexes it may explain these differences. The 
greater increase in strength of Ch:HA complexes could be accounted for by the 
fact that HAM produces covalent bonds within the complex structure. The 
strength of these bonds therefore overshadows the increase in strength due to 
nanoparticles that was seen in the Ch:HA complexes. 
 
It was found that the complex strength increases from unloaded complexes to 
RBITC loaded composites to DXMP loaded composites. This observation 
could be explained by the differences in zeta potential in the nanoparticles as 
the increase in negativity of zeta potentials followed the same pattern. There 
were no significant differences in the nanoparticle incorporation efficiencies 
with different nanoparticles. This suggests that this effect does not occur 
simply through the incorporation of a greater amount of nanoparticles. It is 
more likely that the higher charges influence the bonding of the particles within 
the complex. This may cause a tighter bonding that would account for the 
increases in strength observed. 
 
The degradation of composites in ASF was slow and gradual, which contrasts 
the initial rapid degradation seen in complexes without nanoparticles. A greater 
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mass of complex remained at the end of the study period when nanoparticles 
were included. These observations suggest that the nanoparticles stabilise the 
complexes, which agrees with the increase in strength seen in the rheology 
amplitude sweeps. 
 
The strength and integrity of the composites during their degradation was also 
VWXGLHGDQGIRXQGWKDWVPDOOFKDQJHVRFFXUUHGLQ*ƍYDOXHVDQGJUHDWHUFKDQJHV
were seen in yield stress values. The yield stress values showed a gradual 
decrease over the study period, which shows that complexes remain physically 
resilient throughout their degradation. This would allow complexes to resist the 
physical stresses in the joint after a period of chemical degradation. The results 
presented are only single measurements of each sample due to the sample 
requirements making repeated measurements not possible within this project. 
Therefore these results were included to give an indication that the strength of 
the complexes was not destroyed during their degradation. 
 
The conditions used in the mass degradation study are much less challenging 
than the potential conditions within the joint. Therefore to investigate a more 
challenging degradation it was decided to investigate the degradation of 
complexes with enzymes. Hyaluronidase was selected as the enzyme to be used 
as it is present within the joint and degrades hyaluronic acid, which is one of 
the components of this delivery system. To assess the degradation by this 
method it was decided to monitor particle release from degrading composites. 
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7KLV HQ]\PH GHJUDGDWLRQ VWXG\ ZDVQ¶W GLUHFWO\ ELROogically relevant to the 
osteoarthritic joint. The use of a high enzyme concentration was an easy way to 
assess complex stability in more challenging conditions. Hyaluronidase is 
present within the healthy and osteoarthritic joint (Nagaya et al., 1999), and for 
example HYAL-2 is present on the cell surface through a GPI-linkage (Volpi et 
al., 2009). Despite the presence of this enzyme within the joint it is not clear 
whether it is biologically active. The hyaluronidase enzymes have an optimal 
activity at acidic pHs (around pH 4.5) as they are lysosomal enzymes and are 
inactive at a neutral pH. The natural pH of synovial fluid is 7.4 and is not 
affected by osteoarthritis. For this study a formate buffer of pH 4.5 was used 
which will allow enzyme degradation to occur. The activity of HAase used was 
approximately 100 times the potential activity from synovial fluid (Nagaya et 
al., 1999). 
 
It was necessary to ensure that the release seen was not just due to degradation 
in the buffer, so therefore the release of particles from complexes incubated in 
buffer was also examined.  This found that only a low level of particle release 
occurred during incubation in buffer with an initial rapid release over the first 7 
days and only a minimal release after that. 0.5:1 ratio samples exhibited a 
higher particle release than 1:1 ratio samples. Overall these complexes were 
able to retain the nanoparticles loaded into them. 
 
These results would suggest that the nanoparticles became tightly bound into 
the complex structure. Any particles that were not tightly bound were quickly 
released and account for the initial rapid release. Overall this shows that these 
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complexes are likely to be suitable for a drug delivery system. The drug loaded 
nanoparticles will be retained and allow a slow release to occur. It also 
indicates that the 1:1 ratio complexes have the optimal properties. 
 
The particle release when the composites were incubated with HAase was 
found initially to be unaffected by the enzyme. After this initial period a 
gradual and sustained degradation occurred in the 1:1 ratio complexes, whereas 
the 0.5:1 ratio complexes exhibited a significantly more rapid degradation. At 
the end of the study between 20% and 30% of the loaded nanoparticles were 
recovered from 1:1 ratio complexes, whereas less than 10% of the loaded 
nanoparticles were recovered from 0.5:1 ratio complexes. These results show 
that these complexes exhibit a high stability even under challenging conditions. 
The 0.5:1 ratio complexes showed a more rapid and complete degradation 
which suggests that the 1:1 ratio complexes exhibit the optimal properties. The 
degradation that occurred due to HAase gives confidence that these complexes 
would be fully degraded in vivo and therefore would not remain indefinitely 
within the joint, which could cause more problems and joint damage. 
 
This stability during incubation with enzyme compares well to cross-linked 
hyaluronic acid hydrogels (Lee et al., 2008). Lee et al. found that hydrogels 
were degraded over 48h in 2.5 U/ml HAase, which is a much faster 
degradation than the polyelectrolyte complexes in the present study. This 
suggests that the incorporation of HA into these polyelectrolyte complexes 
protects it from degradation. However the present study used a lower HAase 
concentration of 0.6 U/ml, which will reduce the degradation seen. To fully 
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disrupt the complexes at the end of the study a concentration of 30U/ml was 
required which confirms that the polyelectrolyte complexes protected HA from 
degradation by HAase. 
 
Differences were observed in the response of the complexes produced with HA 
or HAM to degradation by HAase. However these differences depended on the 
polymer ratios used and were not statistically significant. The low level of 
modification present in HAM does not therefore affect its susceptibility to 
degradation by HAase. 
  
One aspect of the complexes that has not been investigated is their internal 
structure. Attempts have been made to determine this using cryo-SEM, 
however a clear image of the internal structure was not produced. There are a 
number of reasons for this but it mainly was due to the samples having 
unfavourable properties for cryo-SEM. The complexes were very tough which 
gave problems when fracturing. Often a scrape rather than a fracture occurred 
which is not suitable for imaging. When a fracture did occur it was often very 
rough and uneven which limits the resolution that the SEM image can achieve. 
The polyelectrolyte nature of the polymers also gave problems with the 
presence of charge, which again limits the imaging possible. 
 
There is a question of the reliability of any images produced as water is integral 
to the complexes. It is likely that the presence of water affects the complex 
structure and so the freezing process may therefore alter the structure. This 
highlights a wider problem in the imaging of aqueous based hydrogels and 
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other aqueous systems. There is a lack of techniques available to study these 
systems within their natural aqueous environment. The processing of these 
systems by drying or crystallisation to render them suitable for current 
techniques will alter the structure. A novel technique to image the internal 
structure of aqueous systems within their natural environment is required to 
overcome these problems. 
 
6.4.2 Dialysis Formation Method 
 
The dialysis formation method was investigated with nanoparticle loaded 
complexes. With the increases in strength and stability seen with nanoparticles 
included into complexes it was important to assess any effects nanoparticles 
had on the dialysis formation method.  
 
An initial study found no major differences in the concentration of salt required 
to prevent complex formation compared to when nanoparticles were not 
present. The reduction in stability in salt seen with HAM compared to HA was 
reversed when nanoparticles were added. A concentration of 0.5M NaCl 
produced a complete disruption of complex formation in all cases and for many 
samples a concentration of 0.4M was sufficient. If the higher salt concentration 
proves to be problematic for the tolerability of this system then a lower salt 
concentration may be able to alleviate this problem. 
 
The formation of composites using the dialysis method was successful with 
both RBITC and DXMP loaded nanoparticles. Visually a good formation 
occurred for all samples, although the 1:1 ratios showed the greatest formation 
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and Ch:HA 0.5:1 ratio complexes showed the worst formation. The formation 
was found to be slower in the 0.5:1 ratio samples. These visual observations 
were confirmed by the rheology results. The rheology also revealed a gradual 
strengthening of the complexes after the initial precipitation that was not 
obvious from the photographic study. Overall these results confirm that the 
dialysis method is suitable for producing nanoparticle loaded complexes. 
 
Visual inspection of complexes showed an even distribution of nanoparticles in 
the Ch:HA 1:1 ratio samples with a less even distribution of particles in other 
samples. In these cases there appeared to be a small number of complexes that 
were enriched with nanoparticles. The limitations of visual inspection were 
revealed with cryo-SEM images obtained on bulk formed complexes. 
Unfortunately cryo-SEM images of the dialysis formed complexes were not of 
sufficient quality to identify the nanoparticles present. The distribution of the 
particles within the dialysis formed complexes remains to be determined. 
However it seems unlikely with the data collected in this study that the 
distribution is entirely even. 
 
The production of a number of smaller complexes occurred with the dialysis 
formation method which causes an increase in the surface area of the 
complexes. Therefore it might be expected to cause changes in the complex 
degradation, particle retention and drug release properties. The properties of 
dialysis formed complexes were investigated to ensure that the complexes were 
still suitable for the intended application. 
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It was found that the nanoparticle incorporation efficiencies were consistently 
lower with the dialysis formation method. These differences were significant in 
the Ch:HA 0.5:1 ratio samples and both 1:1 ratio samples. It might be expected 
that the dialysis method would have massively reduced the incorporation of 
nanoparticles as the slower formation allows a greater chance for the particles 
to escape incorporation into the complexes. The high incorporations show that 
these complexes would still be suitable using this formation method. The 
reductions in the 0.5:1 ratio complexes show that the 1:1 ratio complexes have 
better properties using this formation method. 
 
Rheology amplitude sweeps revealed that this formation method had effects on 
the complex strength and different effects were seen with different ratio 
complexes. The 1:1 ratio complexes exhibit a slightly increased strength, 
whereas the 0.5:1 ratio complexes showed a decrease in strength and the 
Ch:HAM 0.5:1 showed a dramatic reduction in strength. The results suggest 
that the dialysis formation method is advantageous for the structure of the 1:1 
ratio complexes, but is disruptive of 0.5:1 ratio samples. The reliability of these 
results is limited as no repeats were carried out in this project for these data. 
However the similar results seen with samples at the same polymer ratio help 
to show that these results are likely to be an accurate representation. 
 
The improved strength of the 1:1 ratio complex may be due to the dialysis 
formation method giving better polymer incorporation into the complexes. It 
has been reported that for optimal formation of polyelectrolyte complexes that 
it is necessary to conduct the mixing at conditions where interaction does not 
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occur and then adjust the conditions so that interaction and formation can occur 
(Berger et al., 2004). The dialysis formation method provides this and so this 
may account for the improved strength seen for the 1:1 ratio complexes. For 
the 0.5:1 ratio samples it may be that the decreased stability in salt has a greater 
effect, with this slowing the formation and preventing the optimal complex 
formation seen with the 1:1 ratio complexes. 
 
The degradation of dialysis formed complexes in ASF buffer followed a 
similar gradual pattern to complexes produced using the bulk formation 
method. In all cases a slightly lower mass remained at the end of the study, but 
the only significant difference was in the Ch:HA 0.5:1 ratio samples. These 
results show that the reductions seen in stability were small and the complexes 
retain a sufficient stability for the intended application. 
 
The release of loaded nanoparticles also followed a similar pattern to that seen 
with bulk formed complexes. The release was more gradual than for bulk 
formed complexes and a lower overall release occurred. This shows that the 
retention of nanoparticles by the complexes was not hindered by the dialysis 
formation method and was, in fact, slightly improved. These results may be 
explained by the slightly lower incorporations seen with the dialysis method. 
The reduction is likely to be due to the removal of the least well bound 
particles and as these particles no longer bind to the complexes they will no 
longer be released, causing the slightly reduced levels of particle release that 
were seen. Also as these particles were the least well bound and could account 
for the initial burst seen with the bulk formed complexes. Therefore their 
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removal would also account for the reduction in this initial burst seen with 
dialysis formed complexes. 
 
The particle release in the presence of hyaluronidase was affected by the 
dialysis formation method. The initial period of minimal degradation with the 
bulk formed complexes was not seen with dialysis formed samples. For the 1:1 
ratio complexes there was no significant difference between the degradation in 
the complexes produced by the two formation methods. A similar amount of 
nanoparticles were also recovered at the end of the degradation study. These 
results show that the 1:1 ratio complexes are still stable under challenging 
conditions when formed by the dialysis method. 
 
The 0.5:1 ratio complexes exhibited a significantly faster degradation when 
they were produced by the dialysis method, causing a release of around 60% of 
the loaded particles within 7 days. However the release then slowed and at the 
end of the study around 10% of the loaded nanoparticles were recovered, 
which is similar to the recovery from the bulk formed complexes. Overall it 
can be seen that the 0.5:1 complexes have a lower stability than the 1:1 ratio. 
As this study was not conducted using a directly biologically relevant enzyme 
concentration this does not necessarily mean that the reduced chitosan 
complexes would not be suitable as a delivery system. 
 
These results show that some of the effects of the dialysis formation method 
appear to be contradictory. For example the increase in complex strength is not 
matched by an increase in stability. However many of these differences were 
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not significant. It may be that the increase in strength of the 1:1 ratio samples 
may represent a more complete formation rather than a formation of stronger 
complexes. This situation would account for the similar or slightly reduced 
stability seen. Other results show a better agreement with the slight reduction 
in nanoparticle incorporation being able to explain the reduction in particle 
release, as discussed above. 
 
The 0.5:1 ratio complexes show a more consistent negative impact with the 
dialysis formation method, showing a decreased strength, nanoparticle 
incorporation and stability. The 0.5:1 ratio complexes are closer to the polymer 
ratio where complex formation was not possible. Therefore this more 
demanding formation method may be expected to show the less optimal 
properties at this polymer ratio. However the properties of the 0.5:1 ratio 
complexes are still promising in general and they are worthy of further 
consideration but it can be clearly seen that the 1:1 ratio complexes provide the 
optimal properties. 
 
6.4.3 Drug Release 
6.4.3.1 Dexamethasone phosphate 
 
The drug release from the composites is a key property for the delivery system. 
Dexamethasone phosphate was the chosen drug and these DXMP loaded 
nanoparticles gave a sustained release over 28 days. The determination of 
DXMP release from the composites has however proven challenging. The low 
incorporation levels of DXMP into nanoparticles meant that only low levels of 
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drugs were available for analysis of the release, which made detection of the 
released drug challenging. 
 
The full release profile was not successfully determined in this study. However 
around 60% of the initially loaded drug was recovered after 56 days of the 
release study. A small release over the first 7 days was detected and only 75% 
to 80% of the loaded drug was recovered. It is likely that the unaccounted drug 
was released and not detected. If release was occurring at just below the 2% 
detection limit throughout the study then the majority of this missing drug can 
be accounted for. Together these results suggest that a gradual drug release is 
occurring. It can also be seen that the complexes retained drug for longer than 
56 days. These results show that these composites have the ability to act as a 
controlled release delivery system. 
 
It would be advantageous to determine the full release profile as this would 
provide confirmation of the potential of complexes loaded with nanoparticles. 
The sensitivity of the assay allows detection of around 2% of the loaded drug, 
and buffer in the release experiment was analysed every 7 days. This 
sensitivity would have been sufficient for the experiment if the release had 
occurred over the 90 days that was desired. A method with a higher sensitivity 
could be used to produce a full release profile with this system.  
 
These results suggest that these complexes may have a release that was slower 
than intended, which is a very unusual situation for a drug delivery system. The 
rate of release during in vitro studies is unlikely to be repeated under in vivo 
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conditions and the release is likely to be significantly faster. This gives hope 
that the desired release can be achieved in more biologically relevant or in vivo 
studies. 
 
It is important that the delivery system is able to maintain a sufficient drug 
concentration. Many sustained release delivery systems use the same dose as in 
an immediate release formulation but deliver it over an extended time period. 
Current intra-articular formulations of DXMP use around 2-4mg of drug 
(Gerwin et al., 2006), with most of this dose lost rapidly to the blood. A 
sustained release system may be able to utilise much lower amounts of drug 
and yet still provide a therapeutic effect. Calculations have shown that the 
current system, in a 2ml formulation for human knee, is capable of maintaining 
a concentration of around 20nM in the joint. This was calculated assuming that 
the entire drug amount was cleared and replaced every hour. The half-life of 
DXMP in the joint is known to be around 1.5 hours (Larsen et al., 2008), and 
so these calculations provide a conservative estimate. A concentration of 20nM 
exceeds the EC50 of this drug and would hopefully be sufficient to cause 
clinical effects. 
 
The drug release from nanoparticles retained within hydrogels has varied 
considerably with the system used. In systems incorporating dexamethasone 
the period of release has varied from around 10 days to around 60 days 
(Cascone et al., 2002, Kim and Martin, 2006, Wang et al., 2010). A system 
composed of an alginate gel retaining PLGA nanoparticles was the most 
similar to the system in this study (Kim and Martin, 2006). It was found that 
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free dexamethasone was very rapidly released from the hydrogel. This release 
was slowed by encapsulation into nanoparticles and slowed further by 
incorporation of nanoparticles into hydrogels. A similar pattern of release was 
seen in the present study but over longer time scales than the 10 days seen in 
the alginate system. 
 
The system reported in the literature that has provided a release over the 
longest period was composed of aggregating nanoparticles (Wang et al., 2010). 
This system was able to provide a complete release of dexamethasone over a 
period of 60 days. The release was significantly slowed compared to free 
nanoparticles, which exhibited release over 20 days (Wang et al., 2010). The 
comparison to the system here is limited by the lack of a full release profile and 
the different drug used. Dexamethasone phosphate was used for the present 
study and this drug is more water soluble than dexamethasone. Therefore the 
release of DXMP would be expected to be quicker than that of dexamethasone 
and so the length of retention observed with these complexes is impressive. 
 
The recovery of dexamethasone phosphate from the complexes after 56 days is 
even more impressive when the release of free drug from the hydrogels is 
considered. The release of free DXMP from polyelectrolyte complexes was 
found to be quite rapid and occurred within 7 days. It can therefore be assumed 
that any drug released from nanoparticles within the complexes will be rapidly 
released to the surrounding media. The release of DXMP from particles in 
solution was almost complete after 28 days which might suggest that the 
release from the composite system would occur over a similar time scale. The 
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much slowed release could be due to the compact structure of the complexes 
excluding water. This would therefore slow the degradation of the 
nanoparticles and hence the rate of drug release. 
 
It can also be noted from these results that the incorporation rates of DXMP 
loaded nanoparticles were similar to those observed with RBITC loaded 
nanoparticles. This is an encouraging result as it shows that these drug loaded 
particles are equally well retained and gives confidence that the results 
obtained with the fluorescently labelled particles are likely to give a good 
indication of the properties of the complexes loaded with DXMP nanoparticles.  
 
This high retention of drug throughout the release study suggests that the 
particles are well retained throughout the study, as occurred with RBITC 
loaded nanoparticles. The initial nanoparticle release seen with RBITC loaded 
nanoparticles would be able to cause the small burst release of DXMP seen in 
bulk formed samples. The results of the incorporation and release of 
nanoparticles also provide encouragement that this system could be adapted for 
use with nanoparticles loaded with other drugs in the future in the confidence 
that they are likely to exhibit similar properties. 
 
6.4.3.2 Dexamethasone crystals 
 
To simplify the system the incorporation of dexamethasone crystals into the 
complexes was considered as a possible alternative delivery system. These 
crystals have a limited solubility and so have been used as a slow release 
system for intra articular administration (Derendorf et al., 1986). However 
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large crystals can cause irritation and damage within the joint so commercially 
available steroid crystal formulations have a tightly defined size of under 20µm 
(Derby et al., 2008). The crystals used for this study were prepared from 
laboratory chemicals and so did not have a tightly defined size. The crystals 
were mostly smaller than 20µm and so provide a good enough sample for this 
investigative study. A more tightly defined crystal sample could be prepared 
for future studies with these complexes. 
 
The release study found that these crystal loaded complexes produced a 
sustained drug release for a period of around 90 days, which was not simply 
due to solubility effects or binding to HA. Hyaluronic acid has a hydrophobic 
patch within its structure that could potentially bind to the hydrophobic steroid. 
If binding occurred this could have provided an explanation for the slow 
release seen. It would therefore seem likely that the slow drug release from 
dexamethasone crystals is also an effect of the compact structure of the 
complexes excluding water. This reduction in available water and the limited 
solubility of dexamethasone could account for the slow release. 
 
This slow release exceeds any seen from a drug directly incorporated into a 
hydrogel. A system using a dexamethasone suspension retained within a cross-
linked hyaluronic acid hydrogel showed a complete drug release over 28 days 
(Kim et al., 2011). These complexes therefore show a vastly improved drug 
release profile and have potential as a directly loaded system with 
dexamethasone. 
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Further study of these crystal loaded complexes is required to determine their 
full potential. The issues with the biocompatibility of crystals may prove 
problematic during in vivo studies and with the long term tolerability of the 
treatment. If this is the case it may mean that the nanoparticle loaded system 
still retains advantages. However the ability of the directly loaded system to 
provide the desired 3 month delivery makes it worthy of further study. 
 
Comparing the release of free dexamethasone phosphate and dexamethasone 
when directly loaded into the complexes is very interesting. The phosphate 
group which is present in DXMP makes this molecule more hydrophilic than 
dexamethasone, but this is the only difference between the two molecules. 
Therefore it would seem that the difference in release is due to the 
hydrophobicity of the compound. 
 
The fact that dexamethasone is in a crystalline state rather than in solution will 
undoubtedly slow the drug release as it must first be dissolved before it can be 
released. The results from the dissolution of free crystals show that this factor 
alone does not explain the differences in release. The exclusion of water from 
the complexes is likely to slow the dissolution of dexamethasone and would 
therefore slow the release. It is also likely that dexamethasone is better retained 
within the complexes due to its hydrophobicity and together these factors 
account for the slow release that was found.  
 
 
 
 
 235 
6.5 Conclusions 
 
The results within this chapter show that complexes were able to hold and 
retain nanoparticles. The complexes are able to hold high levels of 
nanoparticles whilst maintaining a high incorporation efficiency. The presence 
of nanoparticles had few effects on the complex properties and did in fact 
slightly improve the properties of the complexes. The nanoparticles were also 
retained very well, which would be sufficient to allow a drug release over 3 
months as is desired. 
 
The results found a significant difference in nanoparticle release with and 
without protein present. Protein was also found to affect the degradation of 
composites. It would be advantageous to conduct further investigations to 
determine the effects of protein on complex properties. However it is 
questionable whether further in vitro studies are required with more biological 
relevance or whether it is more useful to conduct in vivo studies as an in vitro 
study can never fully mimic in vivo conditions. The current data on this system 
shows its potential and in vivo studies would give more useful results. 
 
The dialysis formation method was also able to produce nanoparticle loaded 
complexes. This formation method had very little effect on the 1:1 ratio 
complexes, with a slight decrease in particle incorporation, a slight increase in 
strength and a slight decrease in particle release seen. The 0.5:1 ratio 
complexes were more greatly affected by the formation method, with a 
significant reduction in nanoparticle incorporation, strength and stability found. 
These results highlight the limitations of the reduced chitosan ratio and shows 
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that the 1:1 ratio complexes have the optimal properties. The 0.5:1 ratio 
complexes still have properties that make them suitable for continued 
consideration. This is especially true as the projected improved compatibility 
of this ratio has not been assessed. 
 
The release of dexamethasone phosphate from these composites was not 
successfully determined and further study is required in order to determine this 
release. The low drug concentrations proved a challenge in the HPLC analysis 
and the use of a method with a higher sensitivity would help. The drug 
determination would also be less challenging if the drug loading levels of the 
PGA nanoparticles could be improved, and would also increase the capacity for 
drug delivery with this system. Overall however the system shows promise as 
there was a high retention of drug within the system for 56 days. 
 
The loading of dexamethasone crystals directly into the complexes produced an 
unexpected alternative delivery system. With this system a drug delivery for 
the desired three month period was achieved, but much further study is 
required to fully understand this system. It is also very important to investigate 
the compatibility with the crystal component in this system. The negative 
effects of crystals within the joint may be prevented through these complexes; 
however it is not known to what extent this would occur. To fully assess the 
viability of this delivery system the compatibility needs to be investigated. The 
other properties of the crystal loaded complexes have not been investigated; 
however the sustained drug release results make these properties less important 
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as they show these complexes are stable and have similar to those previously 
investigated. 
 
Large differences seen between hydrophobic and hydrophilic drugs loaded 
directly into the complexes. This system has the potential to be extended to 
including other drugs. The hydrophilic or hydrophobic properties of the drug 
could determine the more suitable system to provide a sustained release. 
Hydrophobic drugs can potentially be directly incorporated into the complexes 
and this is an easier system to produce and also avoids the necessity to 
investigate the nanoparticles and their drug loading. The observed release here 
may be due to the drug crystals used in this study, but until studies are 
conducted with further hydrophobic drugs it is not possible to be sure. 
Hydrophilic drugs were rapidly released when directly incorporated into 
complexes and therefore nanoparticles are essential to allow a sustained 
release. These options provide this system with the potential to deliver a wide 
variety of drugs. 
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CHAPTER 7 - GENERAL CONCLUSIONS 
 
7.1 Summary and Conclusions 
 
This project started with the aim of investigating potential drug delivery 
systems for osteoarthritis. Through a review of the literature this was 
developed to focus on producing an intra-articular system capable of providing 
a slow release of the corticosteroid dexamethasone phosphate. The aim was to 
produce a delivery system capable of providing a sustained drug delivery over 
at least three months. This period of delivery exceeds what is possible for most 
delivery systems and therefore a system of an injectable hydrogel incorporating 
a nanoparticle drug delivery was proposed. 
 
Polyelectrolyte complexes between hyaluronic acid and chitosan were 
investigated as the hydrogel portion of this system. These complexes showed a 
great potential as a base for a slow release drug delivery system as they had a 
high stability and resilience. The complexes also showed promise that a drug 
release over the desired time scales could be achieved. Unfortunately the full 
release profile of dexamethasone phosphate from nanoparticle loaded 
complexes was not successfully determined, and this limits the conclusions that 
can be drawn. However, around 60% of the initially loaded drug at the end of 
the 56 day release study was recovered which shows that the system is capable 
of retaining drug for long periods. Further study is therefore required to 
determine the full drug release profile to overcome the current uncertainty. 
However the initial release seen and the recovery of unreleased drug at the end 
of the study showed the promise of this system. 
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Dexamethasone crystals loaded directly into complexes were investigated as an 
alternative system that avoided the incorporation of nanoparticles. The removal 
of the nanoparticles is desirable as this simplifies the system. This gives a 
greater likelihood that no unexpected results will be found during in vivo 
studies and also that regulatory approval will be gained. The directly loaded 
system was able to provide a sustained drug delivery over 90 days and 
therefore has a great potential, but the crystals do raise questions over 
compatibility. The extremely promising drug release from this system make it 
worthy of further study, as this exceeds the delivery from any previously 
reported delivery system of this type. 
 
The results gathered show the potential of this system to have a wide variety of 
drugs incorporated. For hydrophilic drugs the nanoparticle portion of this 
delivery system is essential whereas poorly soluble compounds can be directly 
loaded into complexes. Overall this system therefore has the potential to 
provide a sustained release for many drugs. 
 
The drug loading of the PGA nanoparticles was lower than expected. This 
loading was determined using a direct method that was developed and 
validated during this project. The particles did however provide a release in 
line with what was expected, with a sustained release of DXMP over 28 days, 
which exceeds what has been found with most nanoparticle systems. 
Improving the drug loading levels of the nanoparticles, either through further 
work with PGA or through the use of an alternative polymer, would provide 
many advantages for this system. It would allow a higher drug concentration to 
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be maintained within the joint and would also allow for easier analysis of the 
drug released. The project aimed to provide evidence that this delivery system 
was capable of providing a drug release over a minimum of three months. 
Therefore although further work could have been carried out to improve the 
drug loading it was decided that within the time limitations of this project it 
was more important to study the combined nanoparticle and complex system. 
This leaves the nanoparticles as an area of this system which can be improved.  
 
This project also investigated a modified hyaluronic acid (HAM). This polymer 
was produced with a low modification level to ensure that the polyelectrolyte 
characteristics were not lost. The incorporation of HAM into complexes was 
able to improve their properties with a greater resilience and slower 
degradation observed; also a much more rapid formation was found. The cause 
of the increase in the formation speed was not definitively identified as the 
VWUXFWXUH RI +$0 ZDV QRW IXOO\ GHWHUPLQHG (OOPDQ¶V 7HVW FRQILUPHG WKDW
cysteamine had been successfully incorporated but the full structure of HAM 
was not confirmed. This leaves open the possibilities that unexpected reactions 
had occurred, such as the formation of an N-acylurea adduct with EDAC. 
Therefore further investigations to fully characterise HAM are required. 
 
A high salt concentration was used to prevent complex formation and produce 
an injectable formulation of this system. Formation of complexes in the lab 
from these high salt solutions was achieved through dialysis, to mimic the 
diffusion of salt that would occur in vivo. This method was able to successfully 
produce complexes and had few negative effects on the complex properties. 
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The salt concentrations required may prove to cause problems with the 
compatibility of the system, however previous studies have shown that 
chondrocytes can survive this hypertonic shock. It may prove that HAM has 
further advantages here as it appeared to reduce the salt concentration required 
to disrupt complexation. This would allow a lower salt concentration to be used 
which would reduce the potential compatibility problems. 
 
It was desired to utilise the lowest possible concentration of chitosan as it 
potentially causes inflammation within the joint; although its effects in the joint 
are not entirely clear. The use of a reduced chitosan concentration had some 
negative impact on the complex properties; however they still showed 
promising properties for the intended application. As the compatibility of the 
complexes has not yet been investigated the reduced chitosan concentration 
samples may well prove to have advantages that are more important than the 
small reductions in strength and stability. 
 
It has also not been possible to conduct any in vivo studies in the current 
project. There is always the risk that any system will produce unexpected 
results in vivo due to the much more challenging conditions. It is therefore 
important that this system is investigated in vivo to confirm that the promise 
shown by this system in vitro follows through. 
 
7.2 Future Work 
 
There are a number of studies that are required to overcome some of the 
VKRUWFRPLQJVWKDWKDYHQ¶WEHHQIXOO\DGGUHVVHGLQWKHFXUUHQWZRUN7KHZRUN
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that is most needed to prove the value of this system is further release studies, 
and in particular the determination of the full DXMP release profile from PGA 
nanoparticles loaded into polyelectrolyte complexes. The failure to achieve this 
is likely to have been due to the slow rate of drug release and the sensitivity of 
the HPLC assay used. Improving the drug loading or using a more accurate 
analysis method would be able to determine the drug release profile. 
 
Another factor that has not been investigated is the biocompatibility and 
toxicity of HAM, so a study to investigate this is therefore very important. The 
complexes have shown promising properties without using HAM, so if it 
proves to have an unacceptable toxicity then the system can continue to be 
investigated using unmodified hyaluronic acid. There is also a need for further 
studies to fully determine the structure of HAM, to help explain the effects that 
HAM had on the complexes. It is also possible that a version of HAM with a 
higher percentage modification may provide further advantages, and this could 
also be investigated. 
  
This system has shown great in vitro potential as a drug delivery system and 
now requires studying in vivo to ensure that this potential is fulfilled. The first 
factor that these studies would need to focus on is the compatibility of this 
system, as this has not been investigated in this study. The exact physical 
properties of the complexes required to ensure that they do not cause damage 
to the joint are not known and it is hoped that the 1:1 ratio complexes will not 
damage the joint. If it is found that they do damage the joint then the physical 
properties of the complexes can be adjusted by varying the polymer ratio and 
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concentrations and this will hopefully allow complexes with appropriate 
properties to be produced. 
 
Studies of the in vivo drug release and the effectiveness of this system against 
an osteoarthritis disease model would provide very good evidence as to its 
efficacy. Osteoarthritis is a disease of the entire synovial joint, which has often 
been overlooked in animal models (Bonnet and Walsh, 2005). Corticosteroids 
in osteoarthritis act to reduce the synovial inflammation and do not affect the 
cartilage. Therefore any animal model used to study this system needs to 
include the changes seen in the synovial membrane. One possible model that 
could be used is collagen induced arthritis, although this is a rheumatoid 
arthritis model it shows many of the required characteristics of osteoarthritis. 
The methods for these animal studies also need to be considered as normally 
drug release is monitored in the blood. As this system is aiming for a local 
delivery to the joint and is applying low drug concentrations it is likely that 
monitoring via the blood may prove problematic. Synovial fluid sampling has 
many challenges but would provide better information for this system. 
Monitoring the animals for clinical improvement may also give good 
information on the clinical efficacy of the system. 
 
Further studies are required into the system with dexamethasone crystals 
directly loaded into complexes as it has so far only been investigated in terms 
of drug release. The compatibility of this system must be carefully evaluated as 
crystals are known to be damaging within the joint. Steroids crystals with a 
tightly defined size have been administered to the joint to minimise the risk of 
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joint damage. Further work is also required to investigate this system with the 
dialysis formation method required to produce the injectable formulation. 
 
Looking wider and the results show that this delivery system has a potential to 
be developed with other drugs. The system can be formulated with or without 
nanoparticles depending on the drug properties. The PGA backbone polymer 
used for the production of the nanoparticles can be modified to alter its 
properties and allow different drugs to be incorporated (Kallinteri et al., 2005, 
Puri, 2007). Other nanoparticle systems could also potentially be used with this 
system. These possibilities give many options for further investigations and 
show a great potential for this system. 
 
This system also has the potential to be adapted for other applications beyond 
osteoarthritis. Hyaluronic acid hydrogels have been used for anti-adhesion and 
wound healing applications. There is the potential that these complexes could 
be adapted for these applications, with or without drug loading. It is likely that 
drug loaded hydrogels would also provide advantages in these areas. Hydrogel 
patches have also been used as a topically applied drug delivery system. The 
aqueous nature of the hydrogels acts to increase the skin permeability allowing 
the delivery of the drug. The tough and resilient complexes produced in this 
study have the potential to be used as part of a hydrogel based patch system. 
Another potential use for a long term depot forming system is as a base for an 
environmental activated drug delivery system. This system would release small 
bursts of drug when triggered over a long time period and would provide 
further advantages as drug would only be released when needed. 
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APPENDIX I 
 
 
Solutions in PBS, 0.0035g/ml HA, 22°C 
 
 
Solutions in water, 0.0035g/ml HA, 22°C 
Photographs showing the gelation of Pluronic F127 solutions in synovial relevant 
conditions.  
Pluronic F127 solutions at concentrations between 15% and 20%(w/v) were prepared in water 
or PBS. Hyaluronic acid at 3.5mg/ml was included where indicated. The vials were 
photographed at the indicated temperature after being inverted for 1 minute 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  15%     16%      17 %     18%      19%       20% 
  15%     16%       17 %     18%      19%       20% 
 270 
APPENDIX II 
 
Raw size and zeta potential distributions 
 
Size distributions and zeta potentials were determined using a Malvern Zetasizer Nano ZS 
(Malvern Instruments Ltd, UK) at 25°C. Size was determined by dynamic light scattering and 
zeta potential by laser doppler micro-electrophoresis. 
 
Blank Nanoparticles 
 
 
 
 
 
DXMP loaded nanoparticles 
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RBITC loaded nanoparticles 
 
 
 
